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     It is good to have an end to journey toward; 
but it is the journey that matters,  
in the end. 
 
~Ernest Hemingway 
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ABSTRACT 
Background 
Cardiovascular disorders play a crucial role in the global burden of diseases, being in 
most countries the leading cause of death. Coronary artery bypass, introduced in the 
mid-1960s, became the standard treatment in severe coronary artery disease (CAD) in 
the 1980s also in Finland. The role of preventive measures in long-term survival of CAD 
became evident in the 1980s and 1990s. Most studies addressing long-term survival after 
coronary artery bypass grafting (CABG) have covered study periods ranging from five 
to ten years and thus their ability to find slow alterations has been limited. 
 
Aims 
The aim of this study was to evaluate the postoperative prognosis of CABG patients 
for up to 20 years. It was approached through postoperative employment together 
with total and cardiovascular mortality. The aim was also to examine how long-term 
survival was related to obesity, metabolic syndrome (MetS) and diabetes mellitus 
(DM). The effect of statin treatment upon survival was also studied. 
 
Subjects and methods 
Two different populations were included. The follow-up studies comprised 922 
CABG patients operated on during the period 1 January 1993 – 30 June 1994 at 
Tampere University Hospital.  The study population for the annual cohorts 
consisted of 946 CABG patients treated in Kanta-Häme Central Hospital during the 
time period 1 January 1990 – 31 December 2009. Study data was collected from 
patient records, questionnaires and national registries. The relative survival rates 
compared to matched background populations were analysed using the Life Table 
method. To study the independent significance of obesity, MetS and DM for clinical 
outcome, multivariate analysis based on the Bayesian approach was used.  
 
Results 
Almost 60 percent of patients, preoperatively not retired, remained employed after 
surgery. Age and length of preoperative sick leave or temporary retirement were the 
most important factors affecting postoperative employment. Having once returned 
viii 
to work, patients’ retention at work was comparable to that in the general population. 
Diabetes mellitus already during the first postoperative decade and obesity and MetS 
during the second postoperative decade were related to impaired survival. Patients 
without DM or MetS had an equally good prognosis as their operation year, age and 
gender matched background populations. Scant statin use was also related to poor 
survival. Statin use in the annual cohorts population increased up to 20-fold during 
the study period. 
 
Conclusions 
The retention of working capacity is high after CABG. Effective and prompt treatment 
of coronary heart disease and its risk factors significantly improves long-term 
prognosis and continuation in employment. Obesity, MetS and especially diabetes 
mellitus have deleterious impact on mortality rates. In addition, non-adherence to 
statin use is associated with increased mortality. The results encourage the effective 
treatment of metabolic risk factors among patients with coronary artery disease. 
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TIIVISTELMÄ 
Tausta 
Sydän- ja verenkiertoelimistön sairauksilla on tärkeä merkitys ihmiskunnan 
tautikirjossa, koska ne ovat useimmissa maissa johtava kuolinsyy. Sepelvaltimoiden 
ohitusleikkaus, joka ensimmäisen kerran tehtiin 1960-luvulla, kehittyi Suomessakin 
vaikean sepelvaltimotaudin rutiininomaiseksi hoitotavaksi 1980-luvulla. 
Sekundaariprevention keskeinen merkitys sepelvaltimotaudin pitkäaikaishoidossa tuli 
ilmeiseksi 1980- ja 1990-luvuilla. Pääosa sepelvaltimoiden ohitusleikkauksen jälkeisistä 
pitkäaikaisennustetta selvittävistä tutkimuksista on ollut pisimmillään 5 – 10 vuoden 
kestoisia ja siten ne ovat tarjonneet rajallista tietoa hitaiden muutosten merkityksestä. 
 
Tavoitteet 
Tutkimuksen tavoitteena oli selvittää sepelvaltimoiden ohitusleikkauksen jälkeistä 
ennustetta 20 vuoden seurannassa leikkauksen jälkeen työssä olon, 
kokonaiskuolleisuuden ja sydänkuolleisuuden avulla. Tarkoituksena oli myös 
selvittää, miten pitkäaikaisennuste korreloi lihavuuteen, metaboliseen syndroomaan 
(MetS) ja diabetekseen (DM). Statiinilääkkeiden käyttöä selvitettiin osana ennustetta. 
 
Aineisto ja menetelmät 
Tutkimusprojekti käsitti kaksi eri aineistoa. Seurantatutkimukseen osallistui 922 
sepelvaltimoiden ohitusleikkauspotilasta, jotka leikattiin 1.1.1993 – 30.6.1994 
Tampereen yliopistollisessa sairaalassa. Vuosikohorttien tutkimukseen osallistui 946 
Tampereen yliopistollisessa sairaalassa leikattua ja Kanta-Hämeen keskussairaalassa 
1.1.1990 – 31.12.2009 jatkohoidettua sepelvaltimoiden ohitusleikkauspotilasta. 
Tutkimustiedot kerättiin sairauskertomuksista, potilaskyselyistä ja kansallisista 
arkistoista. Suhteellista ennustetta verrattiin vastaavaan taustaväestöön ja analysoitiin 
Life Table-menetelmällä. Lihavuuden, MetS:n ja DM:n itsenäistä merkitystä 
ennusteeseen selvitettiin Bayesin filosofiaan pohjautuvalla monimuuttuja-analyysillä. 
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Tulokset 
Lähes 60 % leikkausta edeltäen eläköitymättömistä ohitusleikkauspotilaista palasi 
leikkauksen jälkeen työelämään. Ikä ja leikkausta edeltävän sairasloman tai 
määräaikaisen työkyvyttömyyseläkkeen kesto olivat tärkeimmät työkykyyn 
vaikuttavat tekijät. Leikkauksen jälkeen työhön palanneiden potilaiden työkyvyn 
säilyminen oli verrattavissa saman ikäiseen muuhun väestöön. Diabetes jo 
ensimmäisellä postoperatiivisella vuosikymmenellä ja lihavuus tai MetS toisella 
vuosikymmenellä huononsivat merkittävästi potilaiden ennustetta. Toisaalta potilaat, 
jotka eivät sairastaneet diabetesta tai MetS:a pärjäsivät yhtä hyvin kuin leikkausvuosi, 
ikä ja sukupuolivakioitu taustaväestö. Vähäinen statiinien käyttö liittyi huonoon 
ennusteeseen. Vuosikohorttien tutkimuksessa statiinien käyttö lisääntyi 20-
kertaiseksi seuranta-aikana. 
 
Johtopäätökset 
Sepelvaltimoiden ohitusleikkauspotilaiden työkykyyn ja ennusteeseen vaikuttavat 
olennaisesti sepelvaltimotaudin ja sen riskitekijöiden tehokas ja viiveetön hoito. 
Lihavuus, metabolinen oireyhtymä ja erityisesti diabetes lisäävät kuolleisuutta. Niin 
ikään statiinien vähäinen käyttö assosioituu huonoon ennusteeseen. 
Tutkimustulokset kannustavat sepelvaltimotautipotilaiden metabolisten 
riskitekijöiden tehokkaaseen hoitoon. 
xi 
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1 INTRODUCTION 
Cardiovascular diseases (CVD) play a crucial role in the global burden of diseases 
being in most countries the leading cause of death and outweighing all cancers and 
pulmonary diseases. Clinically significant atherosclerotic lesions typically evolve over 
the course of decades. However, the symptoms may also manifest suddenly. In the 
worst case, the first symptom of coronary artery disease (CAD) is sudden death. 
Primary prevention, treatment and secondary prevention of cardiovascular diseases 
have changed completely in our lifetime. During the last half-century the nature of 
the disease has often become preventable. In the best case, the course of disease may 
be reversed from progression to regression 1,2. 
The recent successes of CAD treatment are numerous. Coronary artery bypass 
grafting (CABG), introduced in the mid-1960s, became during the following two 
decades the standard treatment for patients with severe CAD. Percutaneous 
coronary intervention (PCI) with intensive postoperative antithrombotic care has 
developed over the past 30 years into an effective and less demanding alternative to 
CABG for most patients. The Scandinavian Simvastatin Survival Study (4S study) 
published in 1994 served to promote statin treatment and secondary prevention of 
CAD, and today we talk about comprehensive risk factor management including 
both lifestyle interventions and medication 3,4. 
In the review of the literature the epidemiology, aetiology, progress and treatment 
of CAD are discussed, with particular interest in medical therapy and CABG. The 
main scope of the studies incorporated in this dissertation is on secondary 
prevention and long-term prognosis after CABG as well as postoperative 
employment and risk-factors affecting it. 
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2 REVIEW OF THE LITERATURE 
2.1 Definition of coronary artery disease 
Atherosclerosis is a lifelong process. Advanced lesions involve disorganization of the 
intima and deformity of the artery, but their precursors are latent minimal changes 
starting in the childhood with an increase in the number of intimal macrophages 
evolving into foam cells and fatty streaks 5. If primary prevention of coronary artery 
disease (CAD) fails, lesions grow gradually expanding to extensive coronary 
atherosclerosis found in autopsy studies even in patients without known CAD. At 
some point of life, the patient may exhibit acute coronary syndrome (ACS) and 
afterwards remain stable for years or even decades with few or no symptoms  6,7. 
In ACS, a gradually growing plaque or sudden thrombosis of ruptured or eroded 
plaque obstructs coronary blood flow. The patient may have severe underlying CAD, 
but on occasion there may be only non-obstructive coronary atherosclerosis or no 
angiographic findings at all. Coronary spasm, endothelial dysfunction, tachy- and 
bradyarrhythmias and various extracardial diseases may lead to imbalance between 
myocardial oxygen supply and demand, and thus to a clinical manifestation of ACS 8,9. 
2.2 Epidemiology of coronary artery disease 
Cardiovascular diseases (CVD) are the most common causes of death worldwide in 
all World Health Organization (WHO) regions, the only exception to this being 
Africa 10. Out of 54.7 million deaths occurring worldwide in 2016, 17.6 million (32%) 
were due to cardiovascular diseases11. CAD mortality peaked in  the 1960s in the 
United States and in the 1970s in Western Europe, including Finland 8,12–15. Since 
then this mortality has decreased in Finland to less than one fifth 16,17.  
The increase in death rates seen earlier in developed countries is nowadays seen 
in developing countries 10. According to Statistics Finland, the National Statistical 
Service, CAD mortality in Finland was 18.9% (10,183 out of 53,964 deaths) of total 
yearly mortality in 2016 18. According to Kela, the Finnish National Social Insurance 
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Institution, 174,596 inhabitants had special medical reimbursement for CAD in the 
same year 19.  
In Finland, the North Karelia Project was initiated in 1972 for a comprehensive 
community based cardiovascular (CV) prevention programme involving two 
provinces and subsequently extending nationwide 20. In 1972, men in Finland had 
the highest CV age adjusted mortality in the world, 500/100,000 and even higher in 
North Karelia, as shown in the Seven Countries Study 20,21. As a result of the 
programme in North Karelia risk factors fell, total cholesterol (TC) from 6.9 mmol/l 
to 5.4 mmol/l, blood pressure (BP) from 150/90 mmHg to 130/80 mmHg and 
smoking (men) from over 50% to less than 30% in the period 1972 to 2012. In North 
Karelia CAD mortality decreased during the study period from 690/100,000 to 
below 100/100,000, reaching the international average level. About 2/3 of the 
decline in CAD mortality can be explained by risk factor modification related to life 
style changes and 1/3 by the new treatments for CAD since 1980 20. Similar, although 
smaller changes in CAD risk factors were found around Europe as documented e.g. 
in Euroaspire studies since 1990 22. 
From the beginning of the 1970s the nature of coronary heart disease has evolved. 
Large, often fatal MIs in middle-aged men have been replaced by smaller non-fatal 
MIs in senior citizens. Beneficial life-style changes especially during the first decades, 
development of medical treatment, thrombolysis and coronary surgery since the 
1990s and eventually percutaneous coronary interventions in the 2000s have 
decreased CV mortality 15,22,23. 
2.3 The atherosclerotic process 
Atherosclerosis is a chronic arterial process involving inflammation. It leads to the 
formation of an atheromatous plaque, a focal lesion located within the intima of 
large and medium-sized arteries 24,25. Crucial for this process is the infiltration and 
retention of apolipoprotein B (apoB) containing lipoproteins, such as low-density 
lipoproteins (LDL) and remnants of very-low-density lipoproteins (VLDL) and 
chylomicrons, in the artery wall 26,27. 
To reach their target organ cells apoB containing lipoproteins have first to exit 
circulation 28,29. The endothelial cells of the arteries react to mechanical and 
molecular stimuli to regulate tone, haemostasis and inflammation throughout the 
circulation 30–32. The impaired integrity of this endothelial barrier is the initial step in 
atherosclerosis and is more likely to occur at arterial curves and branches  
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characterized by turbulent blood flow and low shear stress 33,34. This leads to 
increased accumulation and retention of subendothelial atherogenic apoB containing 
lipoproteins, essentially LDL 26,35. 
The flow of lipoproteins to the media layer is inhibited by a dense and elastic 
lamina between the intima and the media. Due to the properties of cell intima causing 
slow drain, the concentration of LDL particles increases to resemble that of plasma 
and tenfold to resemble that of the interstitial fluid of other cells 36. 
LDL particles remaining in the subendothelial space may become oxidatively or 
enzymatically modified. Cell cultures as well as animal studies and research 
conducted on CAD patients have shown that oxidation of LDL plays a key role in 
atherogenesis 37–43. Modified LDL induces intimal smooth muscle cells to excrete 
chemotactic proteins, which in turn contribute to the activation of endothelial cells 
and recruitment and transendothelial migration of circulating monocytes 44,45.  
Oxidized LDL is eventually taken up by the scavenger receptors (SRs) of monocyte-
derived macrophages in an uncontrolled manner 37,46. Once within the arterial wall, 
the return of macrophages to plasma is prevented by oxidized LDL 37,43,47. Thus, a 
continuous inflammatory process predominates in the atherosclerotic intima causing 
endothelial dysfunction.  
When accumulation of LDL is not matched with reverse cholesterol transport 
(RCT) (see next paragraph), macrophages may become saturated by cholesterol 
during the continuous process and turn into foam cells 47–49. When foam cells die, 
their cholesterol remains in the arterial wall forming the necrotic nucleus of an 
atherosclerotic plaque. Inflammatory macrophages stimulate infiltration and 
proliferation of vascular smooth muscle cells, which produce an extracellular matrix 
providing a stable fibrous barrier between the prothrombotic factors of the plaque 
and the circulating platelets 50. Recent studies also suggest that smooth muscle cells 
may undergo phenotype switch and give rice to a significant number of foam cells 
51. However, progressive inflammation renders stable plaques vulnerable, 
manifesting in increased smooth muscle cell death, decreased extracellular matrix 
production and collagen degradation by macrophage proteinases. Rupture of the 
thinning fibrous cap or its superficial erosion promotes thrombus formation causing 
clinical ischaemic events 8,52–54 (Figure 1).  
 
 
 
 21 
 
Figure 1.  Schematic view of the evolution of the atherosclerotic plaque 18,54,56.  ApoB: Apolipoprotein 
B, HDL: High-density lipoprotein (particle), LDL: Low-density lipoprotein (particle), OxLDL: 
Oxidized LDL. 
Apolipoprotein A1 (apoA1) is the major protein in high-density lipoprotein (HDL) 
and provides both its structure and function along with phospholipids. Small, 
discoidal pre-Ƣ HDL particles increase in size, creating larger, mature alpha-HDL 
particles as they collect cholesterol and are capable of delivering it to the liver for 
elimination 57. Macrophage cholesterol efflux to HDL reduces inflammation and 
oxidative stress and thus atherosclerotic burden, and is the first step in RCT 58–60. 
Epidemiological studies have shown an indisputable association between low high-
density lipoprotein cholesterol (HDL-C) and increased CVD risk independent of 
other risk factors 61,62. In recent studies, however, the rate at which cholesterol flows 
through the RCT pathway, named  HDL efflux capacity or HDL function, has been 
more closely associated with CAD risk than HDL-C 63,64. HDL particles carry a wide 
variety of proteins, lipids and nucleic acids, which contribute to their different 
beneficial functions. Besides RCT, anti-inflammatory, antithrombotic, anti-
apoptotic and anti-oxidative as well as endothelial barrier maintaining and hormone 
like cell-signalling properties are associated with HDL 27. 
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2.4 Risk factors of coronary artery disease 
Traditional risk factors of CAD, which were established in population based studies 
like the Framingham study, the Seven Countries Study and the FINRISK Study, 
comprise age, elevated TC, low HDL-C, current smoking, elevated blood pressure, 
male gender, diabetes mellitus (DM) and positive family history of CAD 21,65,66. 
Oxidation of LDL is exacerbated by smoking and increased angiotensin activity is 
associated with hypertension.  
Traditional risk factors are estimated to account for about 50% of CV events at 
individual level due to the complex interplay among CV risk factors, genetic 
predisposition and personal atheroprotective elements 65.  
2.4.1 Hypercholesterolaemia 
At any given level of hypercholesterolaemia there is considerable variation in the 
clinical manifestation of the disease. Even siblings with familial 
hypercholesterolaemia and very closely matched cholesterol levels may have clinical 
coronary heart disease at very different ages 67. Although the physiologic plasma 
concentration of low-density lipoprotein cholesterol (LDL-C) in several mammals 
including primitive human tribes is around 1.0-1.5 mmol/l, its concentration in 
Finnish population often is around 3 to 3.5 mmol/l, which increases the risk of 
developing atherosclerosis 17,68–71.  
In practice the atherosclerotic burden of lipoproteins is estimated by measuring 
TC, HDL-C and triglycerides (TG) and measuring or calculating LDL-C. It appears 
that apoB (reflecting the number of apoB-containing particles) is a risk marker equal 
to LDL-C, but seems to be less susceptible to laboratory error 72. Non-HDL-C 
comprises cholesterol located essentially in all pro-atherogenic lipoproteins and 
predicts CVD risk even better than LDL-C 73. In the most recent European 
guidelines issued by the European Society of Cardiology (ESC) on CVD prevention 
it has been proposed as a reasonable treatment goal, especially for patients with 
elevated TG 4. Further, the apoB:apoA1 ratio is apparently the strongest single CAD 
risk marker, but due to its laboratory costs, limited availability and insufficient 
evidence as a treatment goal, it is not routinely used 4,74. 
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2.4.2 Obesity and insulin resistance 
Obesity has become a widespread health issue in developed countries and an 
increasing problem even in developing countries 75. Internationally, the age-
standardized prevalence of obesity has increased from 3.2% in 1975 to 10.8% in 
2014 in men, and from 6.4% to 14.9% in women 76. Further, 2.3% of men and 5.0% 
of women are severely obese (BMI > 35.0 kg/m2) 76. 
In 2010, overweight (body mass index (BMI) 25.0 – 29.9 kg/m2) and obesity 
(BMI  30 kg/m2) were estimated to cause 3.4 million deaths, i.e. 3.9 years of life 
lost per person affected. Both genetic and environmental factors facilitate the 
development of insulin resistance. Chronic insulin resistance stimulates insulin 
secretion and subsequently progressive beta cell dysfunction, decreased insulin levels 
and increased plasma glucose can be observed 77–79.  
In obese patients the release of free fatty acids (FFA) and cytokines from adipose 
tissue impairs insulin sensitivity 79. FFAs have an attenuating effect on the 
phosphorylation of nitric oxide synthase resulting in decreased production of nitric 
oxide, endothelial dysfunction and vascular remodelling 80. They precipitate the 
oxidative process leading to increased expression of inflammatory adhesion 
molecules and cytokines.  
Once increased amounts of FFAs have infiltrated the liver, hepatic VLDL and 
apoB production are intensified resulting from increased substrate availability, 
decreased apoB degradation and increased lipogenesis. In metabolic syndrome 
(MetS) and type 2 diabetes mellitus (T2DM) patients these changes lead to a lipid 
profile characterized by decreased plasma concentration of HDL-C and increased 
concentrations of TG, remnant lipoproteins and small dense LDL particles, which 
are especially prone to oxidative modification 78,81,82.  
2.4.3 Metabolic syndrome  
Abdominal obesity and sedentary lifestyle are associated with insulin resistance and 
beta cell failure being followed by decreasing second-phase insulin response and 
continuing hyperglycaemia 83. Abdominal obesity along with hypertension, 
hyperglycaemia, hypertriglyceridaemia and decreased HDL-C are the key 
components of metabolic syndrome (MetS), and microalbuminuria, later addressed 
as albuminuria, has also been proposed as a component 84–86. MetS should however 
not be considered an absolute cardiovascular risk indicator, because it does not 
include many of the factors that determine absolute CV risk like age, sex, cigarette 
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smoking and LDL-C levels85. The cluster of cardiovascular risk factors called MetS 
is associated nevertheless with a two-fold increase in CVD risk and a five-fold 
increase in the development of T2DM 78,87–89.  
MetS was initially introduced in 1988 by GM Reaven, who originally proposed 
the concept of “syndrome X”, later renaming it MetS 90. Since then, multiple 
international organizations and expert groups have published their definitions of 
MetS 86. The definition most commonly used in recent years is a consensus statement 
agreed on by CV disease treating organizations and includes the IDF and 
AHA/NHLBI definitions, intended to harmonize MetS (Table 1) 85.  
Table 1.  Diagnostic criteria of metabolic syndrome (MetS). Diagnosis is made if any three of the 
                 criteria are fulfilled. Modified from Alberti et al 85. 
2.4.4 Type 2 diabetes mellitus 
In the pathophysiology of T2DM the crucial defects are insulin resistance, which 
stimulates insulin secretion, and progressive beta cell dysfunction, which is thought 
to be strongly genetically predisposed. These result eventually in decreased insulin 
concentration and gradually elevated blood glucose 77–79. 
Insulin resistance and its consequences have been associated with low-grade 
endothelial inflammation and dysfunction with further development of 
macrovascular disease even prior to the diagnosis of diabetes 83,91,92. T2DM results 
in a roughly two-fold excess risk for a wide variety of vascular diseases, regardless of 
other traditional risk factors. The adjusted hazard ratios are according to the 
Emerging Risk Factors Collaboration 2.00 for CAD, 2,27 for ischemic stroke and 
1,73 for the aggregate of other CV deaths 93. T2DM typically develops after middle 
Criteria of MetS 
Elevated waist circumference  
(according to population and country-specific definitions) 
Triglycerides  150 mg/dL (1.7 mmol/l) 
HDL-cholesterol < 40 mg/dL (1.03 mmol/l) in men and < 50 mg/dL (1.30 mmol/l) in 
women or drug therapy with fibrates or nicotinic acid 
Blood pressure  130/85 mmHg or antihypertensive treatment and history of 
hypertension 
Fasting blood glucose  100 mg/dL (5.6 mmol/l) or blood glucose lowering drug 
therapy 
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age, but due to increasing obesity in the young and in non-Caucasian populations, 
there is a trend towards a lower age of onset 78,94.  
2.4.5 Hypertension 
Treating hypertension was shown to improve exercise tolerance in patients with angina 
pectoris as early as in the 1960s 95. In a 10-year follow-up study of CABG patients, 
hypertension was already observed in the 1990s to be an incremental and independent 
risk factor of recurrent angina 96. The prevalence of hypertension in adults is 30-45% 
worldwide and has increased globally during the last two decades 4.  
There is a constant association between elevated blood pressure and the 
likelihood of cardiovascular events. According to epidemiological studies 
cardiovascular risk increases from very low blood pressure levels (BP), systolic BP 
115 mmHg, upwards 97,98. Recent studies strongly support the lowering of systolic 
BP below 130 mmHg in a wide range of CVD patients. The current guidelines 
recommend, when drugs are used, that BP should be lowered to <140/90 in all 
patients and to <130/80 in most patients 98,99.  
2.4.6 Sedentary lifestyle and physical activity 
Physical activity and exercise are essential in the prevention and treatment of CVD. 
Accordingly, sedentary lifestyle is one of the major risk factors for CVD 100. In a 
recent Finnish study both the number and accumulated length of exercise bouts were 
associated with CVD risk in primary prevention 101. Regular exercise also enhances 
endothelial function and arterial compliance and reduces oxLDL and local vascular 
low-grade inflammation 102–104. Both aerobic and exercise training should be 
encouraged. ESC guidelines recommend today at least 150 minutes of moderate 
intensity or 75 minutes of vigorous intensity training weekly 4. 
Several studies have addressed the effect of postoperative physical activity on 
recovery after CABG. Studies both immediately after the operation and later in 
secondary prevention have found that exercise training improves the recovery and 
exercise capacity of CABG patients 105–108. These lifestyle interventions are also 
important in the prevention and management of hypertension, MetS and T2DM, 
prominent risk factors for CVD 109–112. 
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2.4.7 Other risk factors of coronary artery disease 
Sleep disorders are connected with cardiovascular (CV) prognosis. A recent meta-
analysis found a significant association between getting less than six hours’ sleep and 
increased risk of stroke, myocardial infarction (MI) and congestive heart failure and  
between more than eight hours’ sleep and angina symptoms 113. Untreated 
obstructive sleep apnea has been related to CV outcomes in several studies 114.  
Psychological stress has been analysed in multiple reports, but due to discrepancy 
in the stress models used, the best evidence of psychosocial stress as a CV risk factor 
is still to be found in epidemiological studies 74,115. At individual level, it has been 
shown that acute mental stress increases vascular reactivity and decreases endothelial 
function resulting in apical ballooning syndrome or so-called Takotsubo 
cardiomyopathy 65,116.  
Some epidemiological studies have associated moderate alcohol consumption 
with decreased CV risk 74,117. A large meta-analysis of 59 epidemiological studies 
found on the contrary no evidence for the benefit of even moderate alcohol 
consumption, thereby suggesting that any amount is associated with elevated BP and 
BMI 118. According to current ESC guidelines on CV disease prevention, alcohol 
consumption should be limited to 20 g/day alcohol beverages for men and 10 g/day 
for women. Drinking 30 g or more daily is associated with higher CVD risk 4. 
Endothelial dysfunction is a systemic disorder widely affecting arterial circulation. 
Like elevated concentration of high-sensitive C-reactive protein, it can be regarded 
as a sum of overall CV risk factors, genetic risk and environmental elements and also 
of vasculoprotective factors 65,119,120. Likewise arterial stiffness is associated with 
increased CAD risk in MetS patients 89,121.  Both endothelial dysfunction and arterial 
stiffness can be seen as an interphase between CAD risk factors and actual disease 
and may form an attractive target in optimizing individualized treatment 119.  
The risk and protective factors of coronary artery disease (CAD) are summarized 
e.g. in the INTERHEART Study 74. This was a standardized case control study of 
acute MI in 52 countries representing every inhabited continent with ~15,000 cases 
and controls. Current smoking, diabetes, hypertension, abdominal obesity, 
psychosocial factors and abnormal ratio of lipid particles were found to be risk 
factors, while consumption of fruit and vegetables, regular physical activity and 
alcohol consumption were reported to be protective factors. Together, they 
accounted for 90% of the population attributable risk in men and 94% in women 
(Figure 2) 74. The strongest single predictors of CV outcome have been smoking, 
hypercholesterolaemia, hypertension and diabetes mellitus in the INTERHEART as 
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well as in many other studies. The risk depends on the number of cigarettes smoked, 
cholesterol concentration and duration of DM 4. The risk is cumulative so that every 
risk factor increases and every protective factor decreases the probability of the index 
outcome in individual subjects 66.  
Figure 2.  Association of risk and protective factors with acute myocardial infarction in men (blue 
square) and women (red square) after adjustment for age, sex and geographic region 
(presented on a logarithmic scale). Above 1 risk is increased. Modified from Yusuf et al 
2004 74.  
2.5 Treatment of coronary artery disease 
Treatment of coronary artery disease comprises risk-modifying i.e. preventive 
therapy and symptomatic treatment. The target of secondary prevention of CAD is 
to enhance long-term survival and quality of life 122. Treatment includes lifestyle 
changes and medical treatment. Statins, other cholesterol lowering medications like 
proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors and ezetimibe, 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II type 1 receptor 
blockers (ARB) and acetylsalicylic acid (ASA) and, with certain limitations, Ƣ-
blockers are considered effective means in the secondary prevention of coronary 
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artery disease 4,123,124. Nitrates and calcium channel inhibitors have been found to be 
symptomatic treatment of CAD 125,126. 
Approximately 25% of deaths in CAD are sudden cardiac deaths, the risk being 
higher in men and older persons due to the increasing prevalence of CAD in those 
patient groups 127,128. In spite of improved primary and secondary prevention of 
CAD and better early revascularization strategies, some patients still end up with 
severely damaged left ventricles (LV). Primary treatment in ischaemic LV 
dysfunction is early revascularization and optimized medical treatment of CAD 
because ejection fraction may recover after revascularization. ICD/CRT is 
recommended to reduce all-cause mortality in patients with symptomatic heart 
failure and LBBB if ejection fraction remains < 35% despite at least three months 
of optimal pharmacological therapy 128. 
2.5.1 Lifestyle changes 
Lifestyle management has a decisive role in the treatment of CVD. Smoking 
cessation, limited salt and alcohol intake, weight loss in obese patients and healthy 
nutrition are of central importance 4,129–133. Healthy diet includes limited intake of 
saturated fatty acids and transisomers of fatty acids as well as monitored 
carbohydrate consumption and increased intake of dietary fibre 134–136.  
In a series of epidemiological FINRISK studies, based on the North Karelia 
project, lifestyle changes have been monitored in Finland for 40 years between 1972 
and 2012. During this period, smoking prevalence has halved in men and the 
unfavourable increasing trend in female smoking has turned into decrease. On the 
national level smoking has further decreased. In 2016, 16% of men and 15% of 
women were smokers. Between 1972 and 2012 T-C decreased 21%, in men to 5.4 
mmol/l and in women to 5.3 mmol/l and systolic BP 10%, in men to 136 mmHg 
and in women to 129 mmHg and 20,22.  
The Finnish Diabetes Prevention Study and the American Diabetes Prevention 
Program were conducted to determine the usefulness and impact of a lifestyle 
programme designed to prevent or delay the onset of T2DM in subjects with 
impaired glucose tolerance 137,138. Lifestyle intervention incorporating physical 
activity and dietary chances, which reduced intake of total and saturated fat and 
increased intake of fiber, resulted in a weight loss and reduced the risk of new-onset 
diabetes by 58% 137,138. The effect of the lifestyle intervention proved lasting in a 
follow-up survey of the Diabetes Prevention Study three years later 139. A 
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corresponding benefit of lifestyle intervention has later been confirmed in other 
diabetes prevention programmes 140,141.  
2.5.2 Drug therapy 
It is possible to delay the progression of coronary artery disease and even to convert 
the process to regression with effective drug therapy. Obvious positive effects on 
survival after CABG have been achieved with statins as such and in combination 
with certain other lipid lowering medications, several antiplatelet drugs, beta blockers 
and ACE inhibitors as well as ARBs 4,131. 
2.5.2.1 Statin therapy 
The crucial role of hypercholesterolaemia in the progress of CAD and the favourable 
prognostic value of lowering it with statins are extensively documented 4,142–144. 
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, the rate limiting 
enzyme of the mevalonate pathway of cholesterol synthesis. Inhibition of this 
enzyme decreases cholesterol production in the liver and thus activates the LDL 
receptors of the liver cells. This results in improved clearance of LDL-C from the 
bloodstream and decrease of LDL-C concentration in plasma 145,146. In addition to 
their lipid-lowering effects, statins have been suggested to have pleiotropic effects; 
for example they increase apoA-1 concentration, improve endothelial function and 
inhibit inflammatory response thus stabilizing the plaque as well as downregulating 
blood coagulation and platelet function 147–151 (Figure 3). 
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Figure 3.  Cholesterol synthesis and statin mode of action (modified from Mason 2003) 146,151,152. 
HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme-A, PP: Pyrophosphate, NO: Nitric oxide. 
The first statin mega-trials in secondary prevention, namely the 4S 153, CARE 154 and 
LIPID 155, demonstrated that cholesterol lowering treatment with statins improved 
the prognosis of patients with CAD when compared with a placebo. Evidence on 
the efficacy of statins in preventing CVD events in diabetes was provided by the 
subgroup analysis of the Heart Protection Study (HPS) 156 and the Collaborative 
Atorvastatin Diabetes Study (CARDS) 157. Studies like the Post Coronary Artery 
Bypass Graft Trial 158, REVERSAL 159 and Prove-It Timi 22 160 and a meta-analysis 
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of several studies 161 showed the advantage of aggressive statin versus moderate 
statin therapy in patients with CVD. Finally, the ASTEROID and SATURN trials 
demonstrated that aggressive lipid lowering to a mean plasma concentration of 1.6 
mmol/l resulted in significant regression of atherosclerosis in CVD patients 1,162,163.  
In the recent literature, statins as a group have been found to be diabetogenic. 
The effect seems to be dose-dependent and apparent in most effective statins. The 
mechanism is associated with impaired insulin sensitivity and insulin secretion. The 
excess risk of T2DM is considered to be 9 – 46% in most population based studies, 
depending on the population studied 164,165.  
Taken together, controlled prospective trials involving over a hundred thousand 
patients have consistently demonstrated the effectiveness and safety of statin 
treatment in the prognoses of CVD patients 166,167. In light of mounting evidence, 
the 2016 European (ESC) guidelines on cardiovascular disease prevention in clinical 
practice recommend for patients at very high cardiovascular risk an LDL-C goal < 
1.8 mmol/l (< 70 mg/dL), or a reduction of at least 50% if the baseline is between 
1.8 and 3.5 mmol/l 4. The current state of lipid-goal attainment has been evaluated 
in large analyses both in the US and Europe 22,136,168. According to them, only 20% 
to 26% of high CV risk patients achieve LDL-C < 1.8 mmol/l. Consequently, many 
patients without statin therapy or with insufficient cholesterol lowering drug therapy 
experience recurrent CV events 169,170. 
2.5.2.2 Other cholesterol lowering drug therapies 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme involved in the 
regulation of LDL receptors and LDL-C. By targeting LDL receptors for destruction 
in the liver, PCSK9 increases concentrations of LDL-C. When its action is blocked, 
concentration of LDL-C in plasma is reduced 171,172. Currently two monoclonal 
PCSK9 inhibitors are commercially available, alirocumab and evolocumab.  The 
efficacy in reducing LDL-C and coronary atheroma volume was recently shown and 
the first large-scale prognostic study results in reducing CV events in secondary 
prevention of high-risk patients were just published with significantly better prognosis 
in the active arm when compared with the placebo 2,173,174. With evolocumab CV 
benefit has even been shown  at LDL-C concentrations below 0.5 mmol/l 173. Large-
scale, randomized phase III prognostic trials will eventually reveal their long-term 
benefits and harms and determine their significance for clinical practice. 
Ezetimibe is a compound which blocks intestinal cholesterol absorption and thus 
decreases plasma LDL-C concentration. It has been on the market for a long time 
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but with scanty prognostic evidence. The IMPROVE-IT trial (n=18,134), with a 
median follow-up of seven years, failed to show the benefit of ezetimibe over 
placebo in mortality when added to simvastatin 175. However, ezetimibe significantly 
reduced primary endpoint, the risk of a composite of CV death, major coronary 
events, or stroke. The effect of ezetimibe on the primary endpoint was greater in 
patients with prior CABG than in those without 176.    
2.5.2.3 Antiplatelet and antithrombotic therapy 
Acetylsalicylic acid prevents platelet aggregation and  has been widely used in the 
treatment of CAD patients since the 1970s 177. In CABG patients ASA prevents 
adverse CV events and improves long-term survival by reducing the odds of graft 
occlusion when administered in low to medium daily doses (100 – 325 mg) 178–180. In 
ASA-treated patients early graft occlusion rates have, however, been high, which is 
attributed to ASA resistance, a phenomenon where ASA is unable to effectively 
inhibit platelet function 181.  
In patients with existing myocardial infarct (MI), stroke or peripheral arterial 
disease, clopidogrel, a thienopyridine antiplatelet agent that irreversibly inhibits the 
platelet P2Y12 receptor, has shown slight superiority with respect to ASA 182. 
Combining ASA therapy with clopidogrel tends to have potent synergistic 
antithrombotic effects 183. Several clinical trials to date have evaluated the use of 
clopidogrel after CABG with mixed results 184. The benefit for dual antiplatelet 
therapy in reducing vein graft occlusion seems to be most applicable in patients 
undergoing off-pump surgery rather than on-pump surgery due to relative 
hypercoagulable state and increased postoperative platelet activity in the former 
procedure 131,184,185. The secondary prevention statement of the AHA has 
recommended ASA alone for the majority of patients after CABG, whereas 
clopidogrel should be combined with ASA after off-pump surgery 131. It should be 
noted, that a genetic Clopidogrel resistance exists due to P2Y12 receptor gene 
polymorphism with potential effects to its antithrombotic efficacy 186. 
Newer P2Y12 inhibitors, prasugrel and ticagrelor, have a more rapid onset of 
action than clopidogrel, and also more potent platelet inhibition and better prognosis 
in acute coronary syndromes 187,188. Several trials are now ongoing to investigate their 
future role in the treatment of CABG patients. 
Warfarin has been compared to ASA in several studies, notably in the 1980s and 
1990s. When used alone or in combination with ASA it has reportedly not improved 
graft patency 179. According to the current AHA guidelines, warfarin therapy should 
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be reserved for CABG patients with other indications for its use, such as atrial 
fibrillation, a history of deep vein thromboembolism and for those undergoing valve 
replacement in conjunction with CABG 131. 
2.5.2.4 Beta-blocker therapy 
In the prevention of atrial fibrillation after CABG, treatment with beta-blockers is a 
key therapy 189. Patients discharged with beta-blockers have a decidedly lower 
mortality rate during long-term follow-up after cardiac surgery 190. Due to side-
effects and lower BP reducing efficacy compared to other antihypertensive agents, 
beta-blocker therapy should not be used for hypertension after CABG, but should 
be reserved for patients with other cardiovascular conditions such as history of MI, 
heart failure and left ventricular dysfunction and thus, at risk of ventricular 
tachycardia 128,191,192.  
2.5.2.5 Inhibition of the renin-angiotensin-aldosterone system 
Drugs inhibiting the activity of the renin-angiotensin-aldosterone system have been 
widely studied. The effects of ramipril on high-risk patients with evidence of either 
vascular disease or diabetes were studied in the large HOPE trial 193,194. Ramipril 
proved beneficial over placebo in reducing mortality, recurrent CV events and 
nephropathy 193,194. Further, in the EUROPA trial, patients with stable CAD on 
perindopril had better CV prognosis than those on placebo 195. In both ACE-
inhibitor studies, the average patient had high normal BP, and systolic BP decreased 
by 3-5 mmHg more in the active treatment group than in the controls. In the ON-
TARGET Study the ARB telmisartan was found to be equivalent to ramipril for 
high-risk patients in preventing major CV endpoints but the combination of the two 
drugs was associated with no additional benefit and more adverse events 196. 
Moreover, in the ONTARGET/TRANSCEND study telmisartan and ramipril were 
equally good and better than placebo in reducing LVH 197. Therefore, ACE 
inhibitors or ARBs should be considered for patients with CAD or at high risk of 
developing it.  
The ACE inhibitor quinapril has been evaluated in two trials early after CABG. 
The results suggest that ACE inhibitors are beneficial after CABG, but their 
initiation should be individualized according to the patient’s associated risk factors, 
the greatest benefit being experienced after the first three months 198,199. Due to their 
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cardioprotective and renoprotective effects, the use of ACE inhibitors or ARBs  has 
been recommended for patients after CABG, especially for those with previous MI, 
heart failure or left ventricular dysfunction, hypertension, diabetes mellitus or 
chronic kidney disease 131,200. 
2.5.2.6 Treatment of hypertension 
In general, lifestyle changes, weight loss in obesity and modern drug therapy for 
elevated BP improve hypertensive patients’ CV prognosis 98. When studying various 
treatments, ACE inhibitor captopril was compared with beta-blocker and diuretic in 
the CAPP Study in hypertensive patients. Captopril was found to be superior to 
other medications in preventing CV events in patients with DM, although in other 
patients no such benefit was  identified 201,202.  
In the LIFE Study losartan, was compared with atenolol in the treatment of 
hypertension with LVH and found to be superior in preventing CVD mortality as 
well as all-cause mortality. New-onset diabetes was also less frequent in the losartan 
group. In patients with DM mortality results were comparable to those of all study 
patients and albuminuria was less frequent in losartan-based treatment 203,204. In 
hypertensive patients amlodipin has reportedly provided protection against MI and 
stroke in several trials 205. To prevent CAD complications in hypertensive patients 
who do not achieve their BP goal by taking ACE inhibitors or ARBs, calcium 
channel blockers, especially long-acting dihydropyridine calcium channel blockers 
and diuretics may be used as next therapy choices 192,206.  
2.5.2.7 Glucose-lowering drug therapy in T2DM 
In the landmark studies of CVD carried out during the last twenty years, 20 – 60% 
of patients have had diabetes 156,159,207,208, which underlines the significance of DM 
among CVD patients. On the other hand, diabetes is a known risk factor for CVD. 
T2DM, having lasted for a decade or co-occurring with proteinuria or with impaired 
kidney function, is considered a CAD risk-equivalent state 209–211.  
In T2DM patients the results with glucose-lowering drug therapy on total or 
cardiovascular mortality have been variable and often disappointing 212–216. Some 
studies even found that various glucose-lowering medications, in spite of improving 
glycaemic control and reducing the risk of microvascular complications, may 
increase the risk of CV events 217,218.  
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Among the controlled randomized trials carried out during the last 20 years the 
occurrence of CV death has been significantly reduced only through therapy with 
three types of drugs, namely metformin, glucagon-like peptide-1 receptor (GLP-1) 
agonists liraglutide and semaglutide, and some sodium glucose cotransporter 2 
(SGLT2) inhibitor group drugs  219–226.  
The UKPDS Study showed the benefits of intensive glucose lowering therapy 
against conventional therapy with diet in recently diagnosed diabetes patients. In 
overweight patients those assigned to drug therapy with metformin had a 
significantly lower risk of MI and overall mortality compared to those treated 
conventionally 219. In a follow-up study of the UKPDS, 10 years after the cessation 
of randomized interventions, the risk reduction in MI mortality in patients initially 
treated with metformin persisted 221.  
In the recently published large LEADER trial, patients with GLP1 analogue 
liraglutide had a 13% lower risk for composite CV endpoint of CV death, non-fatal MI 
or non-fatal stroke compared to those with placebo when liraglutide was added to usual 
medical therapy 222. In a smaller Sustain-6 trial corresponding results with significant 
reduction in composite CV endpoint were seen in semaglutide treatment 227. 
In the EMPA-REG Study, patients on empagliflozin treatment had a 14% relative 
risk reduction in composite CV endpoint. These favourable results were mainly due 
to a reduction in complications associated with heart failure and not with CAD 223. 
Similar benefits in heart failure related cardiac outcomes were recently found with 
canagliflozin in CANVAS trial and with dapagliflozin in DECLARE study 223–225.  
Trials using pioglitazone, have shown decreased CV mortality, but the tendency 
to increased adipose tissue mass and fluid retention followed by congestive heart 
failure have restricted the use of this glucose-lowering medication 228–231.  
Apart from the UKPDS 212, the impact of insulin treatment on CV outcomes had 
not been extensively studied until the Origin Study 232. The latter showed that basal 
insulin-glargine, when compared to standard non-insulin care, had a neutral effect 
on cardiovascular outcomes, but modestly increased weight. 
2.5.3 Cardiac Interventions 
Angina pectoris is associated with impaired quality of life in stable coronary artery 
disease, reduced physical endurance, mental depression and recurrent 
hospitalizations and outpatient visits 233. Revascularization by either PCI or CABG 
is indicated in flow-limiting coronary stenosis to reduce myocardial ischaemia and 
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related adverse clinical manifestations. In non-emergent patients, coronary artery 
bypass grafting (CABG) also improves survival of patients with left-main and/or 
multivessel disease 234,235. 
In acute ST-elevation myocardial infarction (STEMI) primary PCI has replaced 
fibrinolysis, provided it can be performed in high-volume PCI centres without delay 
236. In selected cases in patients anatomically unsuitable for PCI and in cardiogenic 
shock, CABG may also be considered for acute STEMI patients 237. 
Since 1993, the number of CABGs in Finland first increased from over 3,000 
annually to 4,500 in 1997 and then decreased to 3,500 in 2006 and further to below 
1,400 in 2017. During the same time period PCIs multiplied from a few hundred to 
9,000 in 2006 and almost 14,000 in 2017 (personal communication professor 
emeritus Matti Tarkka, University of Tampere) 238,239. It seems likely that during the 
next few years the number CABGs will remain constant but that of PCIs will 
continue to increase (personal communication, docent Vesa Virtanen, University of 
Tampere) (Figure 4). 
 
 
Figure 4.  Number of coronary artery bypass grafting (CABG) and percutaneous coronary 
intervention (PCI) done in Finland from the beginning of the study. Since 2006 the data is 
based on the statistics of the Finnish Cardiac Society, before that year it is estimated from 
several sources (personal communications professor emeritus Matti Tarkka and docent 
Vesa Virtanen) 238,239. 
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2.5.3.1 The early years of coronary artery bypass 
A crucial point in modern CAD treatment was the development of coronary 
angiography and thus the ability to identify stenosis and occlusions requiring targeted 
therapy. The first CABGs were done in the mid-1960s with internal thoracic artery 
anastomosis by Kolesow and saphenous vein bypass from the ascending aorta to the 
anterior descending coronary artery by DeBakey and Favaloro 240,241. When more 
than 10,000 CABG procedures performed before 1971 were evaluated, it was found 
that 60 – 70% of patients had become asymptomatic and as many as 95% had fewer 
symptoms 242. On the other hand, the rates of operative mortality and MIs were high 
at the time, up to 10% and 15% in some large series, although decreasing gradually 
as experience accumulated 241.  
While it was evident that CABG relieved angina, it was uncertain whether it also 
improved the long-term prognosis of CAD. The first modern prospective studies 
comparing medical therapy to elective CABG in selected patients with stable angina 
pectoris were published in the late 1970s. These were the Veterans Administration 
(VA) Cooperative Study in 1972 – 74 243, the European Coronary Surgery Study in 
1973 – 76 244 and the Coronary Artery Surgery Study in 1975 – 79 245 forming the 
basis for clinical decision-making in the early 1980s. A meta-analysis of these and 
several other trials showed the benefit of CABG over medical therapy during 10-
year follow-up in medium and high-risk CAD patients 246. 
2.5.3.2 Evolution of coronary artery bypass techniques 
During the early decades, CABG surgery was performed using cardiopulmonary 
bypass (CPB) and the anastomoses were performed on the arrested heart. Myocardial 
protection was deemed crucial because perioperative myocardial injury led to left 
ventricular dysfunction and thereby poorer prognosis 247. Advanced anaesthesia and 
CPB techniques, shorter operating times as well as more precise suturing and, possibly 
most crucially, developing myocardial protection, all reduced myocardial injury 248.  
In the 1960s and 1970s saphenous vein graft (SVG) was mainly used in bypass 
procedures. In 1978 it was shown that venous bypass grafts occlude early and during 
the following years it was discovered that the failure rate was affected by graft 
thrombosis (early failure), intimal hyperplasia (late failure) and atherosclerosis (late 
failure) 249–252. First internal thoracic artery grafting to the left anterior descending 
artery (LAD) yielded superior graft patency and survival compared to the use of SVG 
grafts alone and some years later bilateral internal thoracic artery grafting turned out 
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to be even more favourable 253,254. The radial artery proved its suitability for grafting, 
especially when its tendency to spasm and intimal hyperplasia had been solved by 
medical therapy 255,256. Various techniques became available to achieve complete 
revascularization in multi-vessel coronary artery disease. In addition to internal 
mammary arteries and SVGs, the right gastroepiploic artery may also be used for 
anastomosis to the proximal descending artery or to the proximal right coronary 
artery and a hybrid procedure with PCI for non-LAD targets can be combined with 
minimally invasive left internal mammary artery (LITA) grafting to LAD 257. 
CABG is most frequently done using cardiopulmonary bypass and cardioplegic 
arrest, which provide a stable and bloodless operating environment. Its complications 
have been systemic inflammatory response, increased red cell damage and risk of 
cerebrovascular embolization arising from manipulation and clamping of the 
ascending aorta 258. Numerous technical improvements in perioperative care and 
myocardial protection, the implementation of sophisticated cardiopulmonary bypass 
and off-pump CABG methods, as well as optimizing postoperative medical treatment 
have improved operative results 241,259–261. LITA-to-LAD minimally invasive 
procedures using a left mini thoracotomy and video-assisted LITA harvesting were 
introduced in the 1990s, gradually decreasing the operational risks 262. Advanced video-
assisted procedures and computer-assisted entirely endoscopic CABGs without the 
use of CPB have recently yielded excellent short-term results 235,263.  
2.5.3.3 Prognosis after coronary artery bypass 
All in all, 30-day survival after surgery has improved, even though patients have 
become older and operative risks greater. Operative mortality in elective CABG is 
currently in the range of 1-3% 264. The incidence of stroke, predominantly ischaemic 
in nature, is also 1 – 3% of CABG patients 265. Other significant complications of 
CABG are postoperative myocardial injury, renal failure, delirium, deep sternal 
wound infection, mediastinitis and atrial fibrillation 241,266. 
The long-term advantage of CABG over medical therapy is more evident in 
patients with complex coronary disease, especially in those with left main disease 246. 
Later trials have also shown benefit of CABG over medical therapy in previously 
challenging patients such as those with left ventricular dysfunction 267–269.  
According to the World Health Organization’s definition, health is not only a 
biomedical, but also a biopsychosocial issue 270. Health related quality of life 
(HRQoL) comprises physical, psychological and social well-being 271–273. In the latest 
systematic review and meta-analysis both PCI and CABG showed significantly 
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bigger positive effect on patients’ HRQoL than did medical treatment. Between 
operative approaches there was no significant difference in HRQoL 273. 
2.5.3.4 Percutaneous coronary interventions 
The first PCI was performed by Andreas Grünzig in 1977 274,275. Over the decades 
PCI techniques have also undergone several major improvements. PCI was first 
done with only balloon angioplasty, but followed by bare metal stents (BMS) and 
drug eluting stents (DES) 276. Stent restenosis has also decreased since recent studies 
demonstrated the advantage of DES and drug-coated balloons for this indication 
277,278. Together with these advances, improvements in antiplatelet and 
antithrombotic treatment have reduced adverse events, especially the need for repeat 
revascularizations 275. PCI compared with optimal medical treatment has repeatedly 
shown benefit in relief from angina. However, in long-term prognosis both 
approaches have been equally good 279–281. 
2.5.3.5 Coronary artery bypass grafting compared with percutaneous coronary 
interventions 
After the landmark trial, the Bypass Angioplasty Revascularization Investigation (BARI) 
282, the prognosis following CABG has been compared to that following PCI over the 
past three decades. Surgery was first compared with balloon angioplasty 282,283, then with 
BMS and finally with DES 284–286. The total of almost 30 trials has shown the trend or 
superiority of CABG over PCI in the prognoses of patients with left main disease or 
complex multivessel disease i.e. patients with high Syntax score 275,287. 
A recent trial comparing CABG with everolimus eluting stents in patients with 
multivessel CAD and severe left ventricular dysfunction highlights the differences in 
outcomes between the procedures. PCI was associated with higher risk of MI and 
repeat revascularizations, whereas CABG was associated with higher risk of stroke 
288. In patients with diabetes mellitus CABG was associated with a clearly better 
prognosis than PCI (Table 2) 289. The current ESC revascularization guidelines 
recommend CABG instead of PCI for patients with diabetes and three-vessel disease 
and for patients without diabetes with left main or three vessel disease with medium 
or high anatomical complexity (syntax score) 235,289,290. 
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Table 2.  Coronary artery bypass grafting (CABG) and percutaneous intervention studies (PCI) 
                 studies: Cumulative meta-analysis by year of publication of the difference in all-cause 
                 mortality between CABG and PCI in patients with and without diabetes. Modified from 
                 Herbison (article includes original references) 289. Balloon: PCI without stenting, BMS: 
                 bare metal stent used, DES: drug eluting stent used, NS: Not significant. 
2.6 Life after CABG  
2.6.1 Resuming work after CABG      
The median age of CABG patients is rising, in the most recent large-scale studies 
being 63 to 65 years 284–286,288,291. Roughly 50% of patients operated on are still in 
working age depending on the country of residence and retirement system. In recent 
years return to work after CABG has increased up to 59 to 87% varying due to the 
time and country of the study. In particular, the return to work of older people has 
improved 292–298. During the first postoperative year 7% to 30% have had angina 
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pectoris symptoms 299,300 and 7% experienced neuropsychological defects as 
determined six months after CABG 291,301. Results were first improved using off-
pump coronary artery bypass grafting but in later studies on-pump technique has 
shown comparable outcomes 261,302,303. 
One in five of patients have reported their quality of life to be postoperatively no 
better than before the CABG 304. Subjective well-being is not related to physical 
status. The reasons for difficulties in returning to work after CABG are 
multifactorial. Hence, psychological and socioeconomic factors may even play a 
more decisive role than medical factors themselves 298,305–308. Staying at work also 
varies across countries. Most studies addressing postoperative working are focused 
on the first 12 months after CABG. Studies with a longer follow-up are rare 296,309. 
The direct and indirect costs of CAD are enormous. Besides the financial burden, 
loss of leisure time activities and psychological stress are other significant losses for 
patients 310. The restoration of normal functional capacity and quality of life, in which 
the resumption of professional activity is an important element, can be considered a 
major objective of coronary surgery 293,311. 
2.6.2 CABG: Postoperative survival  
2.6.2.1 Impact of statin treatment on survival  
Impact of statin treatment on survival has been widely studied from different 
aspects. Its influence on prognosis after coronary syndromes and coronary 
procedures has been the focus of a multitude of studies, but lately short-term 
postoperatrive prognosis has also been reported. Preoperative statin therapy has 
been shown to be associated with decreased early cardiac mortality in general and 
more closely in hyperlipidaemic CABG patients 312–315. 
Several studies have investigated the impact of statin treatment on postoperative 
cholesterol reduction after CABG. One of the landmark studies is the Post-CABG 
trial, where 1,351 patients who had had CABG earlier were randomized to aggressive 
or moderate cholesterol treatment. The aggressive treatment arm got lovastatin 40-
80 mg daily achieving on average cholesterol levels of 2.5 mmol/l and the moderate 
treatment arm lovastatin 2.5 to 5 mg daily reaching on average 3.5 mmol/l during 
the study period. According to angiographic findings four years later, aggressive 
cholesterol treatment decreased the incidence of new vein graft occlusion (10% v. 
21% aggressive v. moderate treatment) 316. After extended follow-up of three more 
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years, the aggressive treatment arm had a 30% lower need for repeat 
revascularization and a 24% reduction in adverse cardiovascular events 158. 
Altogether, the Post-CABG Trial showed that aggressive lowering of LDL-C below 
100 mg/dL (2,6 mmol/l) reduces both CV events and the progression of 
atherosclerosis in native coronary arteries and saphenous vein grafts 158,316. On the 
whole in vitro and clinical studies have shown reduced progression of native 
coronary artery disease 317 and vein graft atherosclerosis 252,318–320.  
Some studies have focused on high-intensity statin therapy to achieve an LDL-C 
reduction to < 1.8 mmol/l. In the Treating to New Targets (TNT) trial, 10,001 CAD 
patients were randomized to two study arms receiving either atorvastatin 80 mg or 
atorvastatin 10 mg daily. In those 4,654 patients who had previously undergone 
CABG, intensified statin therapy was associated with 27% lowered risk for CV events 
over a 4.9-year follow-up 321. Other studies have come to similar conclusions 208,252. 
The AHA guidelines in 2015 on secondary prevention after CABG emphasize 
the importance of long-term high-intensity statin treatment for all patients under 75 
years of age in the absence of contraindications such as liver disease 131. For patients 
older than 75 a lower statin dose is recommended 322. The corresponding ESC 
guidelines are addressed in Chapter 2.5.2.1. 
Several studies have reported prognoses of CABG patients in recent decades. In 
the Randomized Intervention Treatment of Angina (RITA-1) trial, the patients were 
randomized to CABG or PCI in 1988 – 1991. In the CABG group, after 6.5 years’ 
follow-up, the cumulative rate of death was 8.6% and that of MI 7.4% 323. In  recent 
studies 5-year mortality has been between 5% and 15%, depending, for instance, on 
patients’ age, other concomitant morbidities and severity of CAD 324,325. Altogether, 
in multiple studies carried out during the last three decades, the mortality of CABG 
patients has decreased annually by 7% 289. 
2.6.2.2 Impact of obesity and metabolic syndrome on survival 
Obesity increases the likelihood of major CV disease risk factors such as 
dyslipidaemia, elevated blood pressure and glucose abnormalities associated with 
MetS and T2DM. It thus increases the risk of CAD. However, in spite of these CV 
disease risk factors, obese patients with established CAD typically have had a better 
prognosis than normal weight patients with the same disease. This phenomenon is 
called the obesity paradox 326. 
The epidemiology of MetS has been widely evaluated 327–329. MetS can be used as 
a tool to characterize patients at elevated risk 102,330,331. Several studies have suggested 
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that the risks of premature death and cardiovascular disease or diabetes are higher 
among subjects with MetS than among those without. However, follow-up studies 
on long-term survival after CABG have yielded contradictory results with regard to 
the impact of MetS 332,333. 
2.6.2.3 Impact of diabetes mellitus on survival 
Diabetes mellitus is a major cardiovascular risk factor 74,209. There is a considerable 
body of evidence of poor early outcome and higher in-hospital morbidity among 
patients with DM than among those without it after CABG 334–336. On the other 
hand, the association of diabetes with over 10-year survival after CABG has not been 
extensively evaluated. The few trials studying the long-term prognosis of CABG 
patients with diabetes have come to varying conclusions 336–339. 
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3 AIMS OF THE STUDY 
In the present study the postoperative prognosis of CABG patients for up to 20 
years was studied. The specific aims of this study were as follows: 
 
1. To ascertain whether CABG patients return to work after surgery and 
factors affecting postoperative employment.  
2. To determine the retention of CABG patients at work after surgery. 
3. To explore lipid treatment practices in recently operated CABG patents in a 
longitudinal analysis over a 20-year timespan. 
4. To study total and CV mortality related to overweight and obesity in 20-year 
follow-up after CABG. 
5. To document long-term survival according to metabolic status after CABG 
in relation to back-ground population. 
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4 SUBJECTS AND METHODS 
4.1 Patients 
This study includes two different populations. The population for the follow–up studies 
originally comprised 961 CABG patients operated on in the period 1 January 1993 
– 30 June 1994 at Tampere University Hospital (TAUH) and treated postoperatively 
in secondary care hospitals of TAUH expert responsibility area. After exclusions, 
922 patients were included in the analyses. The population for the annual cohorts 
consisted of 953 CABG patients operated on at Tampere University Hospital and 
treated postoperatively in Kanta-Häme Central Hospital during the time period 1 
January 1990 – 31 December 2009. Of these 946 were included in the analyses. 
Patients operated on with CABG during the period 1 January 1993 – 30 June 1994 
at Tampere University Hospital and treated postoperatively at Kanta-Häme Central 
Hospital (n=76) were included in both studies. Consequently, altogether 1,791 
postoperative CABG patients were included in the analyses (Figure 5). 
 
Figure 5.  Patient populations of the studies. TAUH: Tampere University Hospital, KHCH: Kanta-
Häme Central Hospital. Numbers I to V refer to the original publications of the studies. 
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4.1.1 Follow-up studies 
The population of the follow–up studies consisted of all CAD patients who had 
undergone CABG at Tampere University Hospital between 1 January 1993 and 30 
June 1994. Patients having simultaneous valve or carotid artery surgery were also 
included in the study. Those who survived beyond the immediate postoperative 
period of two months were included in the analyses and followed for up to 20 years.  
The catchment population of the hospital comprised 1.2 million inhabitants living 
in southern Finland, about 22% of the total population of the country.  
After the first postoperative days the patients were transferred to their local 
hospitals to convalesce (the central and local hospitals in the hospital districts of 
Etelä-Pohjanmaa, Kanta-Häme, Päijät-Häme and Vaasa). They were discharged 10 
to 14 days after the operation if no significant complications occurred. The patients 
attended a cardiology or internal medicine outpatient clinic 1 to 2 and 3 to 4 months 
after the operation. ECG and basic laboratory parameters were then analysed. After 
a few postoperative months, most patients were transferred to primary care for 
continued secondary prevention. 
4.1.2 Study of annual cohorts 
In Study III, 20 consecutive annual cohorts of CABG patients were evaluated. The 
aim was to analyse the development of postoperative lipid treatment practices over 
a twenty-year time period starting before the statin mega-trials were published and 
extending until the current treatment practices had been established. 
All annual cohorts of CABG patients treated postoperatively in Kanta-Häme 
Central Hospital during the years 1990–2009 were studied. The primary catchment 
population of the hospital is 175,000 inhabitants living in Southern Finland. CABG 
was performed in Tampere University Hospital on 953 patients and after the 
operation they were transferred to Kanta-Häme Central Hospital to continue their 
recovery. After discharge the patients were followed up according to national policy. 
4.2 Clinical definitions 
The patient records were reviewed for cardiovascular and other relevant medical 
history and essential laboratory parameters. Renal function was calculated with the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and 
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renal insufficiency defined as a glomerular filtration rate less than 60 ml/min/1.73 
m2 340. Hypercholesterolemia was defined as total serum cholesterol > 5 mmol/l (200 
mg/dL) or a patient being on lipid-lowering drug therapy 341,342. Estimation of 
perioperative myocardial damage was based on elevated creatinine kinase MB 
fraction. Smoking habits were elicited in a questionnaire completed 21 months 
postoperatively. 
Obesity was defined according to BMI and calculated as mass/height2 (kg/m2). 
The study population was divided into normal weight (BMI 18.5 – 24.9 kg/m2), 
overweight (BMI 25.0 – 29.9 kg/m2) and obese (BMI > 30.0 kg/m2) groups. Only 
one patient had a BMI below 18.5 (17.9) kg/m2 and was analysed along with the 
normal weight patients.  
The classification of MetS was based on the NCEP/ATP III definition with the 
exception that body mass index (BMI) (kg/m2) was used as a measure of obesity 
333,343. During the 1990s waist circumference was not commonly measured 344. 
Modified MetS was defined as the presence of three or more of the following risk 
factors: BMI > 30 kg/m2 for men and > 25 kg/m2 for women, TG concentration > 
1.7 mmol/l, HDL-C < 1.03 mmol/l for men and < 1.30 mmol/l for women and 
systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg or on 
antihypertensive medication. Elevated blood glucose was noted when the patient 
had fasting blood glucose > 5.6 mmol/l (100 mg/dL) 341,345. 
For the diagnosis of diabetes, the 1998 WHO criteria were retrospectively used, 
defining fasting blood glucose level  6.1 mmol/l (110 mg/dL) or random blood 
glucose  10.0 mmol/l (180 mg/dL). Beginning in 2001 corresponding plasma 
glucose cutoff values (fasting plasma glucose  7.0 mmol/l and random plasma 
glucose  11.1 mmol/l) were used 345. 
In the follow-up studies the diagnosis of diabetes was based on either elevated 
glucose levels as stated above or antidiabetic medication according to hospital 
records at the time of the operation. A patient was also deemed having diabetes if 
on antidiabetic medication according to the Kela database during the ten years 
following CABG. The latter definition was used because in the 1990s and early 2000s 
patients with diabetes often had dietary therapy before starting antidiabetic 
medication. The patients with later medication probably already had diabetic 
metabolism during the first postoperative years and were consequently included in 
the patient group with DM 339.   
In the study of annual cohorts, diagnosis of diabetes was based on hospital records.  
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Cardiovascular death was defined as any death caused by coronary heart disease 
or sudden death from two months to 20 years postoperatively. Deaths due to stroke 
and peripheral arterial disease were considered to be cardiovascular deaths.  
Similar clinical definitions were used both in the follow-up studies and in the 
study of annual cohorts. 
4.3 Methods 
4.3.1 Follow-up study 
4.3.1.1 Collection of pre- and perioperative data 
Working After Coronary Artery Bypass Grafting (W-CABG) study personnel 
investigated hospital records after patients’ transfer to primary care. Demographics 
and pre- and perioperative data including BMI were collected manually from medical 
records in both Tampere University Hospital and in the secondary care hospitals 
involved in the patients’ postoperative recovery. A structured form was used for the 
data collection. Laboratory data including lipid and blood glucose values were 
collected from patient records. Standard analytical methods were used in Tampere 
university hospital and other hospitals included in the study. 
4.3.1.2 Patient questionnaires 
The first follow-up data collection was made with a detailed questionnaire in July 
1995, i.e. on average 21 (range 12 – 30) months after the operation. A repeat 
questionnaire was sent two months later when necessary (total response rate 86%). 
Education, employment status, cardiac symptoms and clinical course of CAD were 
specifically elicited. Subjective well-being compared to patients’ expectations as well 
as risk and protective factors were also evaluated.  
The second follow-up was almost identical to the first; during 2003, i.e. 9 to 10 
years after the operation (response rate 83%). Both times the follow-up included 
contact by phone if further clarification of the questionnaire responses was necessary. 
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4.3.1.3 National databases 
Employment status or the date and the reason for retirement were checked from the 
Finnish Centre for Pensions ten years after the last operation. Use of antidiabetic 
and cholesterol lowering medication was ascertained from the reimbursement 
database maintained by Kela until the end of 2008. Possible death, date and cause of 
death were verified from Statistics Finland, with a final check in September 2016. 
All relevant information concerning working status, medication and possible 
death and its cause were obtained from national databases for all patients included. 
4.3.1.4 Analyses of working after CABG 
In Finland the retirement rate increased rapidly at the age of 60 in the 1990s. Over 
60% of unselected Finns were still working at ages 55 – 59, but only some 20% of 
those aged 60 – 64. Thus reasons other than medical seemed to exert a marked 
effect on retirement at that age. In analysing postoperative employment we 
therefore decided primarily to look at patients still younger than 60 years during 
follow-up. The results were compared with the pensioning rate among a matched 
Finnish population 346. 
4.3.1.5 Survival according to BMI 
Survival analyses were conducted after the end of the study period (30 June 2014) 
and were based on data obtained from Statistics Finland. Survival data and causes of 
death were available for a total of 20 years after CABG for all the patients included 
in the study.  
Separate survival analyses (2 months to 10, 15 and 20 years) were carried out for 
all patients with sufficient BMI data and having survived beyond the immediate 
postoperative period. Survival analysis was conducted separately for each BMI group 
(normal weight, overweight and obese). The cumulative, relative mortality for each 
group was calculated against age-, sex- and time-specific national background 
populations as described in the statistical methods in section 4.4.1. Furthermore, the 
relationship of BMI to long-term survival (2 months to 10, 15 and 20 years 
respectively) was analysed by comparing the three patient groups. 
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4.3.1.6 Survival according to metabolic status 
A second set of survival analyses (2 months to 10, 15 and 20 years) was conducted 
for all patients whose metabolic status could be ascertained. These patients were 
divided into those with neither DM nor MetS, those with MetS but not DM and 
those with DM with or without MetS. The cumulative relative mortality for each 
group was calculated in the same way as described in 4.3.1.5 above for BMI. 
4.3.2 Study of annual cohorts 
4.3.2.1 Data collection 
The study personnel scrutinized the patient records of all patients treated after 
CABG in Kanta-Häme Central Hospital in the period 1990 to 2009 to obtain 
demographic data, relevant preoperative and perioperative information and 
postoperative cardiology outpatient clinic visits.  
Data was collected primarily from the 3-month postoperative visit; postoperative 
visits until four months after CABG were included in the analyses. Patients for 
whom laboratory values were available at the first postoperative visit but not at the 
3-month visit were also included; that is, a “last observation – carry forward” 
principle was adopted. Data collected on outpatient visits included postoperative 
medication, lipid values, blood pressure and absence/presence of various CAD risk 
factors including smoking habits, diagnosed diabetes and obesity (BMI). 
4.3.2.2 Material analysis 
The influence of the statin trials and recommendations regarding treatment goals 
were examined by comparing CABG patients’ postoperative lipid values taken over 
a time span of 20 years. The study period was divided into four consecutive 5-year 
time periods, namely 1990–1994, 1995–1999, 2000–2004 and 2005–2009. During 
this 20-year timespan several new statins with different efficacies became available 
on the market. Thus the daily dose and LDL-C lowering effect of each individual 
statin had to be considered. This enabled us to compare the lipid-lowering efficacy 
of each statin therapy during the entire study period.  
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A daily dose of 20 mg simvastatin or equipotent dose of another statin is the 
smallest statin dose used in most prospective trials. Hence, this dose was defined as 
“daily statin dose index (DSDI) 1”, which corresponds to a daily dose of 80 mg 
fluvastatin, 40 mg lovastatin or pravastatin, 20 mg simvastatin, 10 mg atorvastatin or 
5 mg rosuvastatin. The lipid-lowering efficacy of each statin was assumed to be linearly 
correlated with the dose; i.e. the DSDI of 80 mg simvastatin was four 347–350. 
4.3.2.3 Lipid analysis 
Total and high-density lipoprotein cholesterol (HDL-C) concentrations were 
determined from plasma samples by using Hitachi 911 analyser with Boehringer-
Mannheim reagents in 1990–1996. Roche Diagnostics enzymatic methods were used 
since 1996, which also applied to direct LDL-C analysis from 2000 onwards. All 
chemical analyses were carried out in the Laboratory of Kanta-Häme Central 
Hospital. Lipid analyses have been under the Nordic quality control during the entire 
study period. 
In the calculation of classical Friedewald formula LDL-C is TC – HDL-C – 
(TG/2.2) in mmol/l concentrations. Since classical Friedewald formula is only valid 
provided serum TG < 4.5 mmol/l, we also applied a novel extended Friedewald 
approach, which is more tolerant of elevated triglycerides 351,352. The extended 
Friedewald  approach is based on artificial neural network regression algorithms 
which utilize data on classical Friedewald inputs351. This method allowed us to 
calculate LDL-C, intermediate-density lipoprotein cholesterol (IDL-C), and very-
low-density lipoprotein triglyceride (VLDL-TG) concentrations. It also 
computationally yields estimates of apoB and apoA1 concentrations 351. 
4.4 Statistics 
4.4.1 Follow-up study 
In the comparison of patient characteristics, categorical data are tabulated as 
frequencies and percentages, and continuous variables are expressed as means and 
standard deviations (SDs). Differences between the two groups were tested by Chi 
squared test and the Wilcoxon rank test, and in cases of more than two groups by 
Kruskal-Wallis test. Fisher’s exact test was used when appropriate in two-by-two 
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tables with directed hypothesis. Differences in mean values between two groups 
were tested by Student’s t-test and in the case of more than two groups by analysis 
of variance.  
The relative survival rates were analysed by age, gender, diabetes mellitus (DM), 
MetS, BMI and statin medication using the Life Table method 353. In this approach, 
the observed survival rates of the groups are compared to the rates based on age-, 
gender- and time-specific (CABG year) life tables for the entire population of 
Finland. Calculation of survival rates was based on the individual life expectancies 
of the target population for the target years (reference population). For example, at 
the time of the operation (1994), the mean life expectancies of Finnish 65-year old 
men and women were another 14.6 and 18.6 years respectively. The survival of the 
reference population is effectively 1.00. If the survival curve of the group remains 
below that of the reference population there is excess mortality in the group.  
The first two postoperative months were defined as perioperative due to 
increased mortality. In the follow-up studies patients’ prognoses were calculated and 
relative mortality curves were presented for the 2-month to 20-year time period after 
CABG. Double arithmetic smoothing was applied when associations of BMI with 
adjusted all-cause mortality over 10, 15 and 20 years after CABG were presented.  
To study the independent significance of MetS, DM and BMI for clinical 
outcome (2 months to 20 years), multivariate analysis was conducted using an 
optimizing stepwise procedure based on the Bayesian approach 354. The model of 
the individual probability of remaining at work was created using the same method.  
The multivariate analysis procedure was developed for nominal variables and 
does not require a perfect variable matrix. It selects by the heuristic approach the 
combination of variables which best explains the selected outcome factor. The 
Bayesian approach is applied by counting posterior likelihood ratios or odds ratios 
for each combination. The aim was to find an optimal subset of pre- and 
intraoperative variables to provide the best explanation. The parameters included in 
the multivariate analysis were age, gender, BMI, all significant cardiometabolic 
diseases and related operations likewise obstructive pulmonary diseases, lipid values 
and statin medication. Essential intraoperative characteristics of CABG and some 
supplementary parameters from the patient questionnaire were also included in the 
analyses. Altogether 40 parameters were applied in the Bayesian approaches 
(Appendix I - II).  
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4.4.2 Study of annual cohorts 
The evolution of postoperative statin therapy and lipid values over 20 years was 
studied using ANOVA test in the 5-year groups. With dichotomous variables the 5-
year groups were compared using extended ƫ2 test 355. D'Agostino's test was used to 
determine normality and scedasticity. Percentage or mean and standard deviation of 
demographic characteristics and lipid variables are presented. Multiple linear 
regression analysis was used when comparing lipid values with each other. 
4.5 Ethical considerations 
The study was conducted in accordance with the ethical principles outlined in the 
declaration of Helsinki 356. Study material was collected with identification data 
including name and individual social security number allowing combination of 
different data sources. Study results were further analysed and papers published 
without patient identification.  
The follow-up study (Studies I-II and IV-V) and its later amendments were 
approved by the Ethics Committee of Tampere University Hospital (reference 
numbers 95010, R02103). Study III concerning CABG patients evolving secondary 
prevention during a 20-year time-period, done in Kanta-Häme Central hospital, was 
approved by the Ethics Committee of Kanta-Häme Hospital District (reference 
number E511/08). 
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5 RESULTS 
5.1 Study population 
5.1.1 CABG patients for follow-up studies 
Of the 961 CABG patients operated on in the period 1 January 1993 – 30 June 1994 
at Tampere University Hospital, 33 died during the first postoperative month, and 
five more during the second month. In one single patient, a 70-year-old male, neither 
BMI nor metabolic status was ascertained. In total, 922 patients were included in the 
follow-up studies.  
BMI was calculated for all of these 922 patients and the metabolic status was 
determined in 910 of those surviving for more than two months. The study on 
postoperative employment included 529 patients aged less than 64 years at the time 
of the operation (< 65 one year postoperatively). Twenty of these died during the 
first postoperative year. Data on postoperative employment was calculated from the 
remaining 509 patients. No one was lost during the 20-year follow-up (Figure 6). 
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Figure 6.  CABG patients for the follow-up studies. CABG: Coronary artery bypass grafting, TAUH: 
Tampere University Hospital, po: Postoperatively, BMI: Body mass index, MetS: Metabolic 
syndrome, DM: Diabetes mellitus. 
5.1.1.1 Demography of patients according to BMI 
Patients’ demography and clinically relevant co-morbidities are presented according 
to BMI at the time of surgery for all 922 consecutive patients studied (Table 3). 
Overall, 25% were normal weight, 55% overweight and 20% obese. Their mean age 
was 62 (+ 8) years and 21% were women. 
According to data obtained by the questionnaire dispensed on average 21 months 
postoperatively, patients in three BMI groups (normal weight, overweight and obese) 
did not differ significantly from each other in the postoperative use of low-dose 
ASA, statins or ACE inhibitors. Patients who were obese at the time of CABG 
mostly remained obese according to a second questionnaire administered 9.5 years 
postoperatively. Correspondingly, the majority of patients with normal BMI 
continued to have normal BMI.  
 
 
 56 
Table 3.  Preoperative demographic data, clinical characteristics and severity of coronary heart 
                 disease in 922 patients according to BMI. Data on patients surviving two months after 
                 coronary artery bypass grafting. 
 
Abbreviations: BMI: Body mass index (kg/m2), MI: Myocardial infarct, TIA: Transient ischaemic attack, GFR: 
Glomerular filtration rate, Hypercholesterolaemia: Total cholesterol > 5.0 mmol/l or on lipid-lowering medication,  
Low high density lipoprotein (HDL) cholesterol: Men <1.03 mmol/l, women <1.3 mmol/l, Elevated triglyceride (TG): 
>1.7 mmol/l, EF: Ejection fraction, Severely decreased EF: EF 35%, NYHA: Angina pectoris symptoms 
according to New York Heart Association, LM: Left main, NS: Not significant. * Overall P-value for NYHA vs. BMI. 
1 Unadjusted P<0.05 by the pooled t-test for the comparison BMI < 25.0 kg/m2 against BMI > 30.0 kg/m2. 
2 Unadjusted P<0.0001 by the pooled t-test for all comparisons.  
3  Unadjusted P<0.01 by the pooled t-test for all comparisons. 
4 Unadjusted P<0.001 by the pooled T-test for the comparison BMI < 25.0 kg/m2 against both other 
groups. 
 BMI 
< 25.0 
BMI 
25.0–29.9 
BMI 
 30.0 
Overall 
P-value 
Demographic characteristics     
Number of patients 230 506 186  
Female (%) 21 20 25 NS 
Mean age (years) (SD)  63 (9) 62 (8) 60 (8) <0.051 
Concomitant Diseases     
Previous MI (%) 61 73 73 <0.051 
Previous TIA or stroke (%) 10 11 8 NS 
Peripheral arterial disease (%) 13 8 0 <0.051 
DM (%) 17 27 43 <0.00012 
Hypertension (%) 54 62 70 <0.013 
Creatinine clearance     
GFR (ml/min) (SD)  76 (16) 75 (16) 75 (16) NS 
GFR < 60 ml/min/1,73m2 (%) 16 16 16 NS 
Lipid disorder     
Hypercholesterolaemia (%) 72 73 78 NS 
Low HDL-C (%) 54 67 71 <0.0014 
Elevated TGs (%) 37 58 73 <0.00012 
Preoperative Smoking (%) 63 64 67 NS 
Severity of Heart Disease     
EF (%) (SD)  60 (14) 61 (14) 59 (14) NS 
     Severely decreased EF 6 7 7 NS 
NYHA II (%) 11 12 8  
NS* 
 
NYHA III (%) 58 57 59 
NYHA IV (%) 31 31 33 
Three–vessel or LM disease (%) 60 63 57 NS 
Urgent / emergency operation (%) 30 29 31 NS 
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5.1.1.2 Metabolic status of patients  
Of the 910 patients, 41% had neither DM nor MetS, 31% had MetS but not DM and 
28% had DM, when analysed 10 years postoperatively. At the time of CABG, only 
14% had diagnosed DM. Patients with DM were on the average two years older than 
those without it. Patients with MetS had by definition metabolic abnormalities more 
often than those without MetS. Similar findings were obtained in patients with DM, 
of whom 83% had MetS. Renal dysfunction was more frequent in DM+ and DM-
/MetS+ patients and severe heart disease represented by lower ejection fraction and 
New York Heart Association (NYHA) class IV was more common in those suffering 
from DM than in other groups. CVD history or operational characteristics did not 
differ significantly between patient groups. 
5.1.1.3 Demography of the patients of working age  
In those 509 patients operated on and being under 65 years of age and alive one year 
postoperatively, 13 out of 75 women (17%) and 138 out of 434 men (32%) returned 
to work. The average age of those who returned to work was 52 years and of those 
who retired was 58 years. Diabetes mellitus, previous transient ischaemic attack 
(TIA) or stroke and severe cardiac disease determined by decreased left ventricular 
ejection fraction and NYHA class IV were more common in patients who retired. 
They also had on average lower basic education. 
5.1.1.4 Lipid treatment 
In the follow-up study the statin use was evaluated on the average for the first 15 
postoperative years. Patients were divided as follows: Group I, 368 patients (26% 
women) who had been on statins for at least 50% of their postoperative follow-up 
period, group II, 323 patients (16% women) who had been on statins for more than 
three months, but for less than 50% of their postoperative follow-up and group III, 
231 patients (20% women) who had not taken statins postoperatively (or received at 
most one three-month prescription). 
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5.1.2 CABG patients for the study of annual cohorts  
Of the 953 CABG patients treated in Kanta-Häme Central Hospital after CABG 
during the time period 1 January 1990 – 31 December 2009, 946 (99%) attended the  
cardiology outpatient clinic at least once during the first four postoperative months. 
They were divided into four consecutive 5-year periods according to treatment date, 
each group consisting on average of 237 patients, the proportion of male patients 
ranging from 72% to 80%. The patients’ demographics evolved with an increasing 
proportion of patients with DM and older patients operated on as well as decreasing 
measured systolic and diastolic blood pressure in later years. (Table 4).  
Table 4.  Demographics of Kanta-Häme Central Hospital patients undergoing CABG during the 
                 period 1990-2009, divided into 4 consecutive 5-year periods 
 
* Extended ȝ2 test and ANOVA were used for overall analysis. Percentage or mean (SD) is presented. 
DM: Diabetes mellitus, BMI: Body mass index (kg/m2), BP: Blood pressure, NS: Not significant. 
 
5.2 Employment (I, II) 
5.2.1 Resuming work after CABG 
Of the 509 patients operated on while under 64 years of age (< 65 one year 
postoperatively) and who were alive one year after CABG, altogether 251 (49%) had 
5-year period 1990–1994 1995–1999 2000–2004 2005–2009   Overall P*   
Number of patients 256 247 224 219  
Proportion of 
female (%) 22 20 28 21 NS 
Proportion of DM 
patients (%) 10 14 19 27 < 0.01 
Current and ex-
smokers (%) 64 55 54 56 NS 
Age (years) (SD) 62 (8) 64 (9) 65 (9) 67 (8) < 0.0001 
BMI (kg/m2) (SD) 26.5 (3.5) 26.5 (3.3) 27.2 (3.7) 27.0 (4.1) NS 
Systolic BP (mmHg) 
(SD)  150 (25) 148 (23) 138 (22) 130 (20) < 0.0001 
Diastolic BP (mmHg) 
(SD) 85 (12) 82 (11) 80 (10) 78 (9) < 0.0001 
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retired preoperatively. The remaining 258 (51%) were working, unemployed or on 
short-term leave. Of these, 145 were working after the first postoperative year. The 
remaining 112 retired immediately after postoperative sick leave without returning 
to work or after only a couple of months working (one patient returned to work 
later). Of the preoperatively retired patients only six returned to work, while 245 
continued in retirement after CABG. Hence, altogether 151 patients were working 
one year postoperatively. Working, retirement and one-year postoperative mortality 
data on all patients under 65 years (n = 529) and under 60 years (n = 329) one year 
postoperatively are shown in Figure 7.  
 
 
Figure 7.  Working, retirement or postoperative death of coronary artery bypass grafting patients one 
year after the operation. Definitions: < 65 y: Under 65 years one year postoperatively. < 60 
y: Under 60 years one year postoperatively. W/W: Working preoperatively, working one 
year postoperatively, W/R: Working preoperatively, retired one year postoperatively, R/R: 
Retired preoperatively, retired one year postoperatively, R/W: Retired preoperatively, 
working one year postoperatively, R/D: Retired preoperatively, died during the first 
postoperative year, W/D: Working preoperatively, died during the first postoperative year.  
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5.2.2 Factors affecting postoperative working 
The most important factors having a positive effect on postoperative employment 
according to the univariate analysis were patient’s younger age and shorter duration 
of absence from work (P<0.001). After the age of 55 years, preoperatively non-
retired patients’ return to work (RTW) diminished rapidly. Of those under 55 years 
at the time of CABG, 66% returned successfully to work during the first 
postoperative year, while the corresponding figures for older age groups, 55 to 59 
and 60 to 64 years, were 51% and 35%. The mode and duration of preoperative 
sickness leave or pension were related to getting back to work in such a way that 
most patients (71%) being preoperatively only briefly on sick leave returned to work 
postoperatively, 9% of patients on interim benefit for three to six months returned 
to work as did only 2% of those who had been on interim benefit or disability 
pensioned for a longer time.  
In univariate analysis higher level of education and absence of history of TIA or 
stroke also predicted better RTW (P<0.001). Patients’ short height, family history of 
cardiac disease, high total cholesterol, DM, high preoperative NYHA class (IV), and 
low ejection fraction predicted lower return to work (P<0.01).  
In stepwise Bayesian multivariate analysis, best sensitivity and specificity were 
found for a model which included patient’s age, duration of preoperative sickness 
leave, a history of diabetes mellitus and signs of perioperative myocardial damage. 
In this model sensitivity was 94% and specificity 75%. 
5.2.3 Continuing to work 
The analysis of continuing to work included patients at work one year 
postoperatively. In the working status of those aged less than 55 years on the average 
five years after operation, 85% were working full-time and 5% part-time, of those 
aged 55 years to 59 years, 72% and 1% and of those aged 60 years to 64 years, 34% 
and 6% respectively. The corresponding employment figures in Finnish background 
population for 1999 in those aged 45 years to 54 years, 55 years to 59 years and 60 
years to 64 years were 89%, 70% and 21% 346. 
Out of 151 patients working postoperatively, 140 (9% women) were younger than 
60 years at the beginning of the follow-up and 56 were still under 60 years of age ten 
years later. Of these 56 patients 67% were employed full-time and 8% part-time, 
while 25% had retired on disability pensions. Eight deceased patients, all of them 
due to non-CV causes, were excluded from the analysis. Likewise patients were 
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removed from the analysis once they had turned 60 years. The ten-year postoperative 
employment status is presented in Figure 8. 
 
 
Figure 8.  Postoperative employment of coronary artery bypass grafting patients at the end of each 
calendar year. A 10-year follow-up until 31 December 2003 of the originally 140 patients 
who were working one year postoperatively and under 60 years of age. A total of eight 
persons deceased during the follow-up are excluded. Patients were also removed from the 
analysis once they had turned 6o years. 
5.2.4 Factors affecting continuing to work 
In univariate analysis the three most significant factors (P<0.001) affecting 
continuing to work were patient’s age at the time of the operation, duration of 
preoperative sickness benefit and patient’s height. Several other factors describing 
patients’ medical condition (e.g. preoperative kidney function, extent of 
cardiovascular disease, diabetes), postoperative activity and well-being as well as 
social situation also correlated with long-term continuation at work. 
In Bayesian multivariate analysis several patterns of univariately significant factors 
were compared. The best balanced and most useful model included the following 
factors: patient’s age, postoperative cardiac symptoms, patient’s height, being 
married/non-married, diabetes mellitus and participation in household work (Table 5).  
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Table 5.  Probabilities of remaining at work after coronary artery bypass grafting for at least 
                 three, six and nine years.  
 
In this model the individual probability of remaining at work (calculated one year postoperatively) is as 
follows: The patient’s likelihood ratio (LR) for each characteristic is multiplied. Higher LR means greater 
likelihood of remaining at work. If the total LR is greater than 1.00, the probability of remaining at work is 
more than 50% for the given time (3 y, 6 y, or 9 y). Patients in age groups given in parentheses may remain 
at work over the age of 60 years. LR may be expressed as probability as follows: p = 100 * LR/ (1+LR). 
 
As an example, we have a 52-year-old patient who is free of cardiac symptoms, is 176 cm tall, married, 
is not suffering from diabetes and does not participate in household work. His/her total likelihood ratio for 
continuing at work for at least six years is 1.24 x 1.80 x 0.93 x 1.03 x 0.58 = 1.24.  According to the 
model 100 * LR/ (1+LR), we get a 55% probability of continuing to work for at least six years. If our 
patient were an active person, for example participating in household work, his/her total likelihood ratio of 
remaining at work for at least six years would increase to 1.24 x 1.80 x 0.93 x 1.03 x 1.25 = 2.67 and 
thus his/her probability would be 73%. 
Variable 3 years 6 years 9 years (n = 119) (n = 92)  (n = 59)  
1. Age at the time of CABG    
< 50 LR = 6.54 LR = 3.25 LR = 2.42 
50 – 54  LR = 3.80 LR = 1.24 (LR = 0.20) 
> 55 LR = 0.68 (LR = 0.37) (LR = 0.01) 
2. Postoperative cardiac symptoms    
No LR = 1.11 LR = 1.00 LR = 1.08 
Yes LR = 0.51 LR = 1.00 LR = 0.51 
3. Height in centimetres    
< 175 LR = 0.59 LR = 0.58 LR = 1.00 
175 – 179 LR = 1.43 LR = 1.80 LR = 1.00 
180 - LR = 6.29 LR = 2.13 LR = 1.00 
4. Being married    
No LR = 3.51 LR = 1.60 LR = 1.14 
Yes LR = 0.88 LR = 0.93 LR = 0.98 
5. Diagnosed DM    
No LR = 0.92 LR = 1.03 LR = 1.04 
Yes LR = 2.59 LR = 0.80 LR = 0.70 
6. Participation in household work    
Daily  LR = 1.00 LR = 1.25 LR = 1.26 
Less often  LR = 1.00 LR = 0.58 LR = 0.51 
Precision of the model 
False-Positive 10 18 15 
False-Negative 9 17 13 
Sensitivity 55 % 63 % 82 % 
Specificity 92 % 82 % 78 % 
Correct predictions 86 % 75 % 80 % 
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5.3 Lipid treatment (III) 
5.3.1 Impact of statin treatment on survival after CABG 
In a 20-year follow-up of study patients, the most favourable prognosis was seen in 
those patients who had been on statin therapy for at least 50% of their postoperative 
follow-up time, relative survival in comparison with the background population 
being 0.99 (95% CI, 0.89 to 1.08; (P=NS)). Patients having used statins for more 
than three months, but less than 50% of their postoperative follow-up had a poorer 
prognosis, 0.81 (95% CI, 0.67 to 0.94; P<0.001). The poorest prognosis was in those 
patients who had not taken statins at all or only purchased one three-month 
prescription, 0.32 (95% CI, 0.01 to 0.64; P<0.001). The prognosis of each statin user 
group is shown in Figure 9. 
 
 
Figure 9.  Relative 20-year prognosis of coronary artery bypass grafting patients alive 2 months 
postoperatively represented in relation to statin treatment (matched back-ground 
populations 1.00). Use of statins > 50% of time vs. < 50 % P<0.001, use of statins < 50% 
of time vs. no statin use P<0.001.  
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5.3.2 Lipid treatment practice in the study of the annual cohorts  
Altogether 803 patients had their lipid values measured, their share increasing from 
64% over the first five-year period (1990–1994) to 97% in the last period (2005–
2009). During the same time the use of statins increased from 12.0% to 97%. In the 
last years of the follow-up, practically all CABG patients were on statin therapy 
(Figure 10A).  
The daily statin dose indexes (DSDIs) were small in the early years, both due to 
scant use and low effective doses of statins increasing progressively during the study 
period. Thus, the average DSDIs of all patients, even when those without statin 
therapy were included, increased during four consecutive 5-year time periods from 
0.07 to 2.52 (P for trend <0.001) (Figure 10B). The DSDI during the very last year 
of observation corresponds to a mean simvastatin dose of 57 mg/day. 
 
 
Figure 10. A. Statin treatment and low-density lipoprotein cholesterol (LDL-C) after coronary artery 
bypass grafting. Red arrows indicate the publication of landmark statin trials 1,3,154,155,357. 
Blue arrows refer to the publication of lipid lowering recommendations 341,342,358–360.  
 B. Apolipoprotein B (ApoB) and daily statin dose index (DSDI) after coronary artery 
bypass grafting. Black arrows indicate the years, when atorvastatin (1997) and 
rosuvastatin (2003) entered the Finnish market. 
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5.3.3 Plasma lipid and apolipoprotein levels in the study of the annual 
cohorts  
The respective mean concentrations of LDL-C were 3.7 and 2.1 mmol/l, and those 
of apoB 1.3 and 0.8 g/l during the initial (1990–1994) and final (2005–2009) 5-year 
time periods (Figure 10A, 10B). During the last year of follow-up (2009) the mean 
concentrations of LDL-C and apoB were 1.83 mmol/l and 0.78 g/l, respectively. 
The decrease in apoB concentration was progressive throughout the 20-year time 
span. This is seen in the significant decrease of LDL-C concentration, as in the 
concentrations of other apoB-containing lipoproteins, such as VLDL-TG and IDL-
C, which were reduced comparably. Further, HDL-C increased significantly from 
1.02 to 1.22 mmol/l. 
5.4 Survival (IV, V) 
5.4.1 Overall survival 
Perioperative mortality, defined as mortality during the first two postoperative months, 
was 4.0% (38 patients), 60% of them patients with diabetes. In patients younger than 
65 years at the time of the operation 2.2% died perioperatively (13 patients).  
At the end of follow-up, 20 years postoperatively, a further 574 patients had died 
of the 923 alive two months postoperatively. Thus at the end of follow-up 36% of 
the patients originally operated on were alive. 
5.4.2 Impact of BMI on survival 
During the first postoperative years the prognosis was favourable in all patient 
groups. Beyond the first ten years the survival curves diverged significantly. 
Patients with normal BMI (< 25 kg/m2) were associated in long-term follow-up 
with significantly inferior survival when compared to that of the background 
population already 10 years postoperatively. Twenty years postoperatively it was 0.68 
(95% CI 0.49 – 0.87; P<0.001). The survival of overweight patients was comparable 
to that of the background population for the first 15 years, but subsequently 
deteriorated. At 20 years postoperatively the relative survival in this group was 0.82 
(95% CI 0.71 –   0.92; P<0.001). The prognosis of obese patients was for the first 
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10 years similar to that of the background population and then decreased sharply 
during the second postoperative decade. Their survival was 20 years postoperatively 
0.67 (95% CI 0.49 – 0.85; P<0.001).  In normal weight patients most unfavourable 
20-year prognosis was associated with the lowest BMIs and in the obese group in 
patients with BMI > 35.0 kg/m2.  
Survival of the patients according to BMI group is compared in Figure 11, and the 
relative survival of the patients over time periods of 10, 15 and 20 years in Figure 12.  
 
Figure 11. Relative survival of patients after coronary artery bypass grafting 2 months to 20 years 
postoperatively according to BMI group compared to matched background populations 
(relative survival 1.00). BMI: Body mass index. 
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Figure 12. Association of body mass index (BMI) as a continuous variable with adjusted all-cause 
mortality using basic odds ratio (OR) formula 10, 15 and 20 years after coronary artery 
bypass grafting. An OR of 1.0 represents that of an average CABG patient. The curves are 
smoothed and represented on a logarithmic scale.  
5.4.3 Long-term survival according to metabolic status 
The prognosis of patients surviving for the first two postoperative months and 
without DM or MetS was comparable to that of background population. At the end 
of follow-up, 20 years postoperatively, their relative survival was 0.89, (95% CI, 0.78 
– 1.00; P=NS), (Figure 13). In patients without DM but with MetS long-term survival 
was first comparable to that of background population, but over time it deteriorated 
and 20 years postoperatively was 0.80 (95% CI 0.66 –  0.93; P<0.01) (Figure 13). 
The prognosis of patients with diabetes started to deteriorate during the first 
postoperative decade and was significantly less than that of patients without diabetes 
and that of their background population 10 years postoperatively. Their relative 20-
year survival was 0.48 (95% CI 0.26 – 0.71 P<0.001) (Figure 13). Among patients 
with DM, MetS seemed not to affect postoperative survival after adjustment for age, 
gender and year of CABG (P=NS). In multivariate analysis, age, diabetes mellitus, 
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BMI and left ventricular ejection fraction at the time of CABG had an independent 
impact on prognosis.  
Figure 13. Postoperative relative survival of patients with coronary artery bypass grafting according to 
metabolic status (matched back-ground populations 1.00). DM: Diabetes mellitus, MetS: 
Metabolic syndrome. 
5.4.4 Causes of death 
Causes of death are known until the end of the follow-up. Both BMI and metabolic 
status, especially DM were related to cardiovascular mortality. 
Cardiovascular disease was the primary cause of death during the first and second 
postoperative decade in normal weight patients in 56% and 60% and in overweight 
patients 60% and 57%, respectively (NS for both changes). In obese patients 
cardiovascular mortality increased significantly over time accounting for 44% of all 
mortality during the first postoperative decade and for 76% during the second 
decade (P<0.05). 
When the patients were divided according to metabolic status, CV mortality was 
during the first and second postoperative decade in DM-/MetS- 60% and 55%, in 
DM-/MetS+ 54% and 55 % and in DM+ 62% and 69% of all mortality respectively. 
The excess mortality of patients with diabetes during second postoperative decade 
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was largely due to cardiovascular causes. The increase was significant when 
compared to patients without diabetes (p<0.05). 
In reported postoperative CV deaths stroke and ASO played a minor role 
accounting for respectively 10.0% and 0.8% of all CV mortality. 
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6 DISCUSSION 
6.1 Introduction  
The present study evaluates prognosis after CABG assessed in terms of resumption 
of work and survival. The influence of BMI, metabolic syndrome and diabetes 
mellitus as well as statin treatment were of special interest, but all relevant pre- and 
perioperative factors were also taken into account. Evolution of statin treatment has 
been addressed, as well. The major results are represented in table 6. 
Table 6.  Major results of the studies of patients with coronary artery bypass grafting included in 
                 the theses. The studies are numbered I to V according to the original publications. 
 
Publications Principal results 
Employment (I, II) 1) Older age (> 55) and longer sick leave (> 6 months) 
impaired resuming work postoperatively. 
2) Patients who returned to work continued working similarly 
to their age and gender matched background populations. 
Statin treatment (III) 1) In long-term follow-up, duration of statin treatment 
correlated positively with good prognosis. 
2) In annual cohorts between 1990 and 2009 both 
prevalence and dose of statin treatment increased 
substantially, especially after the publication of statin 
mega-trials and the availability of more potent statins. 
BMI (IV) 1) The apparent obesity paradox disappears during the 20-
year follow-up after CABG. 
2) In the second postoperative decade obese patients died 
primarily of cardiovascular causes. 
DM and MetS (V) 1) In the 20-year follow-up survival of MetS patients is inferior 
to that of their background populations. 
2) The prognosis of patients with diabetes is remarkably 
worse than that of MetS patients without diabetes and 
their survival is less than 50% of that of their respective 
background populations. 
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6.2 Postoperative employment after CABG (I, II) 
6.2.1 Postoperative working 
The major objectives in CABG are restoration of normal functional capacity and 
quality of life. For patients of working age resumption of professional activity can 
be considered an essential goal of coronary surgery. 
In our cohort 35% of patients aged 60 – 64 years, 51% of those aged 55 – 59 and 
66% of those aged less than 55 and not retired preoperatively were working one year 
after CABG. The result for patients aged 60 – 64 years was good, since only 17% of 
the national background population of the same age were working in 1994. 
Employment in younger age groups of the background population was more 
frequent, being 63% and 89% in those aged 55 – 59 years and 45 – 54 years, 
respectively 346. Our results are in accordance with other published results where 
patients’ age has been an important predictor of postoperative employment 
295,297,298,311,361. 
The number of women returning to work postoperatively was low for reliable 
statistical comparisons. Therefore, the interpretation of their postoperative work 
activity must be made very carefully. Subsequently, we treated men and women as 
one group in our statistical employment calculations. Nevertheless, it appears that 
postoperative employment and continuing at work were more common among men 
than women. 
The national unemployment rate may affect patients’ return to work (RTW) 361. 
The highest retirement rates in Finland since 1990 were found during a major 
economic depression in 1993 – 97 346. The postoperative recovery and rehabilitation 
phase of the W-CABG patients coincided with that period. Although retirement of 
younger subjects was fairly low in our study, the economic depression may have 
affected the RTW of older patients. A high unemployment rate may reduce social 
activities and motivation to take an active part in the rehabilitation process361.  
Patients’ own wish for RTW and employers’ attitudes towards the employment of 
previously disabled workers also have their effects on the probability of patients with 
CAD retiring 306.  
It can be argued that working life is rigid during times of economic depression. 
In a Swedish study older age was associated with a lower rate of return to full-time 
work after CABG, PCI or MI 361. However, CAD did not affect the return to work 
with reduced working hours. Economic depression is likely to manifest in fewer 
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opportunities for working reduced hours. On the average, only 6% of patients in this 
study worked reduced hours postoperatively. 
6.2.2 Factors affecting postoperative return to work 
Longer preoperative sick leave and being granted a pension significantly deteriorate 
the likelihood of postoperative RTW 297,298,362. Accordingly, in our study patients 
with short preoperative sick leave had the best options for postoperative 
employment, while there was a highly significant inverse correlation between 
preoperative granting of a pension and RTW. It is probable that economic 
depression, age and not working preoperatively have an even greater impact on 
postoperative employment than does health status.   
In multivariate analysis, the best sensitivity was found in a model including only 
patient’s age and retirement. The specificity increased when history of diabetes and 
perioperative myocardial damage were added to the model. The former has been 
confirmed as a predictor of poor prognosis 298,363, while the latter can be considered 
a sign of severe or diffuse coronary artery disease. Low ejection fraction has been 
confirmed to be a predictor of poor RTW 298. 
6.2.3  Continuing to work and factors affecting it 
In Finland the retirement rate increases rapidly after the age of 60, mainly for non-
medical reasons. When considering only patients returning successfully to work and 
being aged less than 60 years, 85% continued to work for five years and 75% for ten 
years after CABG. According to earlier studies, 20 – 51% of CABG patients were 
employed for over five years after successful RTW in UK, Finland and the USA 
296,297,364. The encouraging results in this study may be due to effective secondary 
prevention. Another possible explanation is that only those patients returned to work 
who truly felt able to manage it. One might presume that in the early 1990s in Finland 
it was still relatively easy to get a disability pension after CABG. 
In our study patients who returned to work also continued working comparably 
to age-matched Finnish general population. Only a few published studies have 
evaluated continuation at work over a longer time period. In a British cohort of 
originally 343 patients with a five-year follow-up, the most important predictors for 
continuation were age at the time of the operation, male sex, preoperative working 
and freedom from postoperative angina symptoms 297. In a cohort of 409 PCI and 
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CABG patients in the USA, younger age at the time of the operation and 
preoperative working status, but also work-related medical insurance, were 
associated with more favourable long-term employment 364. 
In this study the model of continuing at work included patient’s age and height, 
postoperative cardiac symptoms, diabetes mellitus, being married/non-married and 
participation in household work. Patient’s age and postoperative cardiac symptoms have 
elsewhere been associated with postoperative employment 297,298,364. Patient’s height is 
related to sex, which is a predictor of postoperative long-term employment 297. Patient’s 
non-married status may emphasize the importance of daily work both socially and 
financially and participation in household work may suggest activity also outside home. 
Diabetes mellitus seems to favour working three to five years postoperatively. The small 
number of diabetes patients in this group may affect the results. 
6.3 Statin treatment (III) 
6.3.1 Effect of statin treatment on survival  
CABG efficiently relieves CAD symptoms. However, without effective secondary 
prevention it does not offer long-lasting help for cardiac symptoms or improvement 
in prognosis 192,316. A central target of secondary prevention is effective lowering of 
LDL-C 3,365. Statin treatment has been shown to be efficient in reducing CV risk, the 
benefit depending on the length of treatment. The balance of gains and harms of the 
treatment has been estimated to be so good that no further findings emerging on  
the effects of statin therapy are expected to alter  it 366. 
One branch of this study addresses the association of statin treatment adherence 
with mortality after CABG. The main finding was a significant overall risk reduction 
in all-cause mortality between high-adherent and medium-adherent and also between 
medium-adherent and non-adherent patients. This concurs with the results of a 
multitude of studies since the 1990s 4,170.   
Pharmacy records have proven to be a useful method for assessing treatment 
adherence. This method is particularly suitable in statins and other drugs intended for 
long-term, constant use 367. Data concerning other than statin medication in this study, 
in particular antiplatelet and antihypertensive medications, were not assessed. Also, the 
individual type and dosage of statins prescribed were not available; on the other hand 
virtually all statins on the market have proven their efficacy in CAD secondary 
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prevention 350,368. It is possible that the poor outcome of the patients not adhering to 
treatment with statins was explained not only by statin underuse but also, for instance, 
by underuse of prescribed medications in general 369,370.  
In this study the data on statin use was limited to fifteen years. Nevertheless,  
according to the existing evidence it is likely that patients continued to take their 
medication in an approximately similar manner from that time on 371. The good 
results of statin adherent patients must be due in part to the long use and 
exceptionally long, 20-year follow-up time in this study. 
6.3.2 Evolution of statin treatment 1990 – 2009 in a non-university hospital 
(Kanta-Häme Central Hospital) 
The praxis of statin’s use in Finland, and particularly in one health care district of the 
main study, Kanta-Häme Health Care District, was addressed by means of a 20-year 
follow-up, since 1990. During this time period the following changes occurred in lipid 
treatment in sequence: 1) The percentage of patients with measured cholesterol levels, 
2) the share of patients on statin therapy and 3) the efficacy of the therapy all increased 
consecutively. The DSDI of 2.86 (+0.41) during the very last year of observation 
corresponds to a mean daily simvastatin dose of 57 (+8) mg. The concentrations of 
LDL-C and of apoB, in which the latter reflects the number of atherogenic apoB-
containing lipoprotein particles, decreased by 45% and 40% respectively.  
The efficiency of secondary prevention of CAD in Europe has been evaluated in 
the Euroaspire studies. The Euroaspire II study was carried out in 15 European 
countries in the years 1999–2000 and also included CABG patients. Of these 42% 
had  TC < 5.0 mmol/l and 61% were on lipid-lowering medication 372.  At the same 
time the corresponding numbers in our patient population were 68% and 76% 
respectively. In an international cross-sectional study, the prevalence of lipid 
abnormalities was assessed in more than 22,000 European and Canadian patients on 
statin treatment in the period 2008–2009 373. In that study, 58% of cardiovascular 
high-risk patients had LDL-C < 2.5 mmol/l. Their mean DSDI was 1.85, 
corresponding to a daily simvastatin dose of 37 mg 373. These changes at the 
international level are parallel to the changes in our practice. 
Although during the 20-year follow-up period the levels of total cholesterol in 
the Finnish population steadily decreased 374, the decrease in our patients was 3- to 
4-fold greater when compared with that of the general population. These evidently 
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beneficial changes are most likely partly due to lifestyle changes but also largely due 
to statin treatment. 
The recent increase in the incidence of metabolic syndrome and diabetes has re-
emphasized the necessity of obtaining additional data on atherogenic triglyceride rich 
lipoproteins like VLDL (remnants) and IDL and how to lower them.  
The theoretical basis of statin treatment effect on Apo-B containing lipoproteins 
originates from the beginning of this century 375–377. Our study confirms during a 20-
year timespan the comparable reduction of VLDL-TG and IDL-C to LDL-C, 
corresponding to the increased statin dose. The HDL-C concentration grew 
simultaneously, and may also be regarded  as an antiatherogenic change 376. As far as 
we know, no observation of diminished IDL-C during gradually intensified statin 
treatment with lipid values taken and analysed over a 20-year timespan, has 
previously been reported. 
It is also of interest that the changes in statin treatment mostly occurred before 
the publication of lipid lowering guidelines. This emphasizes the importance of 
active follow-up of high-impact professional literature and indicates the nature of 
the consensus statement of recommendations. 
A limitation of this study is its retrospective nature, such that knowledge of 
possible statin intolerance is lacking, which is considered a notable problem in statin 
treatment. Although in observational studies as many as  10–30% of patients have 
reported muscle symptoms, most of them could be successfully treated with careful 
management 378–380.  During the last years of our study only about 2% of patients 
were not on statins. This may represent the maximal percentage of patients suffering 
from clinically relevant statin intolerance in this well-motivated patient population. 
A possible explanation for the success of statin therapy is the highly individualized 
care of the cardiovascular patients in our hospital. A corresponding figure has also 
been reported elsewhere 381,382. 
In this study diabetogenicity of statin treatment was not analysed. During 10 
postoperative years, patients got older and treatment practices evolved so that 
treatment of diabetes was initiated earlier. On the other hand, statin treatment may 
have had some influence on the increase of the use of antidiabetic medication for 
CABG patients over a 10-year postoperative period 165.  
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6.4 Survival after CABG (IV, V) 
6.4.1 Impact of BMI  
During the first postoperative decade the prognosis of overweight and obese CABG 
patients was as good as that of their background populations and better than that of 
normal weight patients. This phenomenon, called the obesity paradox, has been seen 
in a wide range of CAD manifestations including CABG patients 383–387. 
Our finding was that the obesity paradox seems to be a consequence of too short 
follow-up. In obese CAD patients who had undergone CABG the initial prognosis 
was good but deteriorated when the follow-up period was extended to 20 years. 
There are several explanations. Obesity is often defined by BMI as it is an easily 
measurable parameter used in routine clinical practice. It has been criticized for its 
lack of accuracy in defining obesity hence it is an aggregate of varying amounts of 
fat-free mass and body fat 388,389. Therefore people with low lean mass but increased 
body fat and conversely trained athletes with high body muscle mass may be 
misclassified by BMI. 
Fat-free mass is widely considered a positive prognostic factor. CAD as a systemic 
disease can result in cachexia similar to that seen in heart failure 390. Poor nutritional 
status has been shown to predict mortality after cardiac surgery 391,392. Hence both 
fat-free mass and body fat may provide a protective metabolic buffer during the 
recovery period after CABG 393. 
There are also other potential explanations for the obesity paradox. Obesity was 
earlier considered a perioperative risk factor in CABG 394. It is therefore possible 
that high-risk obese patients, also in this study population, were excluded from 
revascularization, thereby creating a selection bias, as has been  observed elsewhere 
395.  Furthermore, it has been postulated that obese patients may receive better 
disease-modifying medication than do normal weight patients 384, although in our 
material they did not take significantly more ACE inhibitors, statins or ASA, 
according to the patient questionnaire. 
The 20-year prognosis of overweight patients was better than the prognosis of 
normal weight and obese patients. Nevertheless, during the second follow-up decade 
their survival was also inferior to that of the background population. In our patient 
population diabetes was an important predictor of poor prognosis while 27% of 
overweight patients had diabetes (Table 4). 
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6.4.2 Impact of metabolic status  
Obesity is associated with MetS and T2DM via lipid abnormalities, insulin resistance 
and glucose intolerance combining to form complex relationships, where interacting 
pathophysiological roles are not yet fully understood 77,78,396,397. Insulin resistance 
leads to glucose intolerance if the pancreatic compensation processes are incomplete 
398. Glucose abnormalities with or without diabetes predict cardiovascular events and 
mortality, the risk being a continuum with increasing glycemia 399–401. In UKPDS 
study with newly diagnosed T2DM patients, each 1% reduction in updated mean 
HbA1C was associated with reduction in risk of 21 % for deaths related to diabetes 
and 14 % for myocardial infarction 402. Further, MetS has been shown to impair the 
prognosis of CAD patients 403.        
Our principal finding was that obesity, MetS and T2DM are deleterious to the 
long-term prognosis of CAD patients. Concerning MetS and DM our results 
confirm those of earlier studies 332,404–406. The excessive death rate in the second 
postoperative decade of both obese patients and those with DM in our material was 
mostly related to cardiovascular causes. Our results corroborate the notion that  
long-lasting DM in particular is associated with a high risk of recurrent ischaemic 
coronary events 210,337,407,408. 
6.5 Methodological considerations and study limitations 
6.5.1 Strengths 
Patients in the follow-up studies represent the expert responsibility area of Tampere 
University Hospital, one of the five university hospital districts in Finland, 
comprising totally more than one million inhabitants. The Tampere area has been 
one of the central migration destinations in the urbanization of Finland after World 
War II, thus representing a broad genetic view of the Finnish population. 
The strengths of the follow-up study are the reliability and scope of the national 
registers used, allowing 100% coverage of the retirement, medication and mortality 
data 409. Our follow-up includes all the subjects with CABG, including those who 
migrated within the country and even one patient who relocated to a neighbouring 
country. The length of the individual postoperative follow-up was exactly 20 years 
for all patients, enabling conclusions more reliable than those based on a shorter 
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follow-up. In Finland unregistered and thus uninsured individuals did not present a 
health care problem during the study period, nor did they cause a possible bias in 
our results 410.  
Concerning the cohorts study, between 1990 and 2010, Kanta-Häme Central 
Hospital has had a fairly stable catchment population without any significant national 
or international migration. Thus the genetic and ethnic backgrounds, two factors of 
potential importance considering the length of time analysed and the limited size of 
the study sample, have remained stable 411. 
6.5.2 Limitations 
Certain limitations should also be considered. Firstly, the perioperative data were 
collected retrospectively. Consequently, the researchers had to rely on medical 
records. Even though information was supplemented with patient questionnaires 
and direct contacts, one patient in Study IV (BMI) and 13 (1.4%) patients in Study 
V (DM/MetS) out of the 923 patients alive two months postoperatively were 
excluded due to insufficient data. 
Secondly, in the follow-up study the observed survival rates of the study groups 
were compared to the rates based on age-, gender- and (operation) time-specific life 
tables for the whole population of Finland. This made comparisons between study 
groups easier, nevertheless ignoring some risk factors and concomitant diseases 
(Table 2). Partly due to this, statistically reliable results could not be obtained in 
smaller patient groups, such as women who returned to work.  
Thirdly, in the definition of metabolic syndrome obesity (BMI > 30 kg/m2) 
was used instead of waist circumference. However, BMI is widely used in the 
definition of MetS and studies have demonstrated concordance between various 
definitions 75,344,331.  
Lastly, the diagnosis of diabetes was based on either diabetes according to 
antidiabetic medication or elevated glucose values at the time of the operation or in 
follow-up study also according to the Kela special reimbursement database during 
the first decade after CABG. The latter definition was used because in the 1990s and 
early 2000s patients often had dietary therapy before antidiabetic medication. The 
patients with later glucose lowering medication probably had diabetic metabolism 
already during the first postoperative years and were therefore included in the group 
of patient with DM. However, due to the definition some patients may have been 
misclassified as regards diabetic status. 
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In addition, the cohorts study was a single-centre study and thus does not 
represent postoperative treatment of Finnish CABG patients in general. On the 
other hand, this may also constitute a strength in addressing results achieved with 
active secondary preventive treatment. 
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7 SUMMARY, CONCLUSIONS AND FUTURE 
PROSPECTS 
At the beginning of the 1990s, most modern CABG techniques were already 
established, including myocardial protection during the operation and the use of 
arterial grafts. The benefits of secondary prevention in hindering progression of CAD 
in native coronary arteries as well as in venous grafts were known. The use of aspirin 
and Ƣ-blockers was well-established. The significance of statin therapy and ACE 
inhibitors would be revealed in the following years beginning with the 4S Study in 
1994. Most CABG patients are still currently treated according to the same principles 
as in the late 1990s. Thus in many ways the findings of this study remain valid today. 
In the present study the postoperative prognosis of CABG patients was studied 
for up to 20 years. The results can be summarized as follows: 
1. Almost 60% of patients, who were not retired preoperatively, retained their 
working capacity after surgery. The best predictors of resuming work 
postoperatively were younger age, preoperative working as well as absence 
of diabetes and perioperative cardiac damage.  
2. Having once returned to work, patients’ retention at work was comparable 
to that in the general population with sharply increasing retirement at the 
age of sixty. This study also introduces a model which estimates the 
probability of remaining at work postoperatively including age, 
postoperative cardiac symptoms, diabetes and some nonmedical variables. 
3. Among CABG patients both statin use and the doses prescribed have 
increased considerably since the beginning of the 1990s, the effective dose 
being 36-fold at the end of the 20-year follow-up period. This change in 
treatment practices has de facto halved the mean serum concentrations of 
LDL-cholesterol and apolipoprotein B. The changes in statin treatment 
practice mostly took place immediately after the publication of statin mega-
trials justifying the use of new validated treatment methods. 
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4. The survival of overweight patients was as good as that of their age-, gender- 
and CABG-year-specific background populations for 15 years but 
deteriorated slowly thereafter, which may be associated with the significant 
number of patients with DM in that group. The obesity paradox, standing 
for unexpectedly good prognosis, disappeared soon after the first 10 
postoperative years due to increasing cardiovascular mortality.  
5. Metabolic syndrome is a cluster of cardiovascular risk factors, impairing the 
long-term prognosis of CABG patients. The deleterious effect of diabetes 
was worse than that of MetS without clinical diabetes. At the end of the 20-
year follow-up, only half of the patients with DM were alive compared to 
their matched background populations. Those CABG patients who had 
neither diabetes nor MetS had prognoses as good as those of their matched 
background populations.  
 
Additionally it was found that regular statin use for more than 50% of the 
postoperative follow-up time correlates positively with good prognosis. The poor 
prognosis was especially prominent among statin non-users, although part of it may 
be attributable, for instance, to low adherence to preventive measures in general. 
Ability to work is a crucially important measure of quality of life. This study 
suggests the significance of prompt operative treatment of CAD patients, because 
besides patients’ age, time spent on preoperative sick leave predicts resuming work. 
Several non-medical factors including psychosocial elements are also important in 
employment after MI and its operative treatment 298,306. These nonmedical 
limitations of postoperative employment have not yet been fully ascertained and thus 
would benefit from further research.  
When studying adherence, patients’ non-adherent to statins had the worst 
prognosis. This finding may reflect the insufficient use of medications and other 
means in general 370. We live in a time of “isms”, internet and social media. Besides 
beneficial information, this exposes patients to non-evidence-based advice, even 
hearsay. Public campaigns and preventive educative presentations for CAD patients 
may be useful in explaining the difference between evidence-based medicine and 
hearsay and to improve the use of CV medications.  
Implementation of new methods in clinical practice is often delayed. In the 
cohorts study, it was shown that with precise and individualized treatment almost all 
patients could obtain proper statin medication. This can probably be extended to all 
CV medication. It also includes effective preventive education of CAD patients. 
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Integrating evidence-based medical decision support tools directly into provider 
workflow in the electronic health records has already been studied in selected patient 
groups 412. This kind of new technology is also worth of research on a wide scale in 
CAD patients. 
At the time of the operation, 14% of the patients had the diagnosis of DM. Ten 
years later, 28% were being treated with antidiabetic medication. In addition, patients 
with diabetes had the worst prognosis in the follow-up study. One message of this 
study is that prevention of DM is of key importance for the secondary prevention 
of CAD. Further, likewise important is effective treatment of conditions 
predisposing diabetes in CAD patients, like obesity and MetS. New pharmacological 
treatments for T2DM offer promising results for the reduction of CVD burden 
among patients with T2DM. Further trials to evaluate the practices of prevention 
and treatment of T2DM in CAD patients are of interest in order to individualize and 
optimize their therapy. 
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Abstract 
Objectives To establish which factors influence patients’ return to work and how well they 
remain at work after coronary artery bypass grafting (CABG). 
Design 569 consecutive CABG patients aged less than 65 years were followed for 10 years. 
Data were collected from patient records and by questionnaires supplemented with information 
from Finnish national archives.  
Results Multivariate analysis showed the best predictors for return to work to be younger age, 
preoperative working, as well as absence of diabetes or perioperative cardiac damage. Almost 
half of the patients aged less than 60 and preoperatively not retired were working one year after 
CABG. 
Five years postoperatively, 85% of patients younger than 60 years and once returned to work 
were still working. Correspondingly, of subjects remaining under 60 years during a 10-year 
follow-up, 75% continued working. 
Conclusions Younger age and preoperative employment were the most important predictors of 
successful return to work. Once returned after CABG, patients’ staying at work was compara-
ble with that in the general population.  
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Introduction 
Coronary artery bypass grafting (CABG) is an effective treatment for patients with symptomat-
ic coronary heart disease (CHD). It alleviates angina pectoris and improves the life expectancy 
of patients with multivessel CHD. Most patients’ physical capacity and quality of life are sig-
nificantly enhanced. [1]  
However, many CABG patients still of working age have retired before surgery, and only half 
are working postoperatively. [2,3] During the first postoperative year 20% to 30% have angina 
pectoris symptoms [4] and seven per cent experience neuropsychological defects as determined 
six months after surgery. [5] Results may be improved using off-pump coronary artery bypass 
grafting. [6]  
One fifth of patients treated by CABG have reported their quality of life to be postoperatively 
no better than before the procedure. [7] Subjective well-being is not related to physical status. 
The reasons for difficulties in returning to work are multifactorial, and even freedom from 
symptoms does not necessarily mean that a patient will return to work postoperatively. [8] 
The direct and indirect costs of coronary heart disease are enormous. Besides the financial bur-
den, loss of leisure time activities and psychological stress are other significant losses for pa-
tients. [9] The restoration of normal functional capacity and quality of life, in which the re-
sumption of professional activity is an important element, can be considered a major objective 
of coronary surgery. [10] 
The aim of the Working after CABG (W-CABG) study was to ascertain what pre- or perioper-
ative factors influence patients’ return to work after CABG. We also studied how well patients 
once successfully returned to work continued at work.
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Material and Methods 
Subjects 
CABG was undertaken for 960 patients in Tampere University Hospital from January 1, 1993 
to June 30, 1994. The study population (age <65 years) consisted of 569 (59%) consecutive pa-
tients undergoing CABG. The catchment population of the hospital was 1.2 million inhabitants 
living in southern Finland, comprising about 22% of the total population of Finland. 
After the first postoperative days patients were sent to their local hospitals for further recovery. 
They were discharged 10 to 14 days after the operation if no complications occurred. They at-
tended a cardiology or internal outpatient clinic 1 to 2 and 3 to 4 months after the operation. 
ECG and basic laboratory parameters were then analysed. After a few postoperative months, 
most patients were transferred to primary care for secondary prevention. W-CABG study per-
sonnel checked hospital records after the transfer to primary care. 
 
Data collection and follow-up 
Pre- and perioperative anamnesis and morbidity were collected manually from the patient rec-
ords in Tampere University Hospital. Data on the first postoperative months were collected 
from the patient records in the hospitals responsible for follow-up. Diagnoses of hypertension, 
claudication, previous myocardial infarction, and previous transient ischemic attack (TIA) or 
stroke were also noted. A patient was defined as having type 1 or type 2 diabetes mellitus 
(T1DM or T2DM) when on appropriate antidiabetic medication. Hypercholesterolemia was di-
agnosed when a patient was on lipid-lowering drug therapy or had total cholesterol >5 mmol/l. 
Smoking habits were established by questionnaire 21 months postoperatively. 
The first follow-up data collection was made with a detailed questionnaire in July 1995, i.e. on 
average 21 (range 12 – 30) months after the operation. A repeat questionnaire was sent two 
months later when necessary (response 86% of patients). Especially employment status, heart 
symptoms and clinical course of CHD were asked. Subjective well-being against patients’ ex-
pectations as well as risk and protective factors were also evaluated. 
The second follow-up was made almost identically to the first during the year 2003, i.e. 9 to 10 
years after the operation (response 83% of patients). Both times the follow-up included contact 
by phone if there was a need to clarify answers. Working status and other relevant information 
was obtained from all but two patients. 
Possible death, its date and diagnosis were checked from the Statistical Office of Finland. Em-
ployment status or the date and the reason for possible retirement were checked from the Finn-
ish Centre for Pensions 10 years after the last operation.  
In Finland the retirement rate increases rapidly at the age of 60 years. Over 70% of unselected 
Finns work at 55 – 59, as against only 35% of those aged 60. Thus other than medical reasons 
seem to incline strongly towards retirement at that age. In analysing staying at work we there-
fore decided primarily to confine attention to patients still younger than 60 years during the 
follow-up (n= 372 at the time of CABG). The results were compared with the pensioning rate 
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among a matched Finnish population. [11] The study was approved by the Ethics Committee 
of Tampere University Hospital. 
 
Statistical methods 
Categorical variables were tested using chi-square test and Wilcoxon test (return to work vs. 
pre-, peri- and immediate postoperative medical data, education, type of work, preoperative 
pensioning, patients’ social situation and lifestyle elements such as exercise habits and smok-
ing). A stepwise Bayesian approach with an analysis system created by one of the authors was 
used as multivariate analysis to determine posterior probabilities and likelihood ratios and to 
ascertain the sensitivity and specificity of the rule. [12] The model was calculated taking into 
account all patients alive twelve months after CABG. Patients were considered returnees to 
work if they were working at that time. 
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Results 
Study material 
Altogether 569 patients younger than 65 years underwent CABG during the study period. Pa-
tients’ demographic data and job classification are shown in Table 1a. Clinical characteristics 
and severity of coronary heart disease are compiled in Table 1b.  
A valvular operation was carried out for 3.7% (21 patients) and carotid endarterectomy for 
0.4% (2) in the same operative session as CABG. Perioperative mortality was 2.2% (13). In ad-
dition, 2.1% (12) died during the first postoperative year. Of these 25 patients, 20 were already 
pensioned preoperatively and five died before return to work or retirement. Thus all together 
544 patients (96%) remained alive one year postoperatively. 
 
Return to work after CABG 
Altogether 53 % (301) of patients younger than 65 years were pensioned preoperatively, forty-
three of them having retired less than six months before the operation. The remaining 47 % 
(268 surviving patients) were working, unemployed or on short-term sick pay. Of those, 145 
were working after the first postoperative year. The remaining 123 retired immediately after 
postoperative sick pay without returning to work or after only a couple of months working. Of 
preoperatively pensioned patients only six returned to work, while 295 remained pensioned af-
ter CABG. Hence, altogether 151 patients were working one year postoperatively (Figure 1). 
Among patients younger than 60 years (n = 331), 43% (141) were working one year postopera-
tively, while 28% (93 patients) had been pensioned preoperatively without returning to work 
and 28% (94) retired during the first postoperative year. One per cent (3) of the non-pensioned 
patients died perioperatively or during the first postoperative months (Figure 1). 
 
Factors affecting return to work  
In univariate analysis, the most important factors affecting return to work were patient’s age 
and duration of pensioning or cash rehabilitation benefit (p<0.001). There was an inverse corre-
lation between age and return to work. At the age of 55 years preoperatively non-pensioned pa-
tients’ return to work began to diminish rapidly. When the age was less than 50 years at the 
time of CABG, 70% returned and were successfully working one year postoperatively, while 
the figures for older age groups, 50 to 54, 55 to 59, and 60 to 64 years, were 64%, 48%, and 
21%, respectively. 
The mode and length of preoperative sick pay or pension was related to return to work as fol-
lows. Most patients (71%) being preoperatively only briefly on sick pay returned to work. Re-
turn took place in 9% of cases pensioned for less than six months as against only 1% of those 
pensioned for a longer time. 
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In univariate analysis higher basic education and absence of a history of TIA or stroke also pre-
dicted return to work (p<0.001). Patients’ high total cholesterol, DM, high preoperative NYHA 
classes III-IV, and low ejection fraction seemed somewhat to diminish the return rate (p<0.01) 
(Table 1a and 1b). Short height (173.9 cm (SD 6.1) vs. 175.4 cm (SD 6.1) for men and 159.9 
cm (SD 5.6) vs. 162.3 cm (SD 5.3) for women) and a family history of cardiac disease (78%  
vs. 84%, p<0.01) were also associated with reduced return rate. However, for example postop-
erative heart symptoms were not associated with return to work. 
In stepwise Bayesian multivariate analysis, best sensitivity was found for a model which in-
cluded only patient’s age and pensioning. The specificity increased when history of diabetes 
mellitus as well as signs of perioperative myocardial damage were added. In this model sensi-
tivity was 94% and specificity 75% (Table 2).  
 
Staying at work 
Analysis of continued employment involved patients at work one year postoperatively. All to-
gether 141 patients (13 women) out of 151 working postoperatively were younger than 60 years 
at the beginning of follow-up and  56 remained under 60 years of age 10 years after CABG. Of 
these 67% were still working full-time and 8% part-time, while 25% had retired on disability 
pension before the end of the 10-year follow-up. The postoperative follow-up of employment 
status (until Dec 31, 2003) is presented in Figure 2. 
Looking at patients still alive 5 years postoperatively, 101 were under 60 years and 35 were 60 
– 64 years. Of the former age group 80% were working full-time and 5% part-time. Altogether 
15% were pensioned. After the age of 60 the retirement rate increased rapidly and in the age 
group 60 – 64 years only 34% were working full-time and 6% part-time (Figure 3). 
We also compared patients five years after the operation with an unselected Finnish population, 
the material being obtained from the Finnish Centre for Pensions. It emerged that those CABG 
patients who had successfully returned to work stayed at work as well as did unselected Finns 
of the same age and gender (Figure 3). 
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Discussion 
 Principal findings 
Follow-up of patients remaining under 60 years revealed that one fourth retired preoperatively 
and one fourth during the first postoperative year, while almost half successfully returned to 
work for a longer period. In multivariate analysis the best predictors for return to work were 
younger age, preoperative working, and absence of diabetes or perioperative myocardial dam-
age.  
After 5 years, pensioning of patients once successfully returned to work did not differ from that 
in the matched general population. Furthermore, 75% of patients aged <60 years were still 
working 10 years postoperatively. 
 
Strengths and weaknesses of the study 
The W-CABG study represents as far as we know the longest follow-up of CABG patients’ 
staying at work. In general, the relatively high age of operated patients may be the major reason 
for the lack of longer follow-up data on patients’ working status after CABG. A long follow-up 
is time-demanding, and patient drop-outs may constitute a serious problem for the accuracy of 
studies. The precision of national statistics and the willingness of patients to fill in question-
naires certainly helped us during the present study. 
We analysed data on all consecutive patients operated over a period of 18 months. The catch-
ment area of the study population contained more than 20% of the country’s inhabitants. Pa-
tients came from both industrial and agricultural municipalities, well representing the Finnish 
population.  
The study commenced with a retrospective analysis of patient records. Data were checked with 
written patient questionnaires and telephone contacts. Follow-up data on pensioning and mor-
tality were also verified from national archives. In Finland as in other Nordic countries official 
statistics are particularly precise. Even after these measures some data might be missing, for in-
stance if an individual patient record has contained errors and the subject has given insufficient 
information. We sought to ensure that this would cause no bias. 
 
Differences in relation to other studies 
Return to work 
According to several studies carried out in the USA and Europe, return to work after CABG has 
been between 50% and 84% [3,13,14], and has not changed during the last 20 years. [10] In 
earlier Finnish CABG series, 40% to 60% of non-retired patients resumed work postoperative-
ly. [2,15] However, very few pensioned patients seem to return to work. The possibility of a 
disability pension may influence postoperative return. [8] When considering only non-
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pensioned patients’ return to work, our results were comparable with those in international 
studies.  
 
Factors predicting return to work 
Similarly to other investigators’ findings, patients’ age was here an important predictor of re-
turn to work. [3,8,10,16,17] Among patients at the age of 55 the return rate diminished fast, and 
when the age of 60 was reached the decrease became even steeper.  
The national unemployment rate may affect patients’ return to work. [16] Recently, the highest 
retirement rates in Finland (over 80% among those aged 60 to 64 years) were found during the 
years 1993 – 97, i.e. when a deep economic depression affected the country. [11] The postoper-
ative recovery and rehabilitation phase of W-CABG patients fell during this same period. 
Though pensioning of younger subjects was fairly low in our study, the economic depression 
may have affected older patients’ return to work. A high unemployment rate may reduce an in-
dividual’s social activities and motivation to take an active part in the rehabilitation process. 
[16] Patients’ own wish to return to work and employers’ attitudes towards the re-employment 
of a disabled worker also have their effects on the probability of an individual’s retirement. [17] 
It is conceivable that these factors together have an even greater impact on return to work than 
the medical reality.   
In a Swedish study older age was found to be associated with a lower rate of return to full-time 
work but not with reduced working hours after CABG, PCI or myocardial infarction. [16] In 
Finland likewise some 20% of CABG patients have also earlier returned to an easier job. [15] 
In our study patients mainly returned to their previous employment and on average only 6% 
worked reduced hours during the 10-year follow-up. This rigidity in working life may also ex-
plain the retirement of patients with limited working capacity.  
Preoperative working status was a very important baseline predictor for postoperative employ-
ment status. Our findings are in accord with those in earlier studies, where both pensioning [3, 
18] and the length of preoperative sick leave [18] have been found to be highly significant pre-
dictors for return to work.  
Preoperative DM and perioperative myocardial damage were related to return to work. Our def-
inition for DM might contribute to a fairly small proportion of T2DM. According to this study, 
at least DM treated medically is related to pensioning. Also elsewhere DM has been found to 
predict poor resumption of work. [19] On the other hand, perioperative myocardial damage has 
not previously been confirmed as an independent predictor of postoperative retirement. Perhaps 
it should be understood above all as a sign of diffuse vascular disease. Contrary to some earlier 
findings, for example job characteristics or gender were not predictive for return to work in our 
study. [3,19] 
 
Staying at work 
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In Finland, the retirement rate increases rapidly from the age of 60 solely for non-medical rea-
sons. We therefore decided to follow patients in four age groups in order to reduce the effect of 
age as a confusing factor. 
Five years after the operation 85% and ten years after the operation 75% of patients still under 
60 years were engaged in working life (Figure 2). Staying at work among our CABG patients 
did not differ significantly from that in a matched general Finnish population. [11] In an earlier 
Finnish study, where a rehabilitation program was compared to usual care, only 39%, i.e. 23 
out of 59 patients working one year postoperatively, were still working 4 years later. [2] Ac-
cording to patients’ reports, cardiac condition was the most important reason for not working. 
In a British study more than 20% of patients working at 12 months postoperatively discontin-
ued during the following four years on account of health and for other reasons not related to old 
age pension. [3] In an American study 51% of 177 CABG patients already returned to work re-
tired on account of health problems and factors other than pension during a 4-year follow-up. 
[14] 
One reason for our patients’ relatively good persistence at work might be the steeply increased 
use of cardiac medication, notably statins and ACE inhibitors. Another explanation might be 
that in Finland only those patients returned to work who really felt able to work. In the early 
90s it was still relatively easy to obtain a disability pension after CABG compared with many 
other chronic diseases.  
When compared to a matched general population, CABG patients once successfully returned to 
work kept on working as well as the general population of the same age and gender. The only 
differences were seen in the youngest and oldest age groups, where the small number of pa-
tients might accidentally have influenced the outcome (Figure 3). 
 
Meaning of the study 
The W-CABG study, with a 10-year follow-up, is in a certain sense out of date, in that CABG 
took place in the last decade. Desirable shortening of waiting lists, improved operation tech-
niques, novel pharmacological preconditioning of the heart during CABG, and aggressive pre-
ventive drug therapy with statins and ACE inhibitors have improved the prognosis of CHD pa-
tients. [21-24] However, without studies with a sufficiently long follow-up we cannot be as-
sured of the effects of CABG in real life. Thus, only patiently conducted systematic research 
may resolve this uncertainty. 
If the prognosis of coronary heart patients is to be substantially improved, there is still a contin-
uous need to intensify preventive drug therapy. [25] Besides medical therapy, increased use of 
percutaneous coronary intervention with stenting as treatment for coronary stenosis and occlu-
sion has changed the operational environment in the invasive treatment of CHD. [26] CABG 
has still an important place in this context. [13,26] Studies concerning the effect of shortening 
waiting lists on the comprehensive prognosis of CABG patients are thus urgently needed. 
To conclude, age, preoperative retirement, diabetes mellitus, and perioperative myocardial 
damage negatively predicted return to work among CABG patients. However, patients once 
successfully returned had very good chances of remaining in working life until their usual pen-
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sioning age. For probable returnees to work shortening of preoperative waiting time as well as 
postoperative support and rehabilitation are thus clearly justified.  
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Table 1a: Demographic data and job classification at the time of CABG 
 
 
 Female patients 
<65 years work-
ing one year 
after CABG  
(n = 13) 
% 
Male patients 
<65 years work-
ing one year 
after CABG  
(n = 138) 
% 
Patients <65 
years working 
one year after 
CABG  
(n = 151) 
% 
Patients <65 
years not work-
ing one year 
after CABG  
(n = 418)  
% 
 
Age 
   
 
 
 
< 50 31 38 38      17 ** 
50 - 54 31 33 33       19 ** 
55 - 59 31 25 25      29 ** 
60 - 64 7 4 4      35 ** 
 
Education 
   
 
 
 
Less than high school 82 68 69     78 * 
High school graduate 9 21 20     16 * 
University graduate 9 11 11     6 * 
 
Job classification 
    
Manual worker 
(Factory or construc-
tion work) 
43 43 42 43 
Employee lower level 
(salesperson, nurse) 
17 17 17 16 
Employee higher level  
(teacher, engineer) 
16 16 16 14 
Farmer 5 5 5 8 
Employer or  
entrepreneur 
19 19 20 19 
 
 There were no significant differences between male and female patients. 
The asterisks represent significant differences between patients working and not working one year after 
CABG as follows: *  p < 0.01, **  p < 0.001. 
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Table 1b:  Clinical characteristics and severity of coronary heart disease before CABG 
 
 Female patients 
<65 years work-
ing one year 
after CABG  
(n = 13) 
% 
Male patients 
<65 years work-
ing one year 
after CABG  
(n = 138) 
% 
Patients < 65 
years working 
one year after 
CABG  
(n = 151) 
% 
Patients <65 
years not work-
ing one year 
after CABG  
(n = 418) 
% 
 
Concomitant dis-
eases 
    
Hypertension 77 34 38 43 
Hypercholesterolemia 90 91 91      86 * 
Diabetes mellitus 23 4 5      11 * 
Previous MI 70 62 63 67 
Previous TIA or stroke 0 3 3       9 ** 
Intermittent claudica-
tion 
0 4 3 8 
 
Preoperative smok-
ing 
 
 
27 
 
 
60 
 
 
57 
 
 
65 
 
Cardiac function 
    
EF 35 to < 50 % 8 9 9     12 * 
EF < 35 % 0 3 3     7 * 
NYHA II 8 19 18     14 * 
NYHA III 59 65 65     61 * 
NYHA IV 33 16 17     25 * 
 
Severity of CHD 
    
Three–vessel disease 31 49 47 53 
Left main disease 8 10 10 13 
Elective operation 83 86 86 75 
Urgent operation 17 12 12 19 
Emergency operation 0 2 2 6 
 
 (MI = myocardial infarct, TIA = transient ischemic attack, EF = ejection fraction, NYHA = angina pectoris 
symptoms according to New York Heart Association, CHD = coronary heart disease) 
There were no significant differences between male and female patients. The asterisks displayed as in Table 
1a. 
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Table 2  Probability of being at work one year after CABG (n = 151 out of 544) 
 
 
Pension before CABG 
 
No pension 
 
LR = 3.89 
 < 6 months before CABG LR = 0.34 
 > 6 months before CABG LR = 0.03 
 
Age at the time of CABG 
 
< 45 years 
 
LR = 10.4 
 45 – 49 years LR = 2.86 
 50 – 54 years LR = 2.28 
 55 – 59 years LR = 0.80 
 > 60 years LR = 0.09 
 
Diabetes mellitus 
 
No DM 
 
LR = 1.08 
 T1DM LR = 0.50 
 T2DM LR = 0.31 
Signs of perioperative  my-
ocardial damage 
 
No damage 
 
LR = 1.07 
 Damage* LR = 0.63 
 
LR = likelihood ratio. For an individual patient, the model is used by multiplying the patient’s LR by all 
characteristics described. The greater LR is the better is the possibility of returning to work. LR may be 
expressed as percentage probability as follows: 
p = 100 * LR/ (1+LR). Critical value of LR is 1.00 (Sensitivity of the rule 94%, specificity of the rule 
75%). Total error rate of the model 20%. 
 
* Damage = ECG or biomarker changes related to perioperative myocardial infarct or postoperative low 
output situation.  
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FIGURE LEGENDS 
 
 
Figure 1 Patients’ pensioning and working. 
 
Figure 2  Postoperative employment status at the end of each calendar year. A 10-year follow-up of orig-
inally 141 patients (56 at the end of follow-up) who were working one year postoperatively and 
remained under 60 during the follow-up. Deceased persons, all together eight are excluded. 
 
Figure 3  Pensioning status of those CABG patients who returned to work (n=136), on average five years 
after operation (Dec 31, 1998) together with unselected Finnish population, age and sex stand-
ardized.[10] 
Age groups: 30 – 49 y (n = 22), 50 – 54 y (n = 31), 55 – 59 y (n = 48), 60 - 64 y (n = 35).  
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Hällberg et al, Figure 1 
 
 
 
 
    Pensioning and working of patients                  Pensioning and working of patients aged less   
    aged less than 65 at the time of CABG                than 60 at the start of work follow-up  
                   (= one year postoperatively) 
 
1,1 %
25,5 %
0,9 %
20,7 %
48,3 %
3,5 %
 
1,8 %
40,8 %
28,4 %
26,9 %
1,2 %0,9 %
 
   
Preoperatively retired, Preoperatively non retired, but retired 
remained retired during first postoperative (po) year
Preoperatively retired but working Preoperatively non retired, died during 
one year postoperately first po year
Preoperatively non retired, working Preoperatively retired, died during 
one year postoperately first po year
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Hällberg et al. Figure 2 
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Hällberg et al. Figure 3 
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Background
The major objectives in coronary artery bypass grafting
(CABG) are restoration of normal functional capacity and
quality of life as well as resumption of professional activ-
ity [1]. Factors predictive for return to work after CABG
have been examined in various studies and are fairly well
known. Return rates vary widely around the world, due to
various factors such as different sick insurance systems,
labour market conditions and sick listing traditions
among physicians [2]. Only few studies have focused spe-
cifically on retention of work capacity after CABG.
In the earlier part of the Working after CABG (W-CABG)
study we examined return to work and the length of con-
tinuation in a Finnish CABG patient population. Accord-
ing to the follow-up of patients remaining under 60 years,
almost half returned to work successfully for a longer
period. One fourth retired preoperatively and one fourth
during the first postoperative year. After 5 years, pension-
ing of patients once successfully returned to work did not
differ from that in the matched general population [3].
Aims of the present study
In this paper we report postoperative continuation in
work life among men and women aged less than 60. It was
of special interest to evaluate the following aspects:
1) Which factors influence patients staying on?
Why do people who have resumed work after CABG retire
prematurely?
2) What kind of model would help to estimate patients'
possibilities of staying at work?
Methods
Material
The population of the W-CABG study has been described
elsewhere [3]. Briefly, CABG was undertaken for 960
patients in Tampere University Hospital during a period
of 18 months. The subjects of the present study comprised
141 consecutive patients aged less than 60 who had
undergone CABG and were working one year postopera-
tively.
Data collection
Study personnel checked hospital records after transfer to
primary care. The follow-up checks were made with a
detailed questionnaire on an average 21 months after the
operation and 9.5 years after the operation. The reply per-
cents were 89 and 83 of patients alive, respectively. Work-
ing status and other relevant information was obtained
from all but two patients.
Employment status or date and reason for possible retire-
ment were checked from the Finnish Centre for Pensions
10 years after the last operation [3]. Possible death, its
date and diagnosis were checked from the Statistical
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Office of Finland. The study was approved by the Ethics
Committee of Tampere University Hospital.
Statistical methods
Categorical variables were tested using chi-square test and
Wilcoxon rank test (Return to work vs. pre-, peri- and
immediate postoperative medical data, education, type of
work, preoperative pensioning, patients' social situation
and lifestyle elements such as exercise habits and smok-
ing).
Bayesian analysis
A stepwise Bayesian approach was used in multivariate
analysis to determine posterior probabilities and likeli-
hood ratios and to ascertain the sensitivity and specificity
of the rule [4-8]. The model was calculated taking into
account all patients under 60 and working one year after
CABG.
Theory
The Bayesian approach states how posterior probability of
diagnosis D given symptom × is calculated using the prior
probability of diagnosis D and its absence. These show
how common the diagnosis D and its absence are in the
population. The probabilities of symptoms given the
diagnosis and its absence are commonly estimated by
their frequencies in learning material [6,7].
In the case of a two-valued outcome, the Bayesian
approach is commonly developed to give a likelihood
ratio (probability of × given diagnosis D divided by prob-
ability of × given absence of diagnosis D). The likelihood
ratio (L) of a set of observed symptoms or properties xi is
written as the product of the probability ratios of each xi,
also known in epidemiology as risk ratios.
The posterior probability of a given set of observations is
calculated by dividing the likelihood ratio by "one plus
likelihood ratio". Percentage is obtained by multiplying
by 100.
Derivation of indices
One of the authors (MK) has developed an optimization
procedure to facilitate the Bayesian analysis. The program
goes through all variables given by the parameters and
selects first only one variable which will best predict the
selected outcome, staying at work over the median in our
study. The program then goes through all the remaining
variables and selects as second variable that which will
best predict the outcome together with the first variable.
Adding one variable after another to the model, the pro-
gram goes through all the variables. If there are variables
which correlate with each other the program selects the
best predictor and ignores others. The optimum is the
number of variables which together give the smallest fail-
ure rate (maximum sum of sensitivity and specificity) in
the study group. Usually the optimum does not include
all given variables. Ultimately the program provides the
best combination of variables which will most accurately
predict the outcome.
The program gives the critical area for the total risk index,
where the numbers of false-negative and false-positive
results are minimal. It also calculates a Receiver Operating
Characteristics (ROC) curve. It gives a graphic representa-
tion of the relationship between true-positive and false-
positive rates and can be used to study the effect of chang-
ing the decision rule. The area under the ROC curve is
commonly used to measure the predictive power of a sta-
tistical model [8].
Results
Study population
The study population comprised 141 CABG patients, 12
women and 129 men who were working one year postop-
eratively. Their demographic data and work classification
are shown in Table 1. Clinical characteristics and severity
of coronary heart disease are compiled in Table 2. Besides
CABG an aortic valve replacement was carried out for one
patient (male, age 52 years). Four patients had been pen-
sioned before the operation and returned to work after
CABG, 137 had been preoperatively at most on short-term
sick pay.
Continuation at work after CABG
The yearly employment status (full-time or part-time
work) gradually decreased in men from 100% to 85% (n
= 95) in five years. Correspondingly, it was 73% (n = 49)
ten years postoperatively. The results for women were
affected by their small number (n = 7 five years and n = 3
ten years postoperatively) (Figure 1). Altogether 76% of
patients aged < 60 years were still working 10 years after
CABG.
All 141 patients were younger than 60 one year after
CABG. Twenty-six of them (17%) retired on disability
pension before the age of 60, the main reason being car-
diac condition in 16 cases. Ten patients retired for other
reasons (stroke, pulmonary embolism, psychiatric and
musculoskeletal disorders). During the follow-up, a total
of 15 CABG patients retired to adjusted old-age pension at
the age of 57 – 60 mainly for non-medical reasons. Half
of them retired 1 to 2 years after CABG.
Model of continuation at work
Results of univariate analysis
In univariate analysis, the three most significant factors (p
< 0.001) affecting staying on were patients' age at the time
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of the operation, preoperative working status and
patients' height.
Other factors describing different aspects of patients' med-
ical condition and social situation evinced some lesser
correlation with continuing to work. Some were related to
preoperative conditions such as kidney function, some
others to the extent of cardiovascular disease or postoper-
ative well-being (NYHA class, nitrogen use and subjective
well-being when compared to preoperative condition).
Patients' size was shown not only by patients' height but
also by sex and weight. Other factors described diabetic
Table 1: Demographic data and job classification at the time of CABG
Female (n = 12)
%
Male (n = 129)
%
All (n = 141)
%
Age
< 50 33 41 40
50 – 54 33 35 35
55 – 59 33 24 25
Education
Less than high school 80 68 69
High school graduate 0 22 20
College graduate 20 10 11
Job classification
Manual worker 25 46 44
Employee lower level 12 17 17
Employee higher level 25 16 17
Farmer 0 5 4
Employer or entrepreneur 38 16 18
Table 2: Clinical characteristics and severity of coronary heart disease before CABG
Female (n = 12)
%
Male (n = 129)
%
All (n = 141)
%
Concomitant diseases
Hypertension 83 33 38
Hypercholesterolemia 90 91 91
Diabetes mellitus 25 4 6
Previous MI 70 61 62
Previous TIA or stroke 0 3 3
Intermittent claudication 0 4 3
Smoking
Previous 30 60 58
Current 20 15 16
Cardiac function
EF 35 to < 50% 9 7 7
EF < 35% 0 3 3
NYHA II 17 20 20
NYHA III 58 64 63
NYHA IV 25 16 17
Severity of CHD
Three-vessel disease 33 48 47
Left main disease 8 10 10
Elective operation 91 86 87
Urgent operation 9 12 11
Emergency operation 0 2 2
(MI = myocardial infarct, TIA = transient ischemic attack, EF = ejection fraction, NYHA = angina pectoris symptoms according to New York Heart 
Association, CHD = coronary heart disease)
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burden (body mass index or diagnosed type 2 diabetes
mellitus), overall physical activity (daily walking distance,
walking restrictions and frequency of participation in
household work) and social situation, e.g. patients' mari-
tal status.
Results of multivariate analysis
When forming the model for remaining at work by multi-
variate Bayesian analysis, we compared several patterns of
the factors presented above. Finally, patient's younger age
at the time of CABG was selected as the best predictor for
continuation at work. The best balanced and most useful
model also included the following factors: postoperative
cardiac symptoms, patients height, marital status, diabe-
tes mellitus and participation in household work (Table
3).
As an example, we have a 52 year old married patient,
who does not participate in household work. He/she is
176 cm of height and is not suffering from diabetes or
postoperative cardiac symptoms. Hence, the total likeli-
hood ratio of remaining at work is 1.24 × 1.80 × 0.93 ×
1.03 × 0.58 = 1.24. According to the model [100 * LR/
(1+LR)], we get 55% probability of remaining at work for
at least six years. If our patient would be an active person
for example participating into the household work, his/
hers total likelihood ratio of remaining at work for at least
six years would increase to 1.24 × 1.80 × 0.93 × 1.03 ×
1.25 = 2.67 and thus his/hers probability were 73%.
The ability of the model to predict continuation was ana-
lyzed in annual time intervals throughout the 10-year
postoperative follow-up. In this population the total error
rate was 14% to 26% (Fig 2). The corresponding ROC
curves are shown in Fig. 3.
Discussion
Principal findings
In this paper we present a model for estimating patients'
possibilities to remain in work after CABG. We also report
that 73% of men who returned to work postoperatively
and were aged less than 60 years were still working 10
years later. The number of women was not large enough
for scrutinized statistical comparison, but their continua-
tion at work resembled that of men.
Strengths and weaknesses of the study
To the best of our knowledge this study represents the
longest follow-up of CABG patients' retention of work
capacity. We analyzed data on all consecutive patients
operated over a period of 18 months. Their urban and
rural domiciles comprise more than 20% of the inhabit-
ants of the country, thus well representing the Finnish
population.
The study was commenced with a retrospective analysis of
patient records. In addition, written patient question-
naires and telephone contacts were used. Follow-up data
on pensioning and mortality were verified from national
archives, which in Finland are particularly precise. Even
after these measures some postoperative data, for instance
in patient questionnaires, were missing.
Our study population was only 141 patients. In general,
relevant long-term follow-up data on CABG patients'
working status are somewhat difficult to obtain by reason
of the relatively high age of the patients operated. Espe-
cially the female population was very small, and the inter-
pretation of its postoperative work activity must be made
very carefully. We therefore treated men and women as
one group when forming the model. On the other hand,
patients' uniformity in respect of age and burden of dis-
eases made it easier to make significant calculations also
from a fairly small material.
When building the model, possibly relevant parameters
had first to be selected by univariate analysis. At this stage
some, again, had to be left out owing to insufficiency of
material. Some factors were not selected due to their low
prevalence in the population studied. Of variables
describing different aspects of the same feature, only the
best was selected for the model.
Postoperative employment status at the end of each calendar yearFigure 1
Postoperative employment status at the end of each 
calendar year. A 10-year follow-up of originally 141 
patients, who were working one year postoperatively and 
remained under 60 during the follow-up. Deceased persons, 
altogether eight, are excluded. X-axis: Calendar years. Y-axis: 
Percentages of patients working at the end of each calendar 
year. Blue line: men, red line: women
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The Bayesian approach in multivariate analysis was used
in view of its ability to analyze partly incomplete material
from questionnaires. In this study it also seemed to be
more illustrative than logistic calculations based on an
iterative process.
Retirement before the age of sixty
Three quarters of the patients less than 60 were in working
life ten years after CABG (Fig. 1). The difference seen
between genders was evidently induced by the small
number of women returning to work postoperatively and
working until the age of 60.
Some of the retired patients had evident worsening of car-
diac disease after the initial CABG. However, the majority
of patients in this group were pensioned off because of a
wide range of postoperative problems not necessarily
related to coronary insufficiency. Of retirees aged less than
60 who resumed work 27% were pensioned during the
first follow-up year. This may reflect the early retirement
and disability pensioning system in Finland, which
favours working attempts after CABG before obtaining a
pension.
Results in relation to other studies
Only a few published studies have evaluated continuation
at work over a longer follow-up. None has introduced a
model for remaining in work. However, it is possible to
make some comparisons with shorter follow-up studies of
two to five years which describe retention of working
capacity after CABG. Skinner et al. have introduced a Brit-
ish material of originally 343 CABG patients [9]. At five-
year follow-up the most important factors for continua-
tion were younger age at the time of operation, male sex,
Table 3: The probability of remaining at work for at least three, six and nine years
Variable Over 3 years Over 6 years Over 9 years
(n = 119) (n = 92) (n = 59)
1. Age at the time of CABG
d 50 LR = 6.54 LR = 3.25 LR = 2.42
50 – 54 LR = 3.80 LR = 1.24 (LR = 0.20)
t 55 LR = 0.68 LR = 0.37 (LR = 0.01)
2. Postoperative cardiac symptoms
No LR = 1.11 LR = 1.08
Yes LR = 0.51 LR = 0.51
3. Height
< 175 LR = 0.59 LR = 0.58
175 – 179 LR = 1.43 LR = 1.80
180- LR = 6.29 LR = 2.13
4. Being married
No LR = 3.51 LR = 1.60 LR = 1.14
Yes LR = 0.88 LR = 0.93 LR = 0.98
5. Diagnosed DM
No LR = 0.92 LR = 1.03 LR = 1.04
Yes LR = 2.59 LR = 0.80 LR = 0.70
6. Participation in household work
Daily LR = 1.25 LR = 1.26
Less often LR = 0.58 LR = 0.51
Precision of the model
False-Positive 10 18 15
False-Negative 9 17 13
Sensitivity 55% 63% 82%
Specificity 92% 82% 78%
Correct predictions 86% 75% 80%
In this model, the individual probability of remaining at work (calculated one year postoperatively) is as follows:
The patient's likelihood ratio (LR) of each of six characteristics is multiplied. The greater LR, the better is the possibility of remaining at work. If the 
total LR is greater than 1.00, the probability of remaining at work is more than 50% for the given time (3 y, 6 y, or 9 y). Patients in age groups 
marked in parenthesis may remain at work for over the age of 60.
LR may be expressed as probability as follows: p = 100 * LR/(1+LR).
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The ability of the model to predict remaining at workFigure 2
The ability of the model to predict remaining at work.
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Positive 128 119 111 101 92 80 68 59 56 
False-Positive 6 10 16 20 18 18 21 15 15 
False-Negative 14 9 9 12 17 19 12 13 10 
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preoperative working and freedom from postoperative
angina symptoms. Hlatky et al. have presented an Ameri-
can material of 409 patients with either CABG or PCI [10].
Long-term employment did not differ significantly
between these groups. The authors also found that predic-
tors of longer working postoperatively were younger age
at the time of the operation and preoperative full-time
work, but also a single private source of medical insur-
ance, which would indicate the importance of social fac-
tors. Left ventricular function appeared as a single medical
factor. In the RITA trial [11], over 1000 patients were ran-
domized either to CABG or PCI. Factors predicting work-
ing two years postoperatively were positive preoperative
working status, younger age and male gender.
In the present study the model of continuation in work
included patients' age and height, postoperative cardiac
symptoms, diabetes, patients' matrimonial status and par-
ticipation in household work.
In previous CABG studies age has been the most impor-
tant predictor of continuing at work. As in the present
study absence of postoperative cardiac symptoms was
important in remaining at work also in a study by Skinner
et al. [9]. Cardiac condition was also found in an earlier
Finnish material to be the most important reason for not
working five years postoperatively [12]. Patient's height is
closely related to sex, which has been found to be a pre-
dictor of return [13]. Also diabetes mellitus has emerged
as a negative predictor for return but it is also associated
with a poorer long-term outcome after CABG [14,15]. In
this context it is quite logical that these were selected for
the present model of resumption.
In our model it would appear that diabetes favours work-
ing for three to five years postoperatively. This is coinci-
dentally caused by the small number of diabetics in this
group (one patient).
Finland, like many other European countries, has a
national medical insurance system and thus insurance
issues did not affect remaining at work. Probably for the
same reason type of work likewise did not influence
remaining at work.
Being married often constitutes a form of social and finan-
cial security. Vice versa, being unmarried might accentuate
the importance of daily work as both social and financial
protection. Participation in household work was in our
material associated with other physical activities such as
daily walking distance and exercise habits (data not
shown). This may thus be considered as one dimension of
physically active life. Preoperative working status was not
selected into our model, since almost all patients were
working or only on short-term sick leave preoperatively.
ROC curves of the ability of the model to predict remaining at workFigure 3
ROC curves of the ability of the model to predict remaining at work.
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Conclusion
In this part of the W-CABG study, we have analyzed
patients' postoperative continuing to work. Age and
height, postoperative cardiac symptoms, matrimonial sta-
tus, diabetes mellitus, and participation in household
work were selected into the final model. In the ten year
follow-up, this model predicted 80% of continuation at
work after coronary artery bypass grafting. Correspond-
ingly, the most important single reason for premature
retirement was found to be cardiovascular disease.
Our results encourage medical professionals to effectively
treat the postoperative cardiac problems and diabetic bur-
den of CABG patients as well as to activate them not only
to undertake household work but also all kinds of social
and physical activity.
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Prompt impact of first prospective
statin mega-trials on postoperative
lipid management of CABG patients:
a 20-year follow-up in a single hospital
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Abstract
Background: The long-term success of coronary artery bypass grafting (CABG) depends on secondary prevention.
Vast evidence provided by the results of cholesterol mega-trials over two decades has shown that effective reduction
of LDL cholesterol improves the prognosis of patients with coronary heart disease. However, the implementation of
these results into the clinical practice has turned out to be challenging. We analysed how the information derived from
clinical statin trials and international recommendations affected the local treatment practices of dyslipidaemia of CABG
patients during a 20-year time period.
Methods: The cohort includes all CABG patients (n = 953) treated in Kanta-Häme Central Hospital during the time
period 1990–2009. At the postoperative visits in the cardiology outpatient clinic, each patient’s statin prescription was
recorded, and blood lipids were determined.
Results: During 1990–1994, 12.0 % of patients were on statins and during the following 5-year time periods the
proportion was 57.2, 82.2 and 96.8 %, respectively. During the 20-year observation period (1990–2009), the effective
statin dose increased progressively during these 5-year periods up to 36-fold, while the mean concentration of LDL
cholesterol decreased from 3.7 to 2.1 mmol/l and that of apolipoprotein B from 1.3 to 0.8 g/l. In the very last year
of follow-up, the mean concentrations of LDL-C and apoB were 1.83 mmol/l and 0.78 g/l, respectively. The most
prominent increase in statin use and dosage took place during 1994–1996 and 2003–2005, respectively.
Conclusions: Among CABG patients the lipid-lowering efficacy of statin therapy improved dramatically since
1994. This progress was accompanied by significant and favourable changes of lipid and apolipoprotein-B
values. This study shows that it is possible to effectively improve lipid treatment policy once the results of
relevant trials are available, and that this may happen even before international or national guidelines have
been updated.
Keywords: Coronary artery bypass, CABG, LDL cholesterol, Lipids, ApoB, Extended Friedewald, Statins, Statin
intolerance
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Background
Coronary artery bypass grafting (CABG) efficiently alle-
viates coronary heart disease (CHD) symptoms. How-
ever, without an effective secondary prevention, it does
not offer permanent improvement of cardiac symptoms
or prognosis [1, 2].
The primary target of the secondary prevention of cor-
onary heart disease is effective reduction of low-density
lipoprotein cholesterol (LDL-C), which diminishes car-
diovascular and total mortality [3–6]. The lipid-lowering
therapy is based on two approaches, i.e. change in life-
style and pharmacological therapy [7]. In acute coronary
syndrome patients it is desirable to start an effective
statin therapy immediately after the event, i.e. already
during the hospital stay [8].
According to early mega-trials, the turning points in
secondary prevention of coronary heart disease were the
years 1994, 1996 and 1997 when the first statin mega-
trials 4S and CARE as well as the Post-CABG trial were
published, and showed that effective therapy with statins
improves the prognosis of patients with CHD [2–4]. The
next key observations with a major influence on statin
therapy occurred in 2004–2005, when the beneficial effects
of intensive statin therapy, as compared with moderate
statin therapy, were published [6, 8].
Two lipid-lowering recommendations, one in the U.S.
and the other in Europe, were published just before the
first statin mega-trials, i.e. in 1994 [9, 10]. They pointed
out the central importance of increased cholesterol con-
centrations in determining the CHD risk; yet, due to the
lack of evidence, the recommendations were conservative
in their drug therapy guidelines [9, 10].
In 1998, the European targets for total cholesterol (T-C)
and LDL-C were set below 5.0 mmol/l and 3.0 mmol/l, re-
spectively [11]. One year later in the USA, the target for
LDL-C in CABG patients was set below 100 mg/dL
(2.6 mmol/l) [12]. Further in 2001 and 2003 LDL-C tar-
gets were set below 2.6 mmol/l and 2.5 mmol/l in the
USA and Europe, respectively [13, 14]. Even though the
goals were more demanding, the major emphasis was still
on therapeutic lifestyle changes. Eventually, in 2004 the
American guidelines and in 2007 the European guidelines
for cardiovascular disease prevention recommended that
in patients with established coronary heart disease LDL-C
should be lowered below 2.5 mmol/l, or below 1.8/
2.0 mmol/l, “if achievable” [15, 16].
The evidence indicates that the combined use of differ-
ent apolipoprotein (apo) measures might improve the risk
assessment of cardiovascular disease [17, 18]. Regarding
the atherogenicity of the lipoproteins, the apolipoprotein
B (apoB)-containing lipoproteins are of primary import-
ance. Since one apoB molecule is present in each very-
low-density lipoprotein (VLDL), intermediate-low-density
lipoprotein (IDL) and LDL particle [19, 20], the plasma
concentration of apoB indicates the total number of circu-
lating atherogenic apoB-containing lipoprotein particles.
ApoB concentration as a complementary measure was
included first in recommendations in 2008 [7], and in the
highest risk patients, the treatment goal was set to
0.80 g/l. To achieve this goal, effective lipid-lowering
drug therapy is needed [21].
The aim of our study was to assess whether statin
mega-trials and the recommendations based on their re-
sults influenced the local treatment practice regarding
statin-dependent control of lipid levels in CABG patients
over the critical 20-year period (1990–2009) which
encompassed milestone publications regarding LDL-C
lowering-based pharmacotherapy in preventive cardi-
ology. We also attempted to learn whether the evolving
changes in the LDL-C targets were reflected in the con-
centrations of different lipid classes and apolipoproteins
in the patient cohort.
Methods
Patients
We studied all annual cohorts of CABG patients treated
in Kanta-Häme Central Hospital (K-HCH) during the
years 1990–2009. The primary catchment population of
the hospital is 175 000 inhabitants living in Southern
Finland. CABG was performed in Tampere University
Hospital for 953 patients and, after the operation, they
were transferred to K-HCH for further recovery.
After discharge the patients were followed according
to hospital policy. Of the patients, 946 (99.3 %) had at
least one visit in the outpatient clinic of cardiology during
the first three postoperative months.
Material analysis
Results of all patients who visited the outpatient clinic
were analysed. Patients who had laboratory values on
the first postoperative visit, but not on the 3-month visit,
were also included; that is, a “last observation—carry
forward” principle was adopted. Accordingly, data de-
rived from the final postoperative outpatient visit are
presented, 19 and 81 % of them being derived from the
1 to 3-month visits, respectively.
The year of CABG, postoperative lipid values, medica-
tion, and absence/presence of various CHD risk factors
including smoking, hypertension, diabetes, and obesity
(body mass index, BMI) were collected from the patient
records. Patients’ data were coded, and data analysis was
carried out with the coded material only. The study was
approved by the Ethics Committee of Kanta-Häme
Hospital District (Dnro E511/08).
The influence of the statin trials and recommendations
on treatment goals were examined by comparing CABG
patients’ postoperative lipid values taken at various time
points over a time span of 20 years. The study period
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was divided into four consecutive 5-year time periods,
namely 1990–1994, 1995–1999, 2000–2004, and 2005–
2009. During this 20-year time period several new
statins with different efficacies received their market-
ing authorisation. Accordingly, the daily dose and the
dose-dependent LDL-C lowering effect of each individual
statin had to be taken into account. This enabled us to
compare the lipid-lowering efficacy of the statin therapy
during the entire period.
A daily dose of 20 mg simvastatin or equipotent dose
of another statin is the smallest statin dose used in most
prospective trials, and this dose was defined as “daily
statin dose index (DSDI) 1”. In the Tables and Graphs,
in which the effective doses of various statins are pre-
sented, the DSDI 1 corresponds to a daily dose of 80 mg
fluvastatin, 40 mg lovastatin or pravastatin, 20 mg
simvastatin, 10 mg atorvastatin or 5 mg rosuvastatin.
The lipid-lowering efficacy of each statin was assumed
to be linearly correlated with the dose; i.e. the DSDI of
80 mg simvastatin, 40 mg atorvastatin or 20 mg rosuvas-
tatin was 4 [22–25].
Lipid analysis
Total and high-density lipoprotein cholesterol (HDL-C)
concentrations were determined from plasma samples by
using Hitachi 911 analyser with Boehringer-Mannheim
reagents in 1990–1996. Roche Diagnostics enzymatic
methods were used since 1996, which also applied to direct
LDL-C analysis from 2000 onwards. All chemical analyses
were carried out in the Laboratory of Kanta-Häme Central
Hospital. Lipid analyses have been under the Nordic quality
control during the entire study period.
For the calculation of LDL-C with the classical
Friedewald formula (FW) data on T-C, HDL-C and tri-
glycerides (TG) are required. Since FW is valid provided
serum TG ≤ 4.5 mmol/l, we also applied a novel extended
Friedewald (eFW) approach, which is more tolerant on el-
evated triglycerides [26, 27]. The eFW is based on artificial
neural network regression algorithms which utilize data
on classical FW inputs [26]. This method allowed us to
calculate LDL-C, IDL cholesterol (IDL-C), HDL2 choles-
terol (HDL2-C) and VLDL triglyceride (VLDL-TG) con-
centrations. It also computationally yields estimates of the
apoB and apolipoprotein A-1 (apoA1) concentrations. To
estimate HDL3 cholesterol (HDL3-C), the HDL2-C value
obtained with eFW was subtracted from the measured
HDL-C [26].
Statistical analysis
Evolution of postoperative statin therapy and lipid values
over 20 years was studied using ANOVA test in the 5-year
groups. With dichotomal variables, the 5-year groups were
compared using extended χ2 test [28]. D’Agostino’s test
was used to determine normality and scedasticity. Per-
centage or mean and standard deviation of demographic
characteristics and lipid variables are presented. Multiple
linear regression analysis was used when comparing lipid
values with each other, and also when LDL-C values ob-
tained by enzymatic methods were compared with those
obtained by the classical Friedewald equation or by the ex-
tended Friedewald approach.
Results
Together 400 to 650 CABG patients were operated
yearly in Tampere University Hospital during 1990–
2009. On average, 50 patients of them were postopera-
tively treated annually in K-HCH. Patient records of
altogether 946 subjects who attended postoperative
cardiac outpatient clinic were analysed over a period of
20 years divided into four consecutive 5-year time pe-
riods, each consisting on average of 237 patients (ran-
ging from 219 to 256 patients). The proportion of male
patients ranged from 72 to 80 %. The changes in
patients’ demographics followed both national and inter-
national trends, and the demographic characteristics are
presented in Table 1.
Lipid treatment practice
Altogether 803 patients had their lipid values measured,
81.3 % of them at the 3-month visit. During the first
Table 1 Demographics of patients undergone CABG during 1990–2009, divided into 4 consecutive 5-year periods
5-year period 1990–1994 1995–1999 2000–2004 2005–2009 Overall pa
Number of patients 256 247 224 219 –
Proportion of males (%) 78 80 72 79 0.5193
Proportion of diabetics (%) 10 14 19 27 0.0122
Current and ex-smokers (% 64 55 54 56 0.4544
Age (years) 61.9 ± 7.7 64.0 ± 9.2 65.4 ± 9.4 66.5 ± 8.3 <0.0001
BMI (kg/m2) 26.5 ± 3.5 26.5 ± 3.5 27.2 ± 3.7 27.0 ± 4.1 0.0978
Systolic BP (mmHg) 149.6 ± 24.8 147.9 ± 23.2 137.8 ± 22.0 130.0 ± 20.4 0.0001
Diastolic BP (mmHg) 84.7 ± 11.6 82.1 ± 11.1 80.2 ± 9.8 77.5 ± 9.3 <0.0001
Abbreviations: BMI body mass index (kg/m2), BP blood pressure
aExtended χ2 test and ANOVA were used for overall analysis. Percentage or mean ± standard deviation is presented
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5-year period, 63.6 % of the patients and during the
subsequent 5-year periods 85.6, 94.2 and 96.8 %, re-
spectively, had their lipids analysed. Thus, there was
an initial strong and statistically significant (p < 0.01)
increase in the proportion of patients having their lipids
determined.
During the 20-year observation period, the use of statins
increased markedly, the most prominent increase having
taken place during 1995–1999 (Additional file 1: Table
S1B). Within the last years of the follow-up, practically all
CABG patients were on statin therapy (Fig. 1a).
The DSDIs were small during the initial years, and ef-
fective statin doses increased progressively during the
last years of follow-up. Thus, the average DSDIs of all
patients, even when those without statin therapy were
included, increased during four consecutive 5-year time
periods from 0.07 (±0.23) to 0.46 (±0.53), 1.25 (±1.19)
and 2.52 (±1.52) (p for trend < 0.001) (Fig. 1b, Table 2).
The DSDI 2.86 (±0.41) during the very last year of
observation corresponds to a mean simvastatin dose of
57 (±8) mg/day.
Plasma lipid and apolipoprotein levels
The mean concentrations of LDL-C were 3.7 and
2.1 mmol/l, and those of apoB 1.3 and 0.8 g/l, during the
initial (1990–1994) and final (2005–2009) 5-year time pe-
riods, respectively (Fig. 1, Table 2). During the last single
year of follow-up (2009), the mean concentrations of LDL-
C and apoB were 1.83 mmol/l and 0.78 g/l, respectively.
The decrease in apoB concentration was progressive
during the 20-year time span. It reflects not only the de-
crease in LDL-C concentration, but also in the concen-
trations of other apoB-containing lipoproteins, as seen
in decreases of VLDL-TG and IDL-C, which were re-
duced proportionately (Fig. 2a). HDL-C increased from
1.02 (±0.29) to 1.22 (±0.34) particularly due to an in-
crease in the concentration of HDL2-C, while the con-
centration of HDL3-C remained at a constant level of
0.45 mmol/l (Fig. 2b). The multiple linear correlations of
different lipoproteins are presented in Additional file 2:
Table S2B.
Discussion
Our main findings indicate that during a 20-year follow-
up (1990–2009) of CABG patients the following benefi-
cial changes in lipid and lipoprotein measurements and
in lipid treatment efficacies occurred in sequence. First,
the percentage of patients with measured cholesterol
levels increased, and thereafter, the share of patients on
statin therapy and the efficacy of the therapy increased
consecutively. Moreover, the concentrations of LDL-C
and of apoB, the latter reflecting the number of athero-
genic apoB-containing lipoprotein particles, decreased
by 45 and 40 %, respectively.
Importantly, the primary changes took place immedi-
ately after the first statin mega-trial had been published,
i.e. before their results had been integrated into the
updated formulations of the relevant international guide-
lines [3, 4]. The mean dosage of statin increased rapidly
after 2002, when the most effective statin, rosuvastatin,
had become available in the market. In 2002 and 2005
DSDI-values were 1.08 and 2.56, respectively, see Fig. 1b).
Although during the 20-year follow-up period, the levels
of total cholesterol in the Finnish population steadily
Fig. 1 a LDL-C ± 1 SD calculated by Friedewald formula (mmol/l,
black line ± 1 SD blue shadowing) and the amount of statin users
(%, red line) at postoperative visits. b Plasma correlation of apoB ±
1 SD (g/l, black line ± 1 SD blue shadowing) and daily statin dose
index (DSDI, black line ± 1 SD red shadowing) (see Methods) at
postoperative visits. Red arrows indicate the publication of landmark
studies from left to right: 4S3, CARE4, LIPID5, REVERSAL6 and PROVE IT8.
Blue arrows refer to the publication of lipid lowering recommendations
from left to right: Second European Task Force11, NCEP ATP III12, Third
European Task force13, NCEP ATP III (Implication of recent clinical
trials)14, and Fourth European Task Force15. Black arrows indicate the
years, when the two most effective statins entered the Finnish market,
i.e. atorvastatin in 1997 and rosuvastatin in 2003. LDL-C was calculated
by Friedewald formula and apoB was obtained using extended
Friedewald approach (see Methods)
Palomäki et al. Lipids in Health and Disease  (2016) 15:124 Page 4 of 8
decreased [29], the decrease in our patients was 3- to 4-
fold when compared with that of the general population.
This finding accords with the notion that, at least the
majority of the excess decrease in LDL-C among the
CABG patients must have been due to statin treatment.
Thus our results comply with the observed significant
decreases in LDL-C found in mega-trials in which de-
creased cardiovascular morbidity and mortality with in-
tensified statin therapy could also be achieved [3–6, 8].
The efficiency of secondary prevention of CHD in
Europe has been evaluated in the Euroaspire studies I
and II. In the Euroaspire II study (1999–2000) consisting
of coronary patients (including also CABG patients)
from 15 European countries, 42 % had their T-C <
5.0 mmol/l and 61 % were on lipid-lowering medication
[30]. At the same time the corresponding numbers in
our patient population were 68 and 76 %, respectively. In
an international cross-sectional study by Gitt et al. [31],
the prevalence of lipid abnormalities were assessed in
2008–2009 in more than 22 000 European and Canadian
patients on statin treatment. In this study, 58 % of
patients having a cardiovascular high-risk had their
LDL-C < 2.5 mmol/l. Their mean DSDI was 1.85, corre-
sponding to a simvastatin dose of 37 mg [31]. In an-
other study carried out 2009–2010, out of 151 patients
undergone CABG, 83.4 % had lipid profile measured
during the first postoperative year [32]. In this group,
the mean LDL-C level was 1.86 mmol/l, i.e. at the same
level as it was during the last years of our study. It has
recently been indicated, that physicians’ lipid-lowering
treatment choices are usually more conservative than
Table 2 Postoperative plasma lipid and lipoprotein levels in consecutive 5-year periods in statin-treated patients undergone CABG
5-year period 1990–1994 1995–1999 2000–2004 2005–2009 Overall pa
DSDI 0.07 ± 0.23 0.46 ± 0.53 1.25 ± 1.19 2.52 ± 1.52 <0.0001
T-C (mmol/l) 5.70 ± 1.27 4.86 ± 1.00 4.20 ± 0.91 3.76 ± 0.82 <0.0001
LDL-C (mmol/l)b 3.70 ± 1.09 2.94 ± 0.85 2.35 ± 0.72 2.07 ± 0.64 <0.0001
HDL-C (mmol/l) 1.02 ± 0.29 1.12 ± 0.33 1.24 ± 0.32 1.22 ± 0.34 <0.0001
T-G (mmol/l) 2.20 ± 1.22 1.79 ± 0.96 1.56 ± 0.81 1.40 ± 0.65 <0.0001
Extended Friedewald approach (eFW)c
VLDL-TG (mmol/l) 1.36 ± 0.85 1.12 ± 0.79 0.95 ± 0.6 0.85 ± 0. <0.0001
IDL-C (mmol/l) 0.38 ± 0.14 0.28 ± 0.11 0.23 ± 0.11 0.23 ± 0.16 <0.0001
LDL-C (mmol/l) 3.55 ± 0.78 3.01 ± 0.71 2.49 ± 0.63 2.21 ± 0.51 <0.0001
HDL-2-C (mmol/l) 0.57 ± 0.23 0.67 ± 0.27 0.76 ± 0.27 0.77 ± 0.28 <0.0001
HDL-3-C (mmol/l) 0.46 ± 0.07 0.47 ± 0.07 0.48 ± 0.07 0.48 ± 0.07 0.0121
ApoA1 (g/l) 1.38 ± 0.22 1.38 ± 0.24 1.42 ± 0.24 1.37 ± 0.26 0.1864
ApoB (g/l) 1.30 ± 0.26 1.09 ± 0.26 0.90 ± 0.23 0.81 ± 0.18 <0.0001
Mean ± standard deviation are presented
Abbreviations: DSDI daily statin dose index, where the 1.0 corresponds the dose of simvastatin 20 mg per day (see Methods). In the intention to threat analysis all
patients are included
aANOVA was used for overall analysis
bLDL-C is determined using Friedewald calculation
cThe eFW is based on artificial neural network regression algorithms which utilize data on classical FW inputs (see Methods)
Fig. 2 a Apolipoprotein B (ApoB, g/l), VLDL-triglycerides (mmol/l)
and IDL-cholesterol (mmol/l) at postoperative visits. b Apolipoprotein
A-1 (ApoA1, g/l), HDL-cholesterol (mmol/l), HDL2-cholesterol (mmol/l)
and HDL3-cholesterol (mmol/l) at postoperative visits are shown both
as curves and as linear representations. All parameters except HDL-C
were obtained using extended Friedewald approach
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guideline recommendations [33]. However, our results
reveal that, in a proactive clinic, it is feasible to react with-
out delay to the inflowing relevant information describing
results of new well-conducted lipid-lowering trials pub-
lished in peer-reviewed high-impact journals.
The concentrations of HDL-C and phospholipids, as
well as the HDL2/HDL3-ratio, increased in the CABG
patients during the 20-year observational period. Re-
garding the potential clinical significance of these obser-
vations, following points need to be considered. The
apparently beneficial changes must have been partly due
to statin treatment and partly to life style changes. Inas-
much as beneficial life style changes are accompanied by
beneficial changes in various cardiometabolic measures,
quantitation of the role of changes in Apolipoprotein A-
I containing lipoproteins or their components is not
feasible. Similarly, the clinical relevance of the minor
statin induced increases in various parameters of HDL
particles and their constituents remains uncertain. Inter-
estingly, the moderate increase in HDL-C levels with
statins correlates with regression of coronary athero-
sclerosis [34]. With respect to the size of the HDL parti-
cles, the larger HDL2 particles have been associated with
greater CHD protection than the smaller HDL3 particles
[35, 36]. However in recent meta-analysis of 80 pub-
lished investigations, no differences in cardioprotective
properties between these two HDL subclasses were dis-
cerned [37, 38]. Importantly, regarding the cardioprotec-
tive functions of HDL, the scientific interest is shifting
largely to unravelling the biologic activity of HDL [38].
Thus, assigning any presumed clinical significance to the
modest increases in the various metrics of Apo A-I con-
taining lipoprotein fractions is not possible at present.
Although LDL is considered the main atherogenic
cholesterol-rich particle, also other apoB-containing li-
poproteins contribute to intimal cholesterol deposition,
i.e. they also are atherogenic [20]. Importantly, the re-
cent increase in the incidence of metabolic syndrome
and diabetes has re-emphasized the requirement for
obtaining additional data on triglyceride rich lipopro-
teins like VLDL and IDL. For example, IDL particles and
their cholesterol are contributing to the progression of
coronary and carotid artery atherosclerosis [39]. Besides
the number of apoB-containing lipoproteins, also the
size of these particles is considered a key determinant in
atherosclerosis [40]. The small dense LDL particles,
when being present in high numbers, particularly in-
crease the risk of ischemic heart disease [41]. While the
large chylomicrons fail to penetrate the arterial wall,
triglyceride rich chylomicron remnants and VLDL rem-
nants (IDL) with smaller particle sizes, enter the arterial
wall and so drive atherogenesis [20, 42, 43]. To the best
of our knowledge, an observation of diminished IDL-C
during intensified statin treatment with lipid values taken
and analysed 1–3 months postoperatively over a time span
of 20 years, has not been reported earlier.
A limitation associated with this study is its retrospect-
ive nature. Therefore we lack knowledge of possible sta-
tin intolerance, which is nowadays considered a notable
problem in statin treatment. Although in observational
studies even 10–15 % of patients have reported muscle
symptoms, most of them might be successfully treated
with careful management [44, 45]. During the last years
of our study only about 2 % of patients were not on sta-
tins. That might represent the maximal percentage of
patients suffering from clinically relevant statin intoler-
ance in this well-motivated patient population. A pos-
sible explanation for the success in statin therapy might
be the highly individualized care of the cardiovascular
patients in our hospital.
Due to the retrospective nature of this study, the
investigators had to rely on medical records with all
their imperfections. For example, information concern-
ing laboratory values and medications was occasionally
incomplete. Nevertheless, for 85 % of the patients all
relevant data were available. Moreover, during the last
four decades our hospital has had a fairly stable catchment
population without any significant national or international
migration. Thus the genetic and racial backgrounds, two
factors of potential importance considering the limited size
of our study sample, have remained stable.
Conclusions
To conclude, prominent increase of statin use in patients
undergone CABG took place immediately after the first
statin mega-trial was published. Further, over a 20-year
period (1990–2009) the efficacy of statin treatment grad-
ually increased and the concentration of LDL-C, measured
1–3 months postoperatively, gradually decreased. Also the
decreases of apoB, IDL-C and VLDL-TG were favourable.
Our results show that, based on the outcomes of relevant
mega-trials, it is possible in a single centre to optimise clin-
ical practice without delay even before they have led to
reformulations of international guidelines.
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Abstract
Background: The associations of metabolic syndrome (MetS) or diabetes mellitus (DM) on long-term survival after
coronary artery bypass grafting (CABG) have not been extensively evaluated. The aim of the present study was to
assess the impact of MetS and DM on the 16-year survival after CABG.
Methods: Diabetic and metabolic status together with relevant cardiovascular data was established in 910 CABG
patients operated in 1993-94. They were divided in three groups as follows: neither DM nor MetS (375 patients),
MetS alone (279 patients) and DM with or without MetS (256 patients). The 16-year follow-up of patient survival
was carried out using national health databases. The relative survival rates were analyzed using the Life Table
method comparing the observed survival rates of three patient groups to the rates based on age-, sex- and
time-specific life tables for the whole population in Finland. To study the independent significance of MetS and DM
for clinical outcome, multivariate analysis was made using an optimizing stepwise procedure based on the Bayesian
approach.
Results: Bayesian multivariate analysis revealed together six variables to predict clinical outcome (2 months to 16
years) in relation to the national background population, i.e. age, diabetes, left ventricular ejection fraction, BMI,
perfusion time during the CABG and peripheral arterial disease. Our principal finding was that after postoperative
period the 16-year prognosis of patients with neither DM nor MetS was better than that of the age-, sex-and
time-matched background population (relative survival against background population 1.037, p < 0.0001). The
overall survival of MetS patients resembled that of the matched background population (relative survival 0.998, NS).
DM was associated with significantly increased mortality (relative survival 0.86, p < 0.0001). Additionally, mortality
was even higher in patients receiving insulin treatment than in those without. Excess death rate of DM patients was
predominantly caused by cardiovascular causes.
Conclusion: In this long-term follow-up study patient groups without diabetes had at least equal 16 years’ survival
after CABG than their matched background populations. Survival of DM patients started to deteriorate already few
years after the operation.
Keywords: Coronary artery bypass grafting, Diabetes mellitus, Metabolic syndrome, Follow-up, Mortality
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Introduction
Metabolic syndrome (MetS), was first officially defined by
the World Health Organization (WHO) and the National
Cholesterol Education Program (NCEP) more than ten
years ago [1,2]. Since that time its epidemiology has
been widely evaluated [3,4]. MetS can be used as a tool
to characterize patients at added risk [5-7]. Several
studies have suggested that the risks of premature death
and cardiovascular disease or diabetes are higher among
subjects with MetS compared to those without. However,
follow-up studies on long-term survival after coronary
artery bypass grafting (CABG) have yielded controversial
results with regard to the impact of MetS [8,9].
Diabetes (DM) is a prominent cardiovascular risk factor
[10,11]. There is a considerable body of evidence on poor
early outcome and higher in-hospital morbidity in dia-
betics compared with non-diabetic patients after CABG
[12,13]. The association of diabetes on long-term survival
after CABG has not been extensively evaluated. The few
reports published comparing the type of treatment of
diabetes to the long-term prognosis after CABG have
come to conflicting conclusions [14,15].
Our aim was to evaluate the assumed detrimental impact
of metabolic syndrome and diabetes mellitus on long-term
prognosis after CABG, focusing on survival after the first
two postoperative months.
Methods
Study population
The population of the Working after CABG (W-CABG)
study has been described elsewhere [16]. Briefly, CABG
was done on 961 patients in Tampere University Hospital
during a period of 18 months in 1993-94. Data on MetS
and DM were available on 945 operated patients and 910
patients survived two months after CABG (Figure 1).
These patients formed the study cohort and were followed
for 16 years.
We analyzed the survival of CABG patients in three
groups as follows: neither DM nor MetS (DM-/MetS-),
MetS alone (DM-/MetS+) and DM with or without MetS
(DM+). We combined all DM patients in the same group
regardless of their status concerning MetS, in primary
analyses of diabetic patients the presence of MetS did not
affect survival.
Data collection and clinical definitions
The background of the patients and perioperative data
were collected from the medical records in Tampere
University Hospital and the secondary hospitals involved
in the postoperative care. A survival analysis was made
after the closing day, June 30, 2010, based on data ob-
tained from the Statistical Office of Finland. The results
of the full completed 16-year follow-up are given.
Diagnoses of hypertension, peripheral vascular disease,
previous myocardial infarction, and previous transient
ischemic attack (TIA) or stroke were established from
patient records. Renal dysfunction was defined as a
glomerular filtration rate less than 60 ml/min/1,73 m2
calculated with the CKD-EPI equation [17]. Patients
were defined as hypercholesterolemic if they had total
cholesterol ≥5 mmol/l (200 mg/dl) (NCEP ATP III) or
were on lipid-lowering drug therapy. Smoking habits
were based on a questionnaire completed 21 months
postoperatively [16].
Classification of MetS was made according to the NCEP/
ATP III definition with the exception that body mass index
(BMI) (kg/m2) was used as a measure of obesity. During
the 1990s waist circumference was not commonly mea-
sured [9,18]. Modified MetS was defined as the presence of
three or more of the following risk factors: BMI > 30 kg/m2
for men and > 25 kg/m2 for women, TGL concentration ≥
150 mg/dL (1.7 mmol/l), HDL-C < 40 mg/dL (1.03 mmol/l)
for men and < 50 mg/dL (1.3 mmol/l) for women and
systolic blood pressure ≥ 130 mmHg or diastolic blood
pressure ≥ 85 mmHg or on antihypertensive medication.
Elevated blood glucose was defined as fasting blood glu-
cose ≥ 100 mg/dl (5.6 mmol/l) [1,2]. For the diagnosis of
diabetes the 1998 WHO criteria were used, defining fasting
blood glucose level (fB-gluk) ≥ 110 mg/dL (6.1 mmol/l) or
random blood glucose ≥ 180 mg/dL (10.0 mmol/l) [1]. A
patient was also defined as diabetic if on antidiabetic medi-
cation according either to hospital records or the reim-
bursement database maintained by the Social Insurance
Institution of Finland. Further they were divided in insulin-
Figure 1 Schematic description of study patients. CABG= coronary
artery bypass grafting, DM = diabetes mellitus, MetS =metabolic
syndrome, Non-insulin DM = diabetic patients without insulin
treatment. Insulin DM= diabetic patients treated with insulin.
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treated diabetics regardless of oral antidiabetic medication
and in non-insulin-treated diabetics based on hospital re-
cords at the time of admission for CABG. BMI was calcu-
lated as mass/height2 (kg/m2).
Cardiovascular death was defined as any death caused
by coronary heart disease or sudden death during 2
months to 16 years postoperatively. Stroke was consid-
ered as cardiovascular death.
Survival analysis
Overall survival (0-16 years postoperatively) was analyzed,
including hospital and immediate postoperative survival
for 945 patients. Separate survival analyses (2 months to
10 and 16 years) were then carried out for 910 patients,
focusing on survival after the immediate postoperative
phase. Survival analyses were made according to the meta-
bolic status of the patients (DM-/MetS-, DM-/MetS+ and
DM+). The cumulative relative mortality for each group
was calculated in 2-month steps against age-, sex- and
time-specific national background populations as de-
scribed in Statistical methods. The first subanalysis was
then made in similar manner to reveal survival of DM
patients with and without insulin therapy. In the second
subanalysis the association of MetS (yes or no) with sur-
vival was identically studied in DM patients. The study
protocol was approved by the Ethics Committee of
Tampere University Hospital.
Statistical methods
In the comparison of patient characteristics, categorical
data are tabulated as frequencies and percentages, and
continuous variables are expressed as mean and SD. Dif-
ferences between two groups were tested by Chi squared
test and the Wilcoxon rank test, and in cases of more
than two groups by Kruskal-Wallis test. Fisher’s exact
test was used when appropriate in two-by-two tables with
directed hypothesis. Differences in mean values between
two groups were tested by Student’s t-test and in the case
of more than two groups by analysis of variance.
The relative survival rate was analyzed by sex, age,
DM and MetS using the Life Table method [19]. In this
approach, the observed survival rates of the groups are
compared to the rates based on age-, sex- and time-
specific life tables for the whole population in Finland.
Calculation of survival rates was based on the individual
life expectancies of the target population for the target
years (reference population). The survival of the reference
population is effectively 1.00. If the survival curve of the
group remains below that of the reference population
there is excess mortality in the group.
To study the independent significance of MetS and DM
for clinical outcome (2 months to 16 years), multivariate
analysis was made using an optimizing stepwise procedure
based on the Bayesian approach [20]. This procedure was
developed for nominal variables, and does not require a
perfect variable matrix. It selects, by the heuristic ap-
proach, the combination of variables which best explains
the selected outcome factor. The Bayesian approach is ap-
plied by counting posterior likelihood ratios or odds ratios
for each combination. The aim was to find an optimal
subset of pre-and intraoperative variables to provide the
best explanation. The parameters included in the multi-
variate analysis were age, gender, BMI, all significant
cardiometabolic diseases and related operations as well
as cardiac, lipid lowering and psychiatric medications.
Also essential intraoperative characteristics of CABG
were included in the analysis. Altogether 31 parameters
were included in the Bayesian approach (Additional file 1:
Table S1).
Results
Study population
The essential clinical characteristics of the 910 patients
are shown in Table 1. Their mean age was 61.6 (SD 8.4)
years; 191 of them were women (mean age 64.8 [SD 7.5]
years) and 719 men (mean age 60.8 [SD 8.4] years). Of
the 910 subjects, 41% were free of MetS or DM and 31%
had MetS without DM (Figure 1).
Non-diabetic patients with MetS had by definition more
often metabolic abnormalities than those without MetS
(Table 1). Similar findings were obtained in patients with
diabetes, of whom 82% had MetS. Non-diabetic patients
without MetS had more often normal renal function than
others (P < 0.01). Diabetic patients were older having more
angina pectoris and peripheral arterial disease than other
patients (Table 1). Smoking habits and the prevalence of
hypercholesterolemia did not differ between the three
groups.
Overall survival
No patients were lost during the 16-year follow-up. The
overall postoperative survival is presented in Figure 2.
DM was associated with significantly unfavourable prog-
nosis compared to the non-diabetic patients in the two
other groups (both p < 0.001). The difference in survival
was already seen during the course of the first two post-
operative months, where a total of 35 out of 945 patients
(3.7%) died. Among non-diabetic patients there was no
difference between subjects with or without MetS.
Long-term survival against background population
The analysis between 2 months and 16 years revealed
that of the 910 patients alive two months postoperatively
432 (47.5%) had died. Figure 3A presents the relative sur-
vival of the three study groups matched by age, gender
and calendar year against their respective Finnish back-
ground populations (relative survival = 1.00). After the
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perioperative phase, the 16-year relative survival of
DM-/MetS- patients was 1.037, (95% CI, 1.026 to 1.048;
< 0.0001) compared to that of the background popula-
tion. For the first 10 postoperative years the relative sur-
vival was 1.033 (95% CI, 1.021 to 1.045; p < 0.0001).
Metabolic syndrome and long-term survival
In non-diabetic patients with MetS the long-term survival
between 2 months and 16 years was poorer than among
patients without MetS (P < 0.0001). However, during the
same period the relative survival of DM-/MetS+ patients
Table 1 Preoperative demographic data, clinical characteristics and severity of coronary heart disease in 910 patients
surviving two months after CABG
DM–/MetS– DM–/MetS+ DM+ Overall
n = 375 n = 279 n = 256 p-value
Female (%) 15.2 26.2 23.8 <0.011,2
Mean Age (years) (SD) 61.3 (8.2) 60.7 (8.6) 63.3 (8.4) <0.0012,3
Variables of Modified MetS
BMI (kg/ m2) 25.8 28.7 28.1 NA
Elevated Blood Pressure (%) 40.9 83.1 67.5
HDL Cholesterol (low, %) 44.9 90.2 65.3
Triglyceride (high, %) 27.4 83.7 67.7
Elevated Glucose or DM (%) 4.5 25.8 100.0
Concomitant Diseases
Hypercholesterolemia (%) 69.5 80.3 77.7 NS
Previous MI (%) 70.5 67.8 67.7 NS
Previous TIA or stroke (%) 8.9 8.6 13.9 NS
Intermittent Claudication (%) 6.2 4.7 18.6 <0.0013,4
Renal Function
CreaCl (ml/min) (SD) 76.4 (13.8) 74.2 (18.2) 73.7 (16.9) NS
CreaCl < 60 ml/min/1,73 m2 (%) 11.0 19.0 19.7 <0.011,2
Preoperative Smoking (%) 66.6 60.2 66.4 NS
Severity of Heart Disease
EF (%) (SD) 60 (14) 61 (13) 58 (14) <0.055
EF ≤ 35% (%) 7 4 11 <0.055
NYHA II (%) 11.9 13.0 6.5
NYHA III (%) 59.9 54.3 56.3 <0.055
NYHA IV (%) 28.2 32.6 37.2
Operation Characteristics
Three–vessel Disease (%) 61.1 59.7 58.6 NS
Left Main Disease (%) 13.1 16.6 14.1 NS
Number of Grafts 3.39 3.38 3.35 NS
Use of Arterial Grafts (%) 86.3 83.4 81.0 NS
Concomitant Operation (%) 6.1 3.3 7.6 NS
Perfusion Time (SD) 107.0 (36.6) 108.0 (58.8) 112.3 (34.2) NS
Urgent or Emergency Operation (%) 26.7 29.9 33.5 NS
Abbreviations: MI myocardial infarct, TIA transient ischemic attack, EF ejection fraction, NYHA angina pectoris symptoms according to New York Heart Association,
CHD coronary heart disease, LM left main, low HDL cholesterol: men < 1.03 mmol/l, women < 1.3 mmol/l, elevated triglycerides: ≥ 1.7 mmol/l,
NS = not significant, NA = not applicable.
1Unadjusted p < 0.01 by the pooled t-test for the comparison DM-/MetS+ against DM-/MetS-.
2Unadjusted p < 0.01 by the pooled t-test for the comparison DM+ against DM-/MetS-.
3Unadjusted p < 0.001 by the pooled t-test for the comparison DM+ against DM-/MetS+ .
4Unadjusted p < 0.001 by the pooled t-test for the comparison DM+ against DM-/MetS-.
5Unadjusted p < 0.05 by the pooled t-test for the comparison DM+ against other groups.
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resembled that of the matched background population
(relative survival, 0.998; 95% CI, 0.978 to 1.018; NS).
During the first 10 postoperative years, the relative
survival of DM-/MetS+ patients was 1.8% better than that
of the matched background population (relative survival,
1.018; 95% CI, 1.010 to 1.026; p < 0.0001) but subsequently
deteriorated thereafter (Figure 3A).
Diabetes mellitus and long-term survival
In the postoperative period of 2 months to 16 years, the
survival of patients with DM was significantly inferior
compared to the background population (relative survival,
0.86; 95% CI, 0.82 to 0.90) and to both non-diabetic pa-
tient groups (all p < 0.0001; Figure 3A). DM patients on
insulin therapy had poorer survival than those with not on
insulin (p < 0.01, Figure 3B).
Among patients with DM, MetS seemed not to affect
postoperative survival (2 months-16 years) after adjust-
ment for age, gender and time (absolute survivals, 0.39;
Figure 2 Postoperative absolute survival of patients with
neither diabetes nor metabolic syndrome (DM-/MetS-), patients
with only metabolic syndrome (DM-/MetS+) and patients with
diabetes regardless of metabolic syndrome (DM+) during the
16-year follow-up. Comparison between DM-/MetS- and DM-/MetS+:
NS Comparison of DM+ against both groups: P < 0.001. Follow-up
of the first two months is shown in the small inset (n = 945).
Figure 3 The actual survival 2 months–16 years postoperatively compared to that of the age-and sex-matched Finnish population
(relative survival 1.00, n = 910). A. DM-/MetS- = patients with neither diabetes nor metabolic syndrome. DM-/MetS+ = patients with only metabolic
syndrome. DM+ = diabetic patients. B. No DM = patients without diabetes. Non-insulin DM = diabetic patients without insulin treatment. Insulin
DM = diabetic patients treated with insulin.
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95% CI, 0.28 to 0.50 for DM+/MetS+ and 0.36; 95% CI,
0.10 to 0.62 for DM+/MetS-, NS).
Causes of death
Cardiovascular and non-cardiovascular death rates were
17.1% and 20.5% for DM-/MetS-, 18.3% and 21.5% for
DM-/MetS+ and 38.7% and 28.1% for DM+ patients, re-
spectively. Further, out of all deaths the corresponding
proportions of cardiovascular deaths were 45.4%, 45.9%
and 56.1%, respectively (p < 0.0001 between DM-and
DM+ patients). Stroke was reported as a cause of death
in only five patients.
Best predictors of long-term prognosis
Bayesian multivariate analysis revealed together six vari-
ables to predict clinical outcome (2 months to 16 years)
in relation to the national background population, i.e. age,
diabetes, left ventricular ejection fraction, BMI, perfusion
time during the CABG and peripheral arterial disease.
Using this model, the measure of agreement (kappa =
0.45) was moderate.
Discussion
To the best of our knowledge this study is the first in
which the survival of non-diabetic and diabetic CABG
patients was compared to that of matched background
populations.
Our principal finding was that the long-term prognosis
of patients with neither diabetes nor metabolic syndrome
was better than that of the age-, sex-and time-matched
background population. Further, in non-diabetic patients
the presence of metabolic syndrome reduced long-term
survival after CABG when compared to those without
MetS. However, the mortality of MetS patients was not
significantly inferior to that of the matched background
population, which might reflect the careful postoperative
follow-up and treatment of known risk factors of operated
MetS patients.
Not surprisingly, DM was associated with significantly
increased intermediate-and long-term mortality. Survival
was even shorter if the diabetes treatment strategy in-
cluded insulin compared to patients without insulin
therapy. MetS per se did not impair survival among
diabetic patients.
MetS, glucose intolerance and insulin resistance form
together complex relationships, whose interacting patho-
physiological roles are not yet fully understood. Insulin
resistance leads to glucose intolerance, if pancreatic
compensation processes are incomplete [21]. Glucose
abnormalities with or without diabetes predict cardio-
vascular events and mortality [22,23]. Insulin resist-
ance is also associated with MetS and its components
[24]. Further, MetS has been shown to worsen the
prognosis of coronary heart disease patients [25].
However, until recently no studies have specifically ex-
amined the prognostic significance of MetS for longer
than 10 years after CABG.
Two studies have yielded different results regarding
the impact of metabolic syndrome [8,9]. In the BARI
trial no significant difference was seen in the death-rate
or MI during the 10-year follow-up between patients
with and without MetS [9]. In another study of CABG
patients MetS predicted inferior outcome in the group
of non-diabetic patients [8]. An increase in both all-
cause and cardiac mortality became apparent approxi-
mately 10 years after surgery. The detrimental effect of
MetS on survival was more marked in non-DM patients
than in DM patients [8]. Our data are in concordance
with and expand these findings.
Diabetes is associated with impaired outcome after
CABG [26-28]. However, relation of insulin treatment
on the long-term prognosis after CABG has been con-
troversial [14,15,29]. Thourani and Alserius with their
co-workers found independently that diabetic patients
had a poorer 10-year prognosis than non-diabetic pa-
tients [14,29]. In both studies insulin-treated patients
with diabetes had the poorest 10-year survival rate. Also,
in a 10-year follow-up of CABG patients Mohammadi
and colleagues found insulin-treated DM to be an inde-
pendent risk factor for long-term cardiac mortality [15].
However, in DM patients not on insulin therapy, the
cardiac-specific survival was similar to that observed in
non-diabetic patients [15].
Our results are in accord with the findings of Thour-
ani and Alserius, suggesting inferior survival of DM pa-
tients on insulin compared to those without insulin or
to non-diabetics. Insulin treatment might suggest more
severe and advanced diabetes in this cohort.
We found, that the excessive death rate of diabetics
was mostly but not completely related to cardiovascular
causes. Our results conform to the idea that long-lasting
DM is associated with a generalized vascular disease
which is characterized by impaired vascular endothelial
function and hypercogulation [14,29].
The strength of the present study is the reliability and
scope of the national registers used, allowing 100% cover-
age of the mortality data of our patients [30]. Our follow-
up includes all subjects operated, like those migrated in
the country and one patient moved in the neighbouring
country. The length of the postoperative follow-up was
exactly 16 years allowing conclusions more valid than
those based on a shorter follow-up. According to Finnish
health care policy every citizen has access to health care
mainly financed by taxes. So in the background population
such social factors, like a proportion of non-secured
citizens, did not affect our results [31].
Certain limitations should also be considered. Firstly,
the perioperative data were collected retrospectively [16].
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Even though information was completed with patient
questionnaires and direct contacts, 16 (1.7%) out of the
original sample of 961 patients were excluded by reason
of insufficient data. Secondly, we identified BMI-based
obesity, not waist circumference, as a factor of the
metabolic syndrome. Nevertheless, BMI is widely used
in the modified definition of MetS and studies have
demonstrated concordance between the definitions of
MetS [7,18].
Conclusions
In this long-term follow-up study patients with neither
DM nor MetS had extremely good prognosis for at
least 16 years when compared to the matched back-
ground population. Also the survival of patients with
MetS but without DM had a good prognosis. Survival
of DM patients started to deteriorate already short
after the operation.
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Introduction
Obesity is an increasing health problem worldwide. Being 
overweight is defined as a body mass index (BMI)⩾25 
kg/m2 and obesity is defined as BMI⩾30 kg/m2.1 The 
global prevalence of obesity has almost doubled between 
1980 and 2008.2 According to the World Health 
Organisation (WHO), more than one third of adults world-
wide over the age of 20 were overweight and 12% were 
obese in 2008.2 
While obesity in itself seems to be a risk factor for coro-
nary heart disease (CHD), it is associated with a cluster of 
important conditions including insulin resistance, dyslipidae-
mia and type 2 diabetes mellitus (DM2), which contribute 
directly and indirectly to the development and progression of 
CHD.3,4 In addition CHD is linked to dietary problems and 
abnormal endocrine activity of adipose tissue, which further 
contribute to the risk of CHD in these patients.5,6
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Despite the evidence of causality between obesity and 
development of CHD as well as increased mortality in pri-
mary prevention,7 several studies suggest that obesity might 
be associated with a better prognosis in CHD patients.8 In a 
number of cardio-metabolic conditions the BMI-mortality 
curve has typically been U-shaped, with best survival in 
overweight patients and mild to moderate obesity and 
increasing mortality in slim patients and in patients with 
morbid obesity.9,10
Our aim was to evaluate the presumed finding of an obe-
sity paradox in patients with coronary artery bypass graft-
ing (CABG) over a follow-up period of 20 years, focusing 
on survival after the first two postoperative months.
Methods
Study population
The study population originally consisted of all CHD patients 
who had undergone CABG at Tampere University hospital 
from 1 January 1993–30 June 1994.11 Patients undergoing 
simultaneous carotid artery or valve surgery were also 
included in the analysis. Patients, who survived beyond the 
immediate postoperative period (defined as two months 
postoperatively) were included in the analysis and followed 
for up to 20 years. The study protocol was approved by the 
Ethics Committee of Tampere University Hospital.
Data collection and clinical definitions
Patient demographics and perioperative data including BMI 
were collected from medical records at Tampere University 
Hospital and the secondary care hospitals involved in post-
operative care. A survival analysis was conducted after the 
closing date (14 July 2014) and was based on data obtained 
from Statistics Finland (previously the Statistical Office of 
Finland). Survival data was available for a total of 20 years 
for all patients included in the study, and causes of death 
were available until 31 December 2012.
A history of hypertension, peripheral vascular disease, pre-
vious myocardial infarction, previous transient ischaemic 
attack (TIA) and stroke was collected from patient records. 
Renal function was evaluated preoperatively by glomerular 
filtration rate (GFR), calculated with the CKD-EPI equation 
originally presented by Chronic Kidney Disease Epidemiology 
Collaboration and a GFR of less than 60 ml/min/1.73 m2 was 
regarded as evidence of impaired renal function.12 Patients 
were defined as hypercholesterolaemic if total cholesterol 
was ⩾5 mmol/l (⩾200 mg/dl) (National Cholesterol 
Education Program Adult Treatment Panel III) or patients 
were on lipid-lowering drug therapy.13 Smoking history was 
based on questionnaire data.11 Persistence of obesity was 
recorded by a patient questionnaire 9.5 years after CABG.
Diabetes was defined by the 1998 WHO criteria with a 
fasting blood glucose level (fB-Gluc)⩾6.1 mmol/l or 
random blood glucose⩾10.0 mmol/l as diagnostic.14 A 
patient was also classified as diabetic if hospital records or 
the Social Insurance Institution of Finland database demon-
strated a history of antidiabetic medication. Obesity was 
defined according to BMI and calculated as mass/height2 
(kg/m2). The study population was divided into normal 
weight (BMI 18.5–24.9 kg/m2), overweight (BMI 25.0–
29.9 kg/m2) and obese (BMI⩾30.0 kg/m2) groups. Only one 
patient was underweight with a BMI 17.9 kg/m2 and was 
analysed with the normal weight patients.
Survival analysis
Separate survival analyses (2 months to 5, 10, 15 and 20 
years) were carried out for 922 patients. The postoperative 
period was defined as two months to separate immediate 
postoperative period with higher mortality from the long-
term follow-up.11 Survival analysis was conducted on each 
BMI group (normal weight, overweight and obese) sepa-
rately. The cumulative and relative mortality for each group 
was calculated against age-, sex- and time-specific national 
background populations as described in the Statistical 
methods section. Furthermore, the relationship of BMI to 
long-term survival (two months to 5, 10, 15 and 20 years, 
respectively) was analysed by comparing the three patient 
groups. Cardiovascular mortality was defined as death 
caused by ischaemic heart disease, stroke, peripheral arte-
rial disease or sudden cardiac death.
Statistical methods
In the comparison of patient characteristics, categorical 
data was tabulated as frequencies and percentages, and con-
tinuous variables were expressed as a mean and standard 
deviation (SD).
Differences between two groups were tested by the chi 
square test and the Wilcoxon rank test. In the analysis of 
more than two groups the Kruskal-Wallis test was used. 
Fisher’s exact test was used when appropriate in two-by-two 
tables with directed hypothesis. Differences in mean values 
between two groups were tested by the Student’s t-test and in 
the case of more than two groups by analysis of variance.
The relative survival rate was analysed by sex, age, and 
BMI using the life table method as presented earlier.11,15 
With this approach, the observed survival rates of the 
groups are compared with the rates based on age-, sex- and 
time-specific life tables for the whole population in 
Finland. For example, at the time of the operation (1994), 
the mean life expectancies of Finnish 65-year old men and 
women were 14.6 and 18.6 years, respectively.16 Double 
arithmetic smoothing was applied when associations of 
BMI with adjusted all-cause mortality over 10, 15 and 20 
years after CABG were presented. Overall survival curves 
according to each BMI class were also generated with 
Kaplan–Meier method. Cardiovascular mortality was 
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analysed as described above. If the overall p-value was 
<0.05, the head-to-head comparisons of the groups were 
analysed by Student’s t-test.
To study the independent significance of BMI for clini-
cal outcome, multivariate analysis was made using an opti-
mising stepwise procedure based on the Bayesian 
approach.11,17 This procedure was developed for nominal 
variables, and does not require a perfect variable matrix. It 
is also appropriate, when analysing curve linear variables. 
Starting from the best predictor in univariate analysis, it 
selects, by the heuristic approach, the combination of vari-
ables which best explains the selected outcome factor.
Results
Study population
A CABG was performed in total for 961 patients during the 
study period. Complete data was available for 922 CABG 
patients alive two months postoperatively (Figure 1). These 
patients formed the study cohort that was followed up for 
20 years.
Patient demographics and clinically relevant co-morbid-
ities at the time of surgery for all 922 consecutive study 
patients are presented in Table 1. Mean age was 61.7 (SD 
8.4) years; 193 patients were women (mean age 64.9 (SD 
7.6) years) and 729 patients were men (mean age 60.9 (SD 
8.4) years). Overall 24.9% were normal weight, 54.9% 
overweight and 20.2% obese. No patients were lost during 
the 20-year follow-up. The absolute 20-year mortality was 
67% in normal weight, 56% in overweight and 60% in 
obese patients. Cause of death data was available for 97% 
of deceased patients by the end of 2012.
When the three patient groups were compared, the pro-
portion of women was slightly higher (not significant 
(NS)) and overall patients were younger in the obese 
group (p<0.05, BMI⩽24.9 kg/m2 vs ⩾30.0 kg/m2). DM, 
hypertension and dyslipidaemia associated with meta-
bolic syndrome (MetS) were more frequently found in the 
obese group and least frequent in the normal weight group 
(Table 1). Peripheral arterial disease defined as sympto-
matic claudication was significantly more common in the 
normal weight group than in the overweight and obese 
groups. Other concomitant diseases, rate of renal dysfunc-
tion, cardiac function, severity of CHD and preoperative 
smoking did not differ significantly between the groups 
(Table 1). Neither were the differences in postoperative 
smoking (in normal weight, overweight and obese patients 
11%, 6% and 8%, respectively), nor in the use of low-dose 
acetylsalicylic acid (ASA), statins and Angiotensin 
Converting Enzyme inhibitors (ACE) inhibitors signifi-
cant, when evaluated 21 months postoperatively.
According to data obtained by the questionnaire, patients 
who were obese at the time of CABG mainly remained 
obese at 9.5 years postoperatively and correspondingly 
patients with normal BMI remained with normal BMI 
(p<0.001), (Supplementary Material, Data File S1). In 
addition, during the first 10 postoperative years, 6.1%, 
13.0% and 23.7% of patients (p<0.01) developed new onset 
diabetes in the normal weight, overweight and obese patient 
groups, respectively.
Survival
During the first postoperative years prognosis was favour-
able in all patient groups. At five years the relative survival 
was similar in normal weight patients 1.01 (95% confi-
dence interval (CI), 0.97–1.05; p=NS), overweight patients 
1.03 (95% CI, 1.01–1.06; p<0.05) and obese patients 1.04 
(95% CI, 1.00–1.07; p=NS). Beyond the first five years the 
survival curves separated.
Normal BMI in long-term follow-up was associated with 
significantly inferior survival when compared with the back-
ground population. This prognosis was already seen 10 years 
after CABG 0.92 (95% CI, 0.88–0.96; p<0.01). Thereafter 
survival in these patients continued to deteriorate being 0.68 
(95% CI, 0.49–0.87; p<0.001) at 20 years (Figure 2).
The survival of overweight patients at 10 years was as 
good as that of the background population 1.01 (95% CI, 
0.99–1.03; p=NS), but it subsequently deteriorated. At 20 
years postoperatively relative survival in this group was 
0.82 (95% CI, 0.71–0.92; p<0.001) (Figure 2).
The relative survival of obese patients at 10 years was 
0.98 (95% CI, 0.94–1.02; p=NS) and sharply decreased 
thereafter to 0.67 (95% CI, 0.49–0.85; p<0.001) (Figure 2) 
at the end of the follow-up period of 20 years.
In Figure 3, the relative survival of the three patient 
groups is compared in relation to each other, over the time 
Figure 1. Study flow chart. BMI: body mass index (kg/m2); 
CABG: coronary artery bypass grafting.
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periods of 10, 15 and 20 years. During the first 10 postop-
erative years, obese patients had equally good survival as 
overweight patients. Thereafter survival decreased and at 
20 years was similar to that seen in the normal weight 
group. In normal weight patients the most unfavourable 
20-year prognosis was associated with the lowest BMIs and 
in the obese group in patients with a BMI⩾35.0 kg/m2 
(Figure 3).
Kaplan-Meier curves of absolute survival are shown as 
Supplementary Material, Data file S2. In multivariate anal-
ysis, age, diabetes, left ventricular ejection fraction at the 
time of CABG, and BMI had independent impact on prog-
nosis. This is presented in a model calculating also 
probabilities of postoperative survival (Supplementary 
Material, Data File S3).
Cardiovascular mortality
During the first decade after CABG, cardiovascular disease 
was the primary cause of death in 56% of normal weight 
patients and in 66% of overweight patients and during the 
second postoperative decade this figure was 59% and 58%, 
respectively (NS for both changes). In obese patients car-
diovascular mortality increased significantly with time and 
was 45% during the first postoperative decade and 77% 
during the second decade (p<0.01).
Table 1. Preoperative demographic data, clinical characteristics and severity of coronary heart disease in 922 patients surviving two 
months after coronary artery bypass grafting (CABG).
BMI<25.0 BMI 25.0–29.9 BMI⩾30.0 Overall p-value
Number of patients  
 At the time of CABG 230 506 186 –
 10 Years postoperatively 167 407 150 –
 20 Years postoperatively  75 224  75 –
BMI, kg/m2 23.3 27.3 32.5 –
Female, % 20.6 19.7 24.9 NS
Mean age, years (SD) 62.6 (8.8) 61.7 (8.2) 60.3 (8.3) <0.051
Concomitant diseases  
 Previous MI, % 60.5 72.6 72.9 <0.051
 Previous TIA or stroke, % 10.1 11.1 7.7 NS
 Peripheral arterial disease 13.0 8.0 7.0 <0.051
 DM, % 29.8 36.2 52.4 <0.00012
 Hypertension, % 54.0 61.6 69.6 <0.013
Glomerular filtration rate  
 GFR, ml/min (SD) 75.6 (15.9) 74.7 (16.4) 75.0 (15.9) NS
 GFR<60 ml/min/1.73 m2, % 15.7 15.7 16.3 NS
Lipid disorder  
 Hypercholesterolaemia, % 71.8 72.9 78.3 NS
 Low HDL cholesterol, % 53.5 67.4 71.4 <0.0014
 Elevated triglyceride, % 37.1 58.4 73.0 <0.00012
Preoperative smoking, % 62.5 63.7 67.4 NS
Severity of heart disease  
 EF, % (SD) 59.5 (13.6) 60.7 (13.5) 59.2 (13.9) NS
 EF⩽35%, % 6.3 7.2 7.4 NS
 NYHA II, % 10.8 11.9 7.7  
 NYHA III, % 57.8 57.1 56.6 NS5
 NYHA IV, % 31.4 31.0 32.1  
 Three–vessel or LM disease, % 59.6 63.2 56.6 NS
 Urgent or emergency operation, % 30.3 28.9 30.6 NS
BMI: body mass index (kg/m2); MI: myocardial infarct; TIA: transient ischemic attack; GFR: glomerular filtration rate; Hypercholesterolemia: ⩾5,0 
mmol/l or on lipid-lowering medication, Low high density lipoprotein (HDL) cholesterol: men <1.03 mmol/l, women <1.3 mmol/l, Elevated triglyc-
eride: ⩾1.7 mmol/l; EF: ejection fraction; NYHA: angina pectoris symptoms according to New York Heart Association; LM: left main;  NS: not 
significant.
1Unadjusted p<0.05 by the pooled t-test for the comparison BMI<25.0 against BMI⩾30.0 kg/m2.
2Unadjusted p<0.0001 by the pooled t-test for all comparisons.
3Unadjusted p<0.01 by the pooled t-test for the comparisons for BMI⩾30.0 kg/m2 against both other groups.
4Unadjusted p<0.001 by the pooled t-test for the comparison BMI<25.0 kg/m2 against BMI 25.0–29.9 kg/m2.
5NYHA II–IV as a group NS.
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Discussion
Our key finding was that obesity paradox seems to be a 
consequence of too short a follow-up period. In obese CHD 
patients who had undergone CABG, the initial prognosis 
was good but deteriorated when the follow-up period was 
extended to 20 years. In this study overweight patients 
(BMI 25–29.9 kg/m2) had the most favourable prognosis. 
Their survival even outweighed that of normal weight 
patients. To the best of our knowledge, this is the first study, 
in which the survival of CABG patients graded by weight 
has been followed for two decades postoperatively and 
compared with matched national background populations.
During the first postoperative decade the prognosis of 
overweight and obese CABG patients was as good as that 
of their background populations. Prognosis in these patients 
was even better than the 10-year prognosis of normal 
weight patients. This phenomenon, called the obesity para-
dox, has been seen in a wide range of CHD manifestations 
including CABG patients.4,8
The prognostic impact of BMI in CABG patients over 
3–7 years has been reported in several studies. In most 
analyses CABG patients with BMI <25 kg/m2 had a less 
favourable prognosis, when compared with overweight and 
obese patients, with the best prognosis being in mildly 
obese and overweight patients.18–20 In one study, being 
either obese or normal weight was associated with a reduced 
seven-year survival after CABG, when compared with 
being overweight.21
Several explanations may account for the obesity para-
dox, when the follow-up is restricted for a few years only. 
Obesity is most commonly defined by BMI as it is a readily 
measurable parameter used in routine clinical practice. 
BMI has been criticised for its lack of accuracy in defining 
obesity in a CHD population.10,22 It is an aggregate of vary-
ing amounts of fat-free mass and body fat and correlates 
poorly with body fat especially in overweight subjects. In 
addition, it cannot differentiate central fat from peripheral 
fat. When body fat was measured by bioimpedance, 
BMI⩾30 kg/m2 had a very high specificity (97%), but poor 
sensitivity (42%) in detecting obesity.22,24 The main limita-
tion of BMI is its inability to differentiate body fat from 
lean mass and central from peripheral obesity. Therefore, 
trained athletes with high body muscle mass and vice versa 
people with low lean mass but increase body fat may be 
misclassified by BMI.
Fat-free mass is widely considered as a positive prog-
nostic factor, whereas CHD as a systemic disease can result 
in cachexia similar to that seen in heart failure.25 Both fat-
free mass and body fat might provide a protective meta-
bolic buffer.26 On the other hand, poor nutritional status 
predicts mortality after cardiac surgery.27,28
There are also other potential explanations through 
which the obesity paradox could arise. Obesity was previ-
ously considered a perioperative risk factor in CABG.29 It 
is therefore possible that high-risk obese patients in this 
study population were excluded from revascularisation cre-
ating a selection bias. In addition, normal weight patients 
had an increased tendency for postoperative smoking and 
they had more peripheral arterial disease, which are both 
markers of poor prognosis.7,30 This disparity of BMI groups 
has also been observed previously.21 Furthermore, it has 
been postulated that obese patients might be receiving bet-
ter disease-modifying medication than normal weight 
patients,19 though in our material they did not use signifi-
cantly more ACE inhibitors, statins or ASA.
After the first postoperative decade, prognosis of obese 
patients deteriorated and at 20 years postoperatively it was 
at the same level as that of the normal weight patients. 
Obesity persisted in our patient population during the fol-
low-up period. In addition, patients who were obese at the 
time of CABG developed diabetes more frequently than the 
normal weight patients. DM is a known risk factor of car-
diovascular disease31 and seems to have impaired long-
term prognosis in this group. Obese patients in this study 
Figure 2. Relative survival two months to 20 years 
postoperatively according to each body mass index (BMI) 
class compared with national age-, sex- and time-matched 
background population (relative survival 1.00, n=922).
Figure 3. Association of body mass index (BMI) as a 
continuous variable with adjusted all-cause mortality using basic 
odds ratio (OR) formula 10, 15 and 20 years after coronary 
artery bypass grafting (CABG). An OR of 1.0 represents that of 
an average CABG patient (n=922). The curves are smoothed 
and represented in logarithmic scale.
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had a substantial increase in cardiovascular mortality dur-
ing the second decade following CABG, which accounts 
for their lower survival during long-term follow-up.
The 20-year prognosis of overweight patients was better 
than the prognosis of lean and obese patients. Nevertheless, 
during the second follow-up decade their survival was also 
inferior to that of the background population. We have pre-
viously shown that diabetes in our patient population was 
an important predictor of poor prognosis.11 Out of the over-
weight patients, 36% were diabetic (Table 1), which would 
have affected long-term prognosis in this group.
Strengths and limitations
The strength of the present study is provided by the national 
registers, which allow 100% coverage of mortality data in 
our patients.32 The length of the postoperative follow-up of 
each patient was exactly 20 years or until death (35.4% and 
64.6%, respectively). Our study therefore allows more 
valid conclusions than those based on shorter follow-up 
data. In Finland, health care is mainly publicly managed, 
ruling out the existence of citizens without comprehensive 
health insurance coverage. Therefore, no significant eco-
nomic factors in the background population affected our 
results.
Certain limitations should be considered. Firstly, the 
perioperative data was collected retrospectively.11 Even 
though information was completed with patient question-
naires and direct patient contacts, six patients (0.6%) from 
the original sample of 961 were excluded on the grounds of 
insufficient data. Secondly, we identified obesity based on 
BMI, not on waist circumference or waist-hip ratio. 
Nevertheless, BMI is widely used as a measure of obesity 
in the modified definition of MetS and studies have demon-
strated concordance between all these definitions.33,34
Conclusions
Based on our findings, the so-called obesity paradox disap-
pears in CABG patients, when the follow-up period is 
extended to 20 years. The late survival of obese patients was 
obviously negatively affected by the presence of unfavour-
able cardiometabolic conditions, such as diabetes, which 
were observed during the postoperative years. Slightly over-
weight CABG patients had the best survival over a 20-year 
postoperative follow-up period. Our findings support the 
need for the prevention of obesity and effective weight loss 
in CHD patients, as permanent obesity is associated with 
increased late mortality following CABG.
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